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General Introduction 
Human pregnancy involves a complex, highly choreographed sequence of molecular 
processes. These processes include interactions between the hormonally stimulated 
endometrium and the developing blastocyst, implantation, a period of placental 
and fetal development, and a terminal pathway composed of activation of the deci-
dual cells and fetal membranes, myometrial contractility, and cervical ripening.1,2 
Although the hormonal milieu, metabolic changes, and placental micro-
environment are programmed in a compatible manner, pregnancy remains an im-
munological and hormonal paradox.3 Perturbed pre-existing maternal health or 
altered local environment during the course of pregnancy can lead to pregnancy 
complications such as preeclampsia. 
Preeclampsia occurs in approximately 5 to 8 percent of all pregnancies and is an 
important cause of maternal and fetal morbidity and mortality worldwide.4 The 
placenta is a prerequisite for its development, as it always dissolves after placental 
delivery. The syndrome becomes clinically manifest with the development of new-
onset hypertension, defined as blood pressure of >140/90 mm Hg on at least two 
occasions, 4-6 weeks apart after 20 weeks gestation, along with proteinuria, defined 
as excretion of 300 mg of protein or more every 24 h.5  
A pregnancy-related syndrome linked to preeclampsia is that of hemolysis, elevated 
liver enzyme levels, and a low platelet count (HELLP). The HELLP syndrome develops 
in 2 to 12 percent of women with preeclampsia or eclampsia, but can also occur 
without proteinuria and/or hypertension.6,7 Although it is a distinct clinical entity 
with different risk factors as compared to preeclampsia, many consider it a severe 
variant of the latter. Actually, their clinical features and symptoms often overlap in 
clinical practice.6, 8  
Research on preeclampsia was sporadic until about 20 years ago. Since then, both 
basic and translational research concerning preeclampsia have increased exponen-
tially and, as a result, we now have an abundance of information supporting several 
plausible hypotheses about its causes, including the contribution of oxidative stress, 
inflammation, immunologic and circulatory maladaptation, as well as associated 
humoral, mineral, or metabolic abnormalities.9  
Pathophysiology of preeclampsia 
The Two Stage Model of the pathophysiology of preeclampsia proposes that a poor-
ly perfused placenta (Stage 1) produces factor(s) triggering the clinical manifesta-
tions (Stage 2).10,11 Different pathways, fetal and maternal, can lead to the end-
stage of the disorder. On the one hand, shallow invasion of endovascular and inters-
titial trophoblast at the maternal–fetal interface has proven to result in failure to 
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remodel the maternal spiral arteries.12 The spiral arteries do not undergo appropri-
ate remodeling and remain narrow. This is referred to as the fetal pathway in the 
development of preeclampsia. On the other hand, the maternal pathway is related 
to thrombosis and atherosis of the spiral arteries, both in conjunction with failed 
spiral artery remodeling and inadequate compensatory adjustments.13-15 In this 
scenario the spiral arteries may have undergone conversion, but blockage results in 
deficient utero-placental blood flow. ‘Mixed’ pathways may be possible as well.  
In any case, the clinically most prominent features of the disorder seem to originate 
in the dysfunctional decidua. The end-stage of the placental disorder of preeclamp-
sia is a maternal syndrome defined in terms of disturbances developing in the car-
diovascular and renal functions (new-onset hypertension and proteinuria resolving 
postpartum). The proteinuria is associated with a specific endothelial renal lesion 
(glomerular endotheliosis),16 and there is overwhelming evidence in support of the 
concept that the hypertension is secondary to diffuse endothelial dysfunction.17 
However, the stress response is wider: there are associated changes such as the 
acute-phase and metabolic responses triggered by systemic inflammation.18 
Although we know much about the two stages, their linkage in the pathophysiologic 
model is less clear. It is evident that although reduced placental perfusion seems a 
prerequisite for preeclampsia to develop, it is clearly not sufficient. As a matter of 
fact, not all mothers with growth-restricted infants have preeclampsia and vice 
versa. Some conditions that predispose to preeclampsia (obesity and insulin resis-
tance among othes) are even associated with large infants. In contrast, isolated 
fetal growth-restriction and preterm delivery appears to be preceded by abnormal 
implantation.19-21 Reduced uteroplacental perfusion thus interacts with maternal 
constitutional factors, genetic, behavioral and environmental, to result in preec-
lampsia.22 
Recurrent preeclampsia, a target for counseling and prediction 
Preeclampsia is considered a disease of nulliparous women, as it is twice as com-
mon in primigravidas as in multiparous women.5 However, it is well-established that 
women with a previous pregnancy complicated by preeclampsia are at increased 
risk of developing the disorder in the next pregnancy. For severely preeclamptic 
primigravidas, recurrence rates in the next pregnancy are high, reaching up to 50% 
in some studies.  
Because the disorder is heterogeneous, the pathogenesis may differ in women with 
diverse risk factors.23 For example, in nulliparae the pathogenesis of preeclampsia 
may differ from that in formerly affected women, and preexisting vascular disease, 
diabetes, or multiple pregnancies may affect the patholophysiologic pathway. In 
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line with this, the risk of recurrent preeclampsia varies depending on underlying 
mechanism and previous pregnancy outcome.  
Preconception counseling and care represents an ideal opportunity to evaluate 
current or past medical or obstetric complications, thereby minimizing the risk of 
recurrence in the next gestation.24,25 With regard to recurrent preeclampsia, coun-
seling may address issues related to prediction and prevention of recurrence risk, 
the need for frequent prenatal visits and close fetal surveillance, diagnostic tests to 
identify underlying predisposing factors, and potential impact on future health. The 
first step in the management of women with a history of preeclampsia is thus to 
conduct a detailed evaluation of potential risk factors for preeclampsia prior to a 
next pregnancy, which may provide clues about the risk of recurrence in a next 
pregnancy.23  
The ability to predict or prevent preeclampsia or the development of therapy that 
safely prolongs gestation would be an important achievement in prenatal care. It 
could offer clinicians the possibility to identify subclinical preeclampsia early in 
pregnancy and to provide more tailored care. Underappreciated is the strain that 
preeclampsia places upon health care resources. It increases the need for artificial 
preterm birth and neonatal intensive care and predisposes the infants to health 
problems later in life. Considerable evidence suggests that premature delivery in-
creases the incidence of cardiovascular and metabolic health problems later in life, 
which themselves create enormous economic health burdens.26 
Most of the available prediction tests for recurrent preeclampsia are based on a 
single variable, with disappointing prediction capacity. Preeclampsia is a heteroge-
neous condition, probably involving several separate pathophysiologic pathways. 
Therefore, it may be more appropriate to explore combinations of tests performed 
before and/or during the next pregnancy.23  
Outline of this thesis  
The aim of this thesis was to address issues regarding prediction of and counseling 
for recurrent preeclampsia and related methodological challenges. The thesis con-
sists of three parts.  
Part I  - Preconception prediction of and counseling for recurrent preeclampsia  
Chapter 2 summarizes reported evidence on the performance and clinical useful-
ness of prediction tests for recurrent hypertensive disease in pregnancy. Although 
some of the tests have promising predictive potential, their applicability is ham-
pered by statistical imprecision and clinical drawbacks. Therefore, in Chapter 3, 
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the predictive performance of a new preconception multivariable prediction model 
for early-onset recurrent preeclampsia and/or HELLP syndrome is evaluated.  
In counseling for recurrent preeclampsia, reduction of risk factors often is one of 
the main objectives. In obese formerly preeclamptic women, this may involve at-
tempts to strive for weight loss. However, it is still unclear whether obesity is really 
an independent risk factor for recurrent preeclampsia. Chapter 4 addresses this 
question.  
HELLP syndrome is often considered a severe form of preeclampsia with overlap-
ping symptoms. However, dissimilarities regarding risk factors have emerged as 
well. Hypothetically, the pathogeneses of these two syndromes may differ more 
than currently assumed. Chapter 5 gives this hypothesis a more solid scientific 
basis by evaluating differences in clinical and laboratory variables between former 
patients who had HELLP syndrome with or without preeclampsia and former pa-
tients who had preeclampsia without HELLP.  
Chapter 6 determines the value of the electrocardiogram to detect premature or 
clustering of cardiovascular disease in women with a recent history of preeclampsia, 
in order to estimate both the prevalence of electrocardiographic abnormalities and 
their association with recurrent preeclampsia in the next pregnancy.  
Part II – Early-pregnancy adaptation 
Although in many cases the pathogenesis of preeclampsia seems to begin early in 
pregnancy, the disorder does not become clinically manifest before the 20th week. 
In addition to preconception prediction and counseling, this leaves room for identi-
fying early in the next pregnancy, formerly preeclamptic women at increased risk of 
developing recurrent disease later on. To this end, in Chapter 7, formerly preec-
lamptic women with recurrent preeclampsia are compared with their counterparts 
who do not develop recurrent preeclampsia with respect to the adaptation of the 
lipid profile to pregnancy. Chapter 8 has the same objective but then with respect 
to the cardiac adaptation to pregnancy.  
Part III – Methodological challenges in predicting reproductive outcomes 
Studies on recurrent abnormal pregnancy outcome are becoming increasingly im-
portant for the development of evidence-based guidelines in clinical management. 
However, such studies may be subject to a relatively unknown type of bias, the so-
called “collider bias”. Collider bias may lead to seriously distorted, even inverted 
association estimates, as is further discussed and illustrated in Chapter 9.  
Chapter 10 describes another methodological phenomenon, which is specific for 
preconception prediction models for adverse pregnancy outcome and is caused by 
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selective fertility. Selective fertility may affect predictive accuracy when the latter is 
evaluated after application of the prediction model.  
 
Chapter 11 discusses the main findings described in this thesis. The general dis-
cussion provides recommendations for further development and improvement of 
prediction strategies for recurrent preeclampsia and clinical implications of these 
strategies. Finally, the conclusions of this thesis are summarized.   
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Abstract 
Objective: to summarize reported evidence on the performance and clinical useful-
ness of prediction tests for recurrent hypertensive disease in pregnancy.  
 
Methods: A literature search was conducted in MEDLINE/PubMed and EMBASE. 
Test characteristics were extracted for relevant reports.  
 
Results: Thirty-three of 4,311 articles found met the inclusion criteria. Twenty-four 
potential predictors were identified. Pre-pregnant plasma volume, uterine-artery 
blood flow velocity profiles, and combined longitudinal patterns of in-pregnancy 
laboratory variables had reasonable predictive capacity, but also some practical 
shortcomings. Confidence intervals were often wide. 
 
Conclusions: Although evidence points to promising predictive accuracy of some 
tests, immediate applicability is hampered by statistical imprecision and clinical 
drawbacks. 
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Introduction 
Hypertensive disorders in pregnancy are a major cause of maternal mortality 
worldwide, accounting for approximately 16% of maternal deaths in Western coun-
tries, 9% in Africa and Asia and over 25% in Latin America and the Caribbean.1 
Hypertensive disorders complicate 6% to 8% of all pregnancies, and contribute 
considerably to stillbirth risk and neonatal morbidity and mortality.2 Clinical symp-
toms are preceded by a long subclinical phase, which may even go back to the time 
of implantation. Neither the trigger nor the cascade of patho¬physiologic events 
afterwards is well understood.2 Hypertensive disorders typically occur in the first 
pregnancy. Pregnant women with uneventful previous pregnancies seldom develop 
hypertensive disorders. By contrast, women with a history of hypertensive pregnan-
cy disorders are at increased risk for recurrent disease.  
The ability to predict the risk of recurrent hypertensive disease in pregnancy would 
have several advantages. On the one hand, it could offer clinicians the possibility to 
identify women who require closer surveillance and permit early referral for their 
treatment as soon as signs or symptoms occur. On the other hand, it would enable 
the identification of low-risk women who then could be reassured and offered the 
appropriate regular low-risk care.  
Numerous tests have been proposed for the prediction of hypertensive disorders of 
pregnancy. Most of these tests focus on nulliparous women.3 Parous women with a 
history of hypertensive disorders constitute a patient group far less studied for this 
purpose. These women, though, are often traumatized by their past experience and 
anxious for possible recurrent disease in their next pregnancy.4 The primary objec-
tive of this systematic review was to summarize reported evidence on the perfor-
mance and clinical usefulness of clinical, biophysical, and biochemical tests for the 
prediction of recurrent pregnancy-related hypertensive disorders. To our know-
ledge, this is the first systematic review on this topic.  
Methods 
A literature search was conducted in MEDLINE/PubMed and EmBase to identify 
studies on predictors of the recurrence risk of hypertensive disease in pregnancy. 
The search was performed in December 2007 and we checked for new articles in 
May 2008. No limits were set to the years to be covered by the search. Languages 
were restricted to Dutch, English, French, German, Spanish, Portuguese, and Italian. 
We used keywords related to hypertensive disorders in pregnancy, recurrent dis-
ease, and prediction tests or risk factors (references are made to the online version 
of the report for the detailed search strategy). Case reports were excluded. Reports 
of clinical intervention trials were also excluded because these typically do not pro-
C h a p t e r  2  
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vide any useful information on the prognostic value of patient characteristics (other 
than the intervention studied). The search results of all search strategies were com-
bined using Endnote version 7.  
Titles and abstracts were judged on eligibility by one of the investigators (SS). Po-
tentially relevant reports were retrieved for more detailed evaluation. In case of 
abstract only publications the authors were contacted for more details. All primary 
studies evaluating risk factors for and/or predictors of recurrent hypertensive dis-
ease in pregnancy were initially included. Any setting was considered eligible. Stu-
dies including women who had had pregnancy-induced hypertension, 
(pre)eclampsia, or the hemolysis, elevated liver enzymes and low platelets (HELLP) 
syndrome in a previous pregnancy and who established an ongoing (> 16 weeks 
gestation) subsequent pregnancy were considered for inclusion. Case-control stu-
dies were excluded because they overestimate predictive test characteristics and do 
not allow estimation of the screening effectiveness in the general population.5 The 
outcome measures included were recurrence of the following maternal hyperten-
sive pregnancy complications: pregnancy-induced hypertension, (pre)eclampsia or 
the HELLP syndrome. A distinction was made between early-onset and late-onset 
disease as defined by the authors. As maternal hypertensive disease is associated 
with poor placentation, associated with impaired fetal growth, we also included the 
outcomes growth restriction (birth weight below a cut-off percentile) and low birth 
weight (birth weight below an absolute threshold). References of retrieved articles 
and relevant previously published reviews were hand-searched to identify addition-
al studies.  
Data were extracted by one reviewer (SS) using a standardized data extraction 
form. A second reviewer (LS) was consulted in case of doubt. Besides study charac-
teristics that were extracted, the incidences of recurrent hypertensive disease with 
95% confidence intervals were calculated if not reported. Cross tables were con-
structed to calculate predictive sensitivity and specificity and diagnostic odds ratios 
with corresponding 95% confidence intervals. If one or more cells of the cross table 
did not contain any observation, 0.5 was added to the cells to improve the precision 
of the predictive accuracy measures.6 If the information necessary to construct a 
2x2 table was lacking, the authors were contacted and kindly requested to provide 
raw data. Results were extracted for all thresholds reported. For studies that re-
sulted in multiple publications, the data of the article reporting the largest sample 
size were used. We considered pooling predictive sensitivity and specificity statisti-
cally, but as explained in the discussion section, calculating summary estimates was 
contra-indicated. 
The assessment of the methodological quality of each study was conducted by one 
of the investigators (SS). The assessment was based on criteria derived from a quali-
ty checklist developed for diagnostic studies (QUADAS).7 In adapting this tool, we 
used an existing protocol for systematic reviews of test accuracy in the prediction of 
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preeclampsia.8 We assessed study quality by evaluating 1. patient selection, 2. in-
clusion/exclusion criteria, 3. strategy of data collection, 4. the use of generally ac-
cepted definitions for hypertensive disease in pregnancy, 5. verification bias, 6. 
pregnancy outcome and test outcome being independent, 7. timing of testing, 8. 
testing procedure, 9. blinding of test results, 10. procedure of the final diagnose, 11. 
presentation of inconclusive and/or odd test results, and finally, 12. handling of 
withdrawals. Quality scores were not used as weights or exclusion criteria, but ra-
ther as a subject of discussion.  
Results 
Of the 4311 articles identified by the electronic search, 36 studies met the inclusion 
criteria. Additionally, 34 potentially relevant reports were retrieved from the refer-
ence lists, of which two also met the inclusion criteria.  
Spaanderman et al. evaluated the same predictors on the same, but updated, co-
hort in two articles.9, 10 We considered these results as one study and included the 
most recent report only. Moreover, the cohort reported on by Heath et al.11 was 
part of the cohort studied by Caritis et al.,12 the cohort of Fatini et al.13 overlapped 
the cohort evaluated by Mello et al.,14 and, finally, Trogstad and coworkers reported 
on the same cohort in two articles.15, 16 As different prediction tests were evaluated 
in these six studies, we considered the reports to be independent. In spite of having 
contacted the authors, we were unable to construct 2x2 tables for four of the ar-
ticles selected: Dukler et al. (2001)17, Fatini et al. (2006)13, Caritis et al. (1998)12, and 
Van Rijn et al. (2006)18. It follows that we were able to evaluate the predictive ca-
pacity of tests reported in 33 studies. 
Table 1 summarizes characteristics of all studies included in the systematic review. 
Sample sizes ranged from 23 to 20,285 women. One study reported on a population 
with a history of pregnancy induced hypertension, 23 studies on populations with a 
history of preeclampsia and/or eclampsia, and 3 studies on populations with a his-
tory of the HELLP syndrome. The study populations in 6 studies consisted of women 
with mixed obstetric history. The earliest and most recent study appeared in 1973 
and in 2007, respectively. The incidence rates of recurrent disease ranged from 16% 
to 57% for pregnancy-induced hypertension, from none to 31% for preeclampsia 
and from 3% to 7% for HELLP syndrome. The risk of recurrent eclampsia was 4% and 
16%, respectively, in two studies (table 1). The prediction tests could be subdivided 
into three categories: 1. tests based on anthropometric, demographic and behavior 
related data; 2. tests based on obstetric history; and 3. tests related to vascular 
resistance, endothelial, clotting and immune functions, or uterine blood flow. 
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
Aardema 
(2000)
28
 
The Nether-
lands 
87 
PIH/PE 
HELLP 
Intra-uterine 
demise in previ-
ous pregnancy,  
Doppler ultra-
sound screening 
PIH/PE: 
33% (23-
43%) 
 
IN: history of 
hypertensive 
disorders in 
previous 
pregnancy, no 
current pa-
thology, single-
ton pregnancy 
Aardenburg 
(2003)
41
 
The Nether-
lands 
83 
Early-
onset 
PE/HELLP 
Plasma volume 
(at least 6 
months after 
i.p.) 
PE/HELLP: 
25% (16-
35%) 
IN: history of 
early onset 
PE/HELLP (< 34 
wks) 
Adelusi 
(1986)
37
 
Nigeria 64 E 
Diastolic blood 
pressure (at 
booking) 
E: 16% (7-
25%) 
BW < 
2000g: 6% 
(0-12%) 
IN: previous 
pregnancy 
complicated by 
eclampsia 
Basso  
(2001)
21
 
Denmark 8401 PE 
Change of 
partner, preg-
nancy interval   
PE: 16% 
(15-27%) 
IN: all women 
hospitalised 
with eclamp-
sia/PE in 
Denmark 
between 1980 
and 1994 who 
had subse-
quently given 
birth 
EX: multiple 
births, gesta-
tional age ≤ 27 
wks, non-
Danish citizens, 
pairs where 
children had 
been given in 
adoption. 
 
Branch 
(2001)
 42
 
 
 
USA 
 
 
317 
 
 
PE 
 
Antiphospholipid 
and anticardi-
olipin antibodies 
(13-26 wks of 
t.p.) 
PE: 20% 
(15-24%) 
FGR: 6% (3-
8%) 
IN: women 
with PE in a 
previous 
pregnancy who 
were being 
followed-up in 
a treatment 
Table 1: Study characteristics for individual studies on predicting recurrent hypertensive disease.
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Table 1 continued  
First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
trial 
EX: multifetal 
gestations, 
diabetes, 
proteinuria, 
chronic hyper-
tension 
Brown  
(2007) 
36
 
Australia 
 
369 
 
 
201 
 
 
PIH 
 
 
PE 
 
parity 
PIH: 18% 
(14-22%) 
PE: 4% (2-
6%) 
 
PIH/PE: 
22% (17-
27%) 
IN: women 
with a diagno-
sis of PE or PIH 
between 1988 
and 1998 
Campbell 
(1985) 
32
 
United 
Kingdom 
1618 PIH/PE Proteinuria (i.p.) 
PE: 3% (2-
4%) 
IN: first re-
corded preg-
nancy between 
1967 and 1978, 
two or more 
completed 
pregnancies, 
pregnancies 
terminating 
both before 
and after 27 
wks 
Chames 
(2003) 
38
 
USA 62 HELLP 
Chronic hyper-
tension (before 
or after i.p.) 
PE: 55% 
(42-67%) 
HELLP: 6% 
(0-13%) 
FGR: 27% 
(16-39%) 
IN: Previous 
HELLP at ≤ 28 
wks of gesta-
tion and fol-
low-up visits 
for at least 2 
years 
Cnattingius 
(2004) 
22
 
Sweden 10351 PE 
Change of 
partner 
PE: 14% 
(13-14%) 
IN: Previous 
PE/eclampsia, 
singleton 
pregnancy 
EX: record of a 
twin pregnancy 
Frusca 
(1996) 
46
 
Italy 56 
 
PE 
 
Uterine artery 
velocimetry (24 
wks t.p.) 
PIH: 16% 
(6-26%) 
Recurrent 
IN: history of 
PE, normoten-
sive 
C h a p t e r  2  
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
PE: 5% (0-
11%) 
FGR: 23% 
(12-34%) 
Gudnasson 
(2004) 
34
 
Sweden 139 PE 
Uterine artery 
Doppler (i.p.), 
parity 
PE: 31% 
(23-39%) 
IN: previous 
PE, pregnancy 
evaluated by 
Doppler 
Hargood 
(1991) 
33
 
Australia 
140 
 
PIH/PE 
 
Proteinuria in 
previous preg-
nancy 
PIH: 45% 
(37-53%) 
PE: 2% (0-
5%) 
IN: nulliparous, 
normotensive 
women, no 
history of 
hypertension 
or renal dis-
ease, subse-
quent preg-
nancy 
Hauth 
(1998) 
11
 
USA 259 PE 
Thromboxane B2 
reduction (24-28 
wks and/or 34-
34 wks of t.p.) 
PE: 19% 
(15-24%) 
 
IN: PE in a 
previous 
pregnancy who 
participated in 
a treatment 
trial 
Hjartardottir  
(2004) 
25
 
Iceland 
468 
146 
PIH 
PE 
Change of 
partner 
PIH/PE: 
66% (62-
71%) 
PIH/PE: 
56% (48-
64%) 
IN: de-novo 
hypertension 
during previ-
ous pregnancy, 
2 pregnancies, 
family history 
of PIH/PE 
EX: chronic 
hypertension 
Hjartardottir 
(2006) 
19
 
Iceland 
511 
 
151 
PIH 
 
PE 
Overweight 
(before i. p.), 
weight gain 
(between preg-
nancies), onset 
of hypertension 
(i.p.) 
PIH: 47% 
(42-51%) 
PE: 7% (5-
10%) 
 
PIH: 34% 
(27-42%) 
PE: 13% (8-
19%) 
IN: ≥ 2 single-
ton births, 
hypertensive 
disease in the 
first pregnancy 
EX: hyperten-
sion due to 
renal or vascu-
lar diseases 
Table 1 continued.
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
Li 
(2000) 
23
 
USA 2833 PE 
Change of 
partner 
PE: 9% (8-
10%) 
IN: two con-
secutive single-
ton births, PE 
in the first 
pregnancy 
Lie 
(1998) 
24
 
Norway 12869 PE 
Change of 
partner 
PE: 13% 
(13-14%) 
IN: more than 
16 wks of 
completed 
gestation, 
complicated by 
PE, subsequent 
pregnancy 
López-Llera 
(1974) 
27
 
Mexcio 110 E 
Onset of 
eclampsia (i.p.) 
PE: 35% 
(27-24%) 
IN: subsequent 
pregnancy 
after eclampsia 
with convul-
sions 
Makkonen 
(2000) 
20
 
Finland 144 PE 
Age, BMI (before 
t.p.), pregnancy 
interval, intra-
uterine death 
(before t.p.)  
PE: 15% (9-
20%) 
IN: singleton 
birth beyond 
24 wks, primi-
parous, second 
delivery  
EX: structural 
or chromoso-
mal abnormali-
ties 
Mello 
(2001) 
50
 
Italy 187 PE 
Logit model: 
parity, age, 
number of 
abortions, urea, 
creatinine, total 
proteins uric 
acid hematocrit 
(longitudinal 
pattern 9-20 wks 
of t.p.) 
PE: 25% 
(18-31%) 
IN: Pregnant 
women with a 
history of PE, 
whites, nor-
motensive, 
absence of 
proteinuria, 
absenece of 
chronic renal 
and major 
systemic 
diseases, body 
mass index < 
26 
 
Mello Italy 106 PE 
ACE I/D poly-
morphism 
PE: 16% (9-
23%) 
IN: history of 
PE 
Table 1 continued.
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
(2003) 
14
 FGR: 29% 
(21-38%) 
EX: kidney 
disease, car-
diovascular 
pathology, pre-
existing diabe-
tes, thrombo-
philic abnor-
maltities 
Morris 
(1998) 
45
 
Australia 50 PE 
Uterine artery 
waveform (18th 
wk of t.p.) 
PE: 26% (8-
44%) 
IN: pregnant 
women with 
second trimes-
ter PE in a 
previous 
pregnancy 
Patterson 
(1986) 
29
 
USA 
 
539 
 
 
PIH 
 
FGR (i.p.) 
PIH: 17% 
(14-21%) 
FGR: 12% 
(9-15%) 
IN: Hispanic 
surname, two 
singleton live 
born infants 
without 
anomalies of ≥ 
26 wks’ gesta-
tional age 
Rasmussen 
(2000) 
30
 
Norway 12489 PE 
Birth weight, 
birth weight 
centile (i.p.) 
PE: 14% 
(13-14%) 
IN: gestational 
age ≥ 16 wks 
EX: only one 
pregnancy 
between 1967 
and 1992, first 
delivery before 
1967, no 
information 
about last day 
of last men-
strual period 
Sibai 
(1992) 
35
 
USA 
 
182 
 
 
E 
 
Parity 
E: 4% (1-
7%) 
PE: 44% 
(37-51%) 
FGR: 12% 
(7-17%) 
IN: pregnancies 
delivered 
beyond first 
trimester, 
previous 
eclampsia 
Sibai 
(1995) 
39
 
USA 152 HELLP 
Chronic hyper-
tension 
HELLP: 3% 
(0-6%) 
PE: 16% 
IN: first preg-
nancy compli-
cated by 
Table 1 continued.
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
(11-22%) 
FGR: 15% 
(9-21%) 
HELLP, preg-
nancies be-
yond first 
trimester 
Simon 
(1988) 
43
 
France 41 PIH/PE HLA DR4 
PIH/PE: 
56% (41-
71%) 
IN: PIH or PE in 
the previous 
pregnancy 
Spaanderman 
(2005) 
51
 
The Nether-
lands 
31 PE 
Central hemo-
dynamic, vascu-
lar, and clotting 
function 
FGR: 26% 
(10-41%) 
IN: formerly 
preeclamptic, 
nondiabetic 
women, preg-
nancy occur-
ring within one 
year after the 
prepregnant 
measurements, 
only ongoing 
singleton 
pregnancies 
(>16 wks) in 
women with-
out preexisting 
hypertension 
Spaanderman 
(2005) 
10
 
The Nether-
lands 
47 PE Plasma volume 
PIH: 51% 
(37-65%) 
PE: 26% 
(13-38%) 
IN: Formerly 
preeclamptic, 
nondiabetic, 
normotensive, 
thrombophlic 
women, ongo-
ing (> 16 wks) 
singleton 
pregnancy 
within one 
year 
Sullivan 
(1994) 
31
 
USA 
 
122 
 
 
HELLP 
 
Class I HELLP (< 
50,000 plate-
lets/μL) 
HELLP: 27% 
(20-34%) 
IN: Previous 
HELLP, et least 
2 year follow-
up, subsequent 
pregnancy 
Trogstad 
(2001) 
15
 
Norway 19970 PE 
Change of 
partner 
PE: 14% 
(14-15%) 
IN:both single-
ton pregnan-
cies with 
deliveries after 
Table 1 continued.
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First author 
(year) 
Country N 
Obstetric 
history 
Prediction test(s) 
Outcome 
subsequent 
pregnancy 
(95%-CI) 
Population 
16 wks of 
gestation 
Trogstad 
(2004) 
16
 
Norway 20285 PE Twin 
PE: 14% 
(13-14%) 
IN: first and 
second deliv-
ery between 
1967 and 1998, 
PE in the first 
pregnancy 
EX: three or 
more fetuses in 
the first preg-
nancy and two 
or more fe-
tuses in the 
second preg-
nancy 
Zhang 
(2001) (26) 
USA 
 
321 
 
 
PIH/PE 
 
Onset of gesta-
tional hyperten-
sion (i.p.) 
PIH/PE: 
24% (20-
29%) 
IN: singleton 
first and sec-
ond pregnancy, 
registered 
before 25 
weeks of 
gestation, with 
at least three 
prenatal visits, 
infants born 
after 25 weeks  
PIH: pregnancy-induced hypertension; PE: preeclampsia; HELLP: hemolysis, elevated liver enzymes and 
low platelets syndrome; FGR: fetal growth restriction; BW: birth weight; IN: inclusion criteria; EX: exclu-
sion criteria; i.p.: index pregnancy; t.p.: target pregnancy. 
Tests based on anthropometric, demographic and behavior related data  
Seven studies evaluated the effect of anthropometric, demographic or behavior 
related variables on the risk of recurrent hypertensive disease in pregnancy. Two 
studies investigated maternal overweigh,19,20 of which one also investigated mater-
nal weight gain19 and one also investigated maternal age.20 Change of partner was 
evaluated in six studies.15, 21-25 All tests mentioned had very low predictive sensitivi-
ties (between 3% and 4%) along with moderate to high predictive specificities (be-
tween 63 and 97%) (table 2). The sensitivity of change of partner as a predictor for 
recurrent PIH/preeclampsia in women, who had a history of PIH/preeclampsia 
Table 1 continued.
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combined with a family history (mother/sister) of hypertensive disease in pregnancy 
was18-24% (table 2).25  
Tests based on the obstetric history  
Predictive accuracy of tests based on obstetric history information was assessed in 
14 studies. Gestational age at the time of diagnosis in the previous pregnancy was 
evaluated in three studies.19,26,27 Three studies evaluated birth weight percentile of 
the previous child as a predictor,28-30 of which one also evaluated absolute birth 
weight.30 Two studies evaluated previous intra-uterine demise.20,28 One study fo-
cused on previous twin pregnancy as a predictor for recurrent disease.16 The predic-
tive capacity of severity of previous disease was investigated in four studies.28,31-33 
Three studies reported on multiparity.34-36 Severity in these studies was expressed 
as HELLP syndrome complicating pregnancy-induced hypertension or preeclampsia, 
very low platelet count in HELLP syndrome, and the degree of proteinuria in preec-
lampsia. One study evaluated the effect of a short pregnancy interval on recurrence 
risk, and three studies the effect of parity on the recurrence risk. The predictive 
sensitivity of most of the factors mentioned was lower than 50% (table 2). Excep-
tions were gestational age at diagnosis predicting recurrent preeclampsia (Se: 75% 
[95%-CI: 55-89%], Sp: 42% [95%-CI: 65-77%]),19 very low platelet count in HELLP 
predicting class I HELLP syndrome (Se: 56% [95%-CI: 23-85%], Sp: 87% [95%-CI: 80-
92%]),31 and multiparity as predictor for preeclampsia after previous PIH (Se: 73% 
[44-92%], Sp: 88% [84-91%]) (table 2).36   
Tests related to vascular resistance, endothelial, clotting and immune functions, 
or uterine blood flow  
Predictive capacity of tests related to placental perfusion and vascular resistance 
was investigated in 14 studies. Predictors evaluated were: high diastolic blood pres-
sure at booking (> 90 mmHg),37 chronic hypertension,38,39 low pre-pregnant plasma 
volume,40,41 declining circulating thromboxane B2 levels in pregnancy,11 circulating 
level of anticardiolipin antibodies,42 angiotensine converting enzyme (ACE) I/D po-
lymorphism,14 human leukocyte antigen (HLA) DR4,43 and Doppler ultrasonogrophy 
of the uterine arteries.28,34,44-46 Overall, predictive sensitivity of chronic hyperten-
sion, serum thromboxane B2 alterations, anticardiolipin antibodies, and HLA DR4 
antigen was low (<50%) (table 2). Better test characteristics were obtained for 
plasma volume (Se: 83% (95%-CI: 51-97%) and Sp: 100% (95%-CI: 90-100%) for re-
current preeclampsia),10 and some uterine artery blood flow velocity parameters 
(table 2). 
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Table 2: Prediction tests found in the literature with (ranges of) predictive sensitivity and specificity 
(95%-confidence interval), summary table. 
Prediction test % Test 
positive 
Sensitivity 
(%) 
Specificity  
(%) 
Obstetric 
history 
Outcome 
Maternal overweight (BMI ≥ 25) 
(19, 20)  
25 
19 
19-32 
29 (23-35) 
19 (11-32) 
29-33 (14-57) 
77 (72-82) 
74 (65-81) 
68-77 (59-83) 
PIH 
PE 
PE 
PIH 
PIH 
PE 
Weight gain (> 2 kg m-2)  
(19) 
 
 
33 
28 
28 
36 (30-43) 
26 (16-39) 
43 (25-63) 
69 (63-74) 
63 (54-72) 
69 (61-76) 
PIH 
PE 
PE 
PIH 
PIH 
PE 
Maternal age (> 35 years) (20) 8 5 (0-26) 91 (84-95) PE PE 
Change of partner (15, 21-25) 18 
26 
3-9 
18 (13-22) 
24 (15-35) 
3-8 (2-10) 
82 (75-87) 
72 (59-82) 
91-97 (90-97) 
PIH 
PE 
PE 
PIH/PE 
PIH/PE 
PE 
Gestational age at diagnosis (< 
34 wks) (19, 26, 27) 
 
 
 
48 
34 
60 
29 
48 (41-54) 
51 (40-63) 
75 (55-89) 
39 (24-55) 
52 (46-58) 
72 (65-77) 
42 (35-50) 
76 (64-85) 
PIH 
PIH/PE 
PE 
E 
PIH 
PIH/PE 
PE 
PE 
Birth weight percentile  
(≤/< p10) (28-30) 
 
 
 
17 
17 
6 
24 
20 (13-30) 
30 (19-43) 
10 (3-28) 
32 (30-43) 
84 (80-87) 
85 (81-88) 
97 (87-99) 
77 (76-78) 
PIH 
PIH 
PIH/PE 
PE 
PIH 
FGR 
PIH/PE 
PE 
Intra-uterine demise (20, 28) 
 
6 
17 
19 (6-43) 
16 (6-35) 
96 (90-98) 
83 (71-91) 
PIH/PE 
PE 
PIH/PE 
PE 
Twin pregnancy (16) 2 1 (0-1)  98 (98-98) PE PE 
HELLP as a complication of 
PIH/PE (28) 
16 21 (9-40) 87 (75-94) PIH/PE PIH/PE 
Class I HELLP (31) 
 
 
16 
16 
16 
16 (9-27) 
25 (14-41) 
56 (23-85) 
85 (75-91) 
88 (80-93) 
87 (80-92) 
HELLP 
HELLP 
HELLP 
PE/HELLP 
HELLP 
Class I 
HELLP 
Proteinuria (≥ 0.5 g/24h) (33) 
 
Proteinuria (> 0.25 g/24h) (32) 
14 
14 
17 
16 (8-28) 
33 (2-87) 
44 (29-58) 
88 (79-94) 
87 (80-92) 
84 (82-86) 
PIH/PE 
PIH/PE 
PE 
PIH 
PE 
PE 
Pregnancy interval ≤ 12 months 
(20) 
16 19 (6-43) 85 (77-99) PE PE 
Multiparity (34-36) 
 
 
 
 
14 
14 
20 
13 
13 
26 (18-36) 
73 (44-92) 
28 (16-44) 
8 (4-16) 
0 (0-44) 
89 (85-93) 
88 (84-91) 
83 (74-90) 
83 (74-90) 
87 (81-91) 
PIH 
PIH 
PE 
E 
E 
PIH 
PE 
PE 
PE/E 
E 
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Prediction test % Test 
positive 
Sensitivity 
(%) 
Specificity  
(%) 
Obstetric 
history 
Outcome 
13 9 (2-32) 87 (80-92) E FGR 
Chronic hypertension (38, 39) 
 
 
 
9-16 
9-16 
9-16 
9 
9 
21-28 (9-35) 
17-25 (1-78) 
26-41 (11-67) 
20 (4-56) 
25 (1-78) 
89-97 (71-99) 
84-92 (86-95) 
93-95 (81-98) 
93 (81-98) 
92 (81-97) 
HELLP 
HELLP 
HELLP 
E 
E 
PE 
HELLP 
FGR 
E 
FGR 
Low plasma volume  
(≤ 49 mL kg lbm-1) (10) 
(≤ 42 mL kg lbm-1) (10) 
(< 228.4 mL kg-1) (41) 
 
64 
21 
28 
 
100 (83-100) 
83 (51-97) 
57 (34-77) 
 
74 (51-89) 
100 (90-100) 
82 (70-90) 
 
PE 
PE 
PE 
 
PIH 
PE 
PE/HELLP 
Angiotensine converting en-
zyme, homozygous ACE D (14) 
35 
35 
53 (29-76)  
52 (33-69) 
69 (58-78) 
72 (60-81) 
PE 
FGR 
PE 
FGR 
Serum thromboxane B2 reduc-
tion (≥ 15 ng mL-1 or ≥ 50%) 
(11) 
23-37 28-36 (17-51) 62-78 (55-83) PE 
PE 
PE 
FGR 
Anticardiolipin antibodies  
IgG or IgM (42) 
3 
3 
3 (1-12)  
6-17 (0-42) 
97-98 (94-99) 
97-98 (94-99) 
PE 
PE 
PE 
FGR 
HLA DR4 antigen (43) 22 39 (20-61) 100 (78-100) PIH/PE PIH/PE 
Doppler blood flow velocity 
profiles 
PI LUA ≥ 2.66 (51) 
PI RUA ≥ 2.33 (51) 
Carotid artery compliance 
coefficient ≥ 1.11 (51) 
Femoral artery compliance 
coefficient ≥ 0.36 (51) 
PI ≥ 1.3 in at least 1 of the 
uterine arteries (28) 
 
Diastolic notch in at least 1 of 
the uterine arteries (28) 
At least 1 PI > 2 SD above the 
mean and/or a diastolic notch 
(34) 
At least 1 PI > 2 SD above the 
mean (34) 
S/D ratio >3.3 or S/D ratio >3.0 
plus diastolic notch (45) 
Resistance index > 0.58 (46) 
 
 
Diastolic notch (46) 
 
 
 
32 
35 
39 
 
58 
 
36 
 
 
24 
 
30 
 
 
16 
 
43 
 
43 
43 
43 
38 
38 
 
 
88 (47-99) 
63 (26-90) 
75 (36-96) 
 
88 (47-99) 
 
45 (28-64) 
 
 
35 (20-55) 
 
49 (34-64) 
 
 
21 (11-36) 
 
100 (46-100) 
 
100 (31-100) 
89 (51-99) 
85 (54-97) 
100 (31-100) 
78 (40-96) 
 
 
87 (65-97) 
74 (42-78) 
74 (42-78) 
 
52 (31-73) 
 
68 (55-79) 
 
 
81 (69-89)  
 
78 (68-86) 
 
 
88 (79-93) 
 
72 (46-89) 
 
60 (46-73)  
66 (51-79) 
70 (54-82) 
66 (52-78) 
70 (55-82) 
 
 
PE 
PE 
PE 
 
PE 
 
PIH/PE/ 
HELLP 
 
PIH/PE/ 
HELLP 
PE 
 
 
PE 
 
PE 
 
PE 
PE 
PE 
PE 
PE 
 
 
FGR 
FGR 
FGR 
 
FGR 
 
PIH/PE 
 
 
PIH/PE 
 
PE 
 
 
PE 
 
PE 
 
PE 
PIH 
FGR 
PE 
PIH 
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Prediction test % Test 
positive 
Sensitivity 
(%) 
Specificity  
(%) 
Obstetric 
history 
Outcome 
 
Resistance index > 0.58 and 
diastolic notch (46) 
38 
14 
14 
14 
85 (54-97) 
33 (2-87) 
22 (4-60) 
46 (20-74) 
77 (61-88) 
87 (74-94)  
87 (74-95) 
95 (83-99) 
PE 
PE 
PE 
PE 
FGR 
PE 
PIH 
FGR 
Multivariable model including 
longitudinal in-pregnancy 
patterns (47) 
28 79 89 PE PE 
PIH: pregnancy-induced hypertension; PE: preeclampsia; E: eclampsia; HELLP: hemolysis, elevated liver 
enzymes and low platelets syndrome; FGR: fetal growth restriction. When a range is presented for pre-
dictive sensitivity or specificity, the confidence interval reported refers to the lowest lower-bound and 
highest upper-bound of the original 95%-confidence intervals. 
 
We identified one study that combined the longitudinal patterns of several va-
riables (parity, age, number of abortions, urea, creatinine, total proteins, uric acid, 
and hematocrit) during the first half of the target pregnancy (from 8 to 20 weeks 
amenorrhea) in formerly preeclamptic women.47 The authors compared the ob-
served value of each marker with an individual ‘theoretical physiological pattern’. 
The match or mismatch to this pattern was included in a logistic regression analysis 
with recurrent preeclampsia later in pregnancy as dependent variable. After an 
internal validation procedure, the predictive sensitivity of the model was 79% (95%-
CI: 64-89%) and the predictive specificity was 89% (95%-CI: 82-93%).  
None of the studies included in this review fulfilled all 12 methodological criteria 
stated. Ten studies met 9, 10, or 11 criteria, 16 studies scored positive on 7 or 8 
criteria, whereas seven studies fulfilled 6 criteria or less. The results of the metho-
dological quality assessment are summarized in figure 1. 
Discussion 
We identified few single predictors in the literature that proved to predict the risk 
of recurrent hypertensive disease in pregnancy with both high predictive sensitivity 
and predictive specificity. Only 3 types of prediction tests had both sensitivity and 
specificity values that were significantly higher than 50%, including: 1) low plasma 
volume predicting PIH or preeclampsia in women with previous preeclampsia,10 2) 
high resistance index (>0.58) and the presence of early diastolic notch in the uterine 
arteries at 24 weeks amenorrhea predicting PIH and FGR after previous preeclamp-
sia,46 and, finally,  3) the multivariable model including longitudinal in-pregnancy 
patterns by Mello et al. predicting recurrent preeclampsia (table 2).47 Although the 
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S y s t e m a t i c  r e v i e w   
 
 
 
35 
predictive capacities of these predictors proved to be reasonable, some aspects 
hamper their clinical relevance and/or generalisability. Low plasma volume, for 
instance, was evaluated in a highly specific study population of formerly preeclamp-
tic women with at least one abnormality in clotting function. A study on plasma 
volume evaluated in a different population of former preeclamptics revealed less 
promising results (table 2).41 Moreover, the method of assessment used (iodine 
125-albumin indicator dilution) is expensive and requires the intravenous adminis-
tration of radioactive material. Less expensive non-radioactive indicators to meas-
ure plasma volume, such as dextran-70, require the same invasive procedure while 
predictive performance still has to be evaluated.  
 
 
0% 20% 40% 60% 80% 100%
Spectrum of patients clearly described?
Selection criteria clearly described?
Prospective data collection?
Def initions of  hypertensive disorders in accordance w ith internationally accepted standards?
At least 90% of the sample received ver ification?
Final diagnosis independent of prediction test?
Execution of  prediction test clearly described?
Timing of  test equal to all subjects?
Test results interpreted w ithout know ledge of f inal diagnosis?
Final diagnosis made w ithout know ledge of  test results?
Uninterpretable test results reported?
Withdrawels explained?
Yes No Unclear
 
Figure 1: Summary of quality assessment. 
 
 
In the report on uterine artery velocimetry by Frusca et al.46 a clear description of 
the population characteristics was lacking, as well as a clear definition of the dis-
orders studied. Furthermore, the investigators failed to specify that the Doppler 
measurements were independent of the final diagnoses. A possible clinical draw-
back of the blood flow velocimetry tests is that the result will follow until well in the 
target pregnancy (24 weeks of gestational age),46 which could be a disadvantage of 
Mello’s logit model as well (20 weeks of gestational age).47  
Besides the predictors mentioned, other variables with reasonable predictive capac-
ity (point estimates of sensitivity and specificity > 50%) were: gestational age at 
diagnosis (< 34 weeks) during the previous predicting recurrent PIH/preeclampsia,26 
previous HELLP with very low platelet count (≤ 50,000/μL) predicting class I HELLP 
C h a p t e r  2  
 
 
 
36 
syndrome,31 multiparity predicting preeclampsia after previous PIH,36 and homo-
zygous ACE D genotype predicting recurrent preeclampsia and FGR (table 2).14 
However, these predictors all had imprecise estimates of predictive sensitivity be-
ing, except for multiparity, about 50% (table 2). Noteworthy, very high specificity 
(100%, 95%-CI: 78-100), but disappointing sensitivity (39% (95%-CI: 20-61%) was 
found for the presence of HLA DR4 antigen predicting recurrent PIH/preeclampsia.43  
Since hypertensive disorders in pregnancy are heterogeneous conditions, probably 
involving several separate pathophysiologic pathways, it is not surprising that pre-
dicting the recurrence of these disorders based on a single variable has been disap-
pointing. While some hypertensive disorders are probably best detected by uterine 
artery Doppler, other forms may be better detected using abnormal levels of circu-
lating markers for endothelial stress. Therefore, it may be more appropriate to 
explore combinations of tests of different categories. In an attempt to do so, Mello 
and others combined the longitudinal patterns of several variables during the first 
half of pregnancy in a logistic regression model to predict recurrent preeclampsia. 
The characteristics of this prediction model are promising, but as mentioned earlier 
the usability of the model is somewhat limited because of its late application (>20 
weeks) and need for repeated measurements in the target pregnancy. Regrettably, 
the cut-off value of the predictive probability used was not described in the report. 
Different clinical manifestations of hypertensive disease of pregnancy are related to 
different pathological pathways. The risk for developing preeclampsia varies de-
pending on the underlying mechanism and the outcome in a previous pregnancy.48 
Increasing clinical homogeneity of the study population could facilitate the selection 
of relevant predictors. Therefore, in addition to combining single predictors, future 
prediction studies should include women with similar types of hypertensive disease 
in their previous pregnancy, e.g. late- or early-onset disease. 
The quality of reporting of all studies included in this review was often suboptimal. 
Only ten studies fulfilled 75% or more of the quality criteria stated. Seven reports 
met only half of the criteria or less. However, not all studies included in this review 
were prediction studies, making some quality criteria less appropriate. Neverthe-
less, complete and accurate reporting is needed to enable readers to assess the 
potential for bias in the study and to evaluate the generalisability of the results. 
Although not completely applicable to predictive studies, tools for the quality as-
sessment of studies of diagnostic accuracy, like QUADAS,7 can serve as helpful 
guidelines in writing a report on prediction tests. Moreover, researchers have de-
veloped a statement to improve the quality of reporting of studies of diagnostic 
accuracy, the STARD statement.  
We believe that it is unlikely that publication bias has affected the overall conclu-
sions of this review. (Small) studies with non-significant or 'negative' results may 
have had a lower probability of being published or being cited by others than stu-
dies with positive findings. As we did not identify strong evidence for the existence 
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of clinically useful prediction tools, adding more negative studies would not have 
changed the picture. Exclusion of reports in other languages then those mentioned 
in the methods section might have had the same effect. After our systematic litera-
ture search, Sibai et al.49 published an article on inhibin A, soluble fms-like tyrosine 
kinase-1 (sFlt-1), and the ratio of sFlt-1 to placenta growth factor measured before 
16 weeks of gestational age as predictors for early-onset preeclampsia (< 27 weeks 
of gestational age). However, the study population consisted of both women with 
previous preeclampsia, chronic hypertension, or both.  
As can be concluded from tables 1 and 2, wide variety existed in the obstetric histo-
ry of the women in the study populations, both prediction tests and thresholds that 
were evaluated, and the outcomes studied. Predictive sensitivity and specificity are 
less responsive to variations in a priori probabilities compared to predictive values. 
We feel that the comparability of predictive performances of the tests would have 
been affected when we would have used predictive values in stead of sensitivity 
and specificity. Furthermore, statistically pooling test characteristics was hampered 
by the same problem of variety. Therefore, we preferred to present prediction data 
more as an overview of available evidence than as summary estimates of test cha-
racteristics. To our knowledge, this is the first systematic review on this topic. Bar-
ton and Sibai (2008)48 provided an update on recently published reports on me-
thods to identify women at risk for recurrent preeclampsia. In this non-systematic 
appraisal, neither test characteristics nor precision of point estimates were eva-
luated.   
In summary, an extensive review of the literature resulted in only a small number of 
predictors with potential to identify women destined to develop recurrent hyper-
tensive disease, i.e. with both satisfying predictive sensitivity and specificity (pre-
pregnant low plasma volume, in-pregnancy uterine-artery Doppler flow velocity 
profiles, and a multivariable model including the longitudinal patterns of several 
variables during the first half of pregnancy). Their clinical usefulness and/or genera-
lisibility were limited however. To increase worldwide applicability of prediction 
tests in clinical practice, predictors should be easily obtainable. Future research on 
prediction tests for recurrent hypertensive disease in pregnancy should focus on a 
combination of parameters in homogenous study populations. The first attempts to 
combine potentially relevant variables have shown potential. 
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Abstract 
Objective: We aimed to develop a clinically useful prediction rule for early-onset 
recurrent preeclampsia or HELLP syndrome that is easy to apply.  
 
Methods: Women with previous early-onset preeclampsia and/or HELLP syndrome, 
enrolled between 1996 and 2007, and a subsequent ongoing pregnancy were in-
cluded. Pre-pregnant cardiovascular, metabolic, renal and clotting parameters were 
evaluated as potential predictors for recurrent disease by logistic regression analy-
sis.   
 
Results: Early-onset preeclampsia and/or HELLP syndrome recurred in 16 (9%) of 
186 next pregnancies. The prediction model included HDL-cholesterol (mmol L-1) 
and 24h urinary total protein excretion (mg mmol-1 creatinine). The Receiver Oper-
ating Characteristic area was 0.77 (95%-CI: 0.68-0.87). Predictive sensitivity and 
specificity were 94% (69-99%) and 53% (45-60%), respectively. Near 50% of the 
women could be classified as having <1% risk of recurrent early-onset disease.  
 
Conclusion: The prediction rule identified, with clinically relevant predictive capaci-
ty, those women at very low risk for recurrent early-onset disease. 
P r e c o n c e p t i o n  p r e d i c t i o n  r u l e   
 
 
 
43 
Introduction 
The pregnancy-induced hypertensive disorders, preeclampsia (PE) and the syn-
drome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP), affect 2-7% 
of all pregnancies in nulliparous women.1 Although the aetiology is only partly un-
derstood, there is general agreement that the placenta plays a central role in the 
pathogenesis and that dysfunctional endothelium triggers the typical clinical symp-
toms. In most nulliparous women the disease develops near term with limited unfa-
vourable impact on pregnancy outcome.1 However, approximately 10% of the cases 
have early-onset disease severe enough to require early pregnancy termination, 
which is related to serious maternal and/or foetal sequels.1 
Despite marked improvements in perinatal care in recent decades, the incidence of 
hypertensive complications of pregnancy has not decreased. Prevention has fo-
cused on early identification of women at increased risk.2 Although this approach 
does not prevent the development of hypertensive pregnancy complications, it 
enables adaptation of intensity of follow-up to the expected probability of recurrent 
disease.   
In the last two decades, various screening methods have been considered with 
respect to their ability to identify women at risk for hypertensive pregnancy compli-
cations. Most studies were aimed at assessing the predictive performance of a sin-
gle parameter, in nulliparous women.3 Parous women with a history of hypertensive 
complications constitute a patient group far less studied for this purpose. In these 
women, the recurrence rate has been reported to be up to 50%,4 depending on 
definitions for onset and severity of the disease. Since hypertensive disorders in 
pregnancy are heterogeneous conditions, probably involving several separate pa-
thophysiologic pathways, it is not surprising that predicting the recurrence of these 
disorders based on a single variable has been disappointing. It may be more appro-
priate to explore combinations of variables.   
This study was designed to develop a prediction rule evaluating multiple prepreg-
nant potential predictors, instead of using a single factor, to predict recurrent early-
onset preeclampsia and/or HELLP syndrome in the next pregnancy. We aimed to 
develop a simple tool that could identify all prospective cases of recurrent early-
onset hypertensive disease, and simultaneously designate a considerable fraction of 
patients as test-negative. To this end, cardiovascular, metabolic, renal, and clotting 
parameters were combined with demographic variables and obstetric-history in-
formation in 186 women with a first pregnancy complicated by early-onset 
PE/HELLP.  
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Methods 
Women with a hypertensive complication during their previous pregnancy (the 
index pregnancy), who were referred to our tertiary referral centre from June 1996 
onwards were screened for eligibility. They were referred for the detection of asso-
ciated disorders and for counseling prior to a possible future pregnancy. We ex-
cluded women who were multiparous, had no previous early-onset preeclampsia or 
HELLP syndrome (diagnosed before or at 34 weeks and resulting in delivery before 
or at 37 weeks amenorrhea), and/or no subsequent ongoing (> 20th pregnancy 
week) singleton pregnancy resulting in delivery before December 2007. The catch-
ment area of the university hospital was the Province of Limburg with 10,000-
12,000 births per year during the study period, of which approximately half were 
first births. 
Preeclampsia was defined in accordance with the criteria of the International Socie-
ty for the Study of Hypertension in Pregnancy (ISSHP),5 as de novo hypertension 
(blood pressure > 140/90 mmHg, occurring after 20 weeks’ gestation) accompanied 
by proteinuria (≥ 300 mg in a 24-hour urine sample). Preeclampsia superimposed on 
chronic hypertension was defined as new-onset proteinuria (≥ 300 mg in a 24-hour 
urine sample) after 20 weeks’ gestation or a sudden increase in proteinuria or blood 
pressure in women whose hypertension had previously been well controlled.5 The 
HELLP syndrome was defined in accordance with criteria suggested by Sibai et al., as 
the combination of haemolysis (evidence on peripheral blood smear, serum biliru-
bin > 20 μmol.L-1 and serum LDH level > 600 IU.L-1), elevated (≥ 70 IU.L-1) serum 
aspartate amino-transferase (ASAT) and/or alanine aminotransferase (ALAT) and a 
low platelet count (< 100x109.L-1).6 The initial diagnosis in the index pregnancy was 
made by the patient’s own obstetrician and later verified by an expert (LP) based on 
the definitions described above. The onset of complications was considered early if 
the diagnosis had been made before or at 34 weeks amenorrhea and pregnancy 
duration was shorter than or equal to 37 weeks. A small-for-gestational-age (SGA) 
infant was defined as a child with a birth weight below the 10th percentile accord-
ing to the most recent Dutch birth weight reference curves.7 
The main outcome measure in this study was recurrent early-onset (superimposed) 
preeclampsia and/or HELLP syndrome. We obtained information on course and 
outcome of the ‘target pregnancy’ using a short standardized questionnaire. Where 
possible this was supplemented with information deduced from correspondence by 
the patient's own obstetrician. To reduce loss-to-follow-up, non-respondents were 
contacted by telephone. In the event of change of address, the patient’s general 
practitioner was contacted to obtain new contact details. During the target preg-
nancy, all women used low-dose aspirin (80 mg/dL) from 12 until 37 weeks.  
In order to detect associated disorders and for counseling purposes, a diagnostic 
work-up has been performed routinely in our tertiary referral centre since 1996, 
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The work-up is performed at least six months after the index pregnancy. Most po-
tential predictors evaluated in this study were derived from this post partum evalu-
ation. After an overnight fast, a blood sample was collected to assess the following 
laboratory variables using standardized techniques: circulating levels of calcium, 
urea, creatinine, ASAT, ALAT, fasting glucose and insulin, platelet count, haemoglo-
bin, haematocrit, high-sensitivity C-reactive protein (hs-CRP), free thyroxine 4, thy-
roid stimulating hormone, total cholesterol, high- and low-density lipoproteins and 
triglycerides. Clotting factors assessed were fibrinogen, antithrombin, proteins S 
and C activity, activated protein C resistance, protrombin G20210A and Factor V 
Leiden mutations. “Thrombophilia” was diagnosed on the basis of 1) being at least 
heterozygous for the Factor V Leiden or the prothrombin G20210A mutation and/or 
2) a detected protein C, S (antigen) and/or antithrombin deficiency, activated pro-
tein C resistance, and/or the presence of lupus anticoagulant. Detectable circulating 
anticardiolipine antibodies (IgG and IgM) were measured at two occasions with an 
interval of at least six weeks. A 24-h urine sample, collected on the preceding day, 
served to determine the excretion of total protein, calcium, micro-albumin and 
creatinine. Furthermore, the homocysteine metabolism was assessed by performing 
a methionine loading test. Hyperhomocysteinemia (HHC) was diagnosed on the 
basis of either the starved or the post-loading homocysteine level being more than 
2 SD above the mean of a normal population of middle-aged women (>15 mmol/L 
and >55 mmol/L, respectively).8 Women diagnosed with HHC were supplemented 
with folic acid (5 mg daily) and vitamin B6 (20 mg daily). We monitored the blood 
pressure (systolic, diastolic and mean arterial pressure) for 30 minutes in standar-
dized conditions using a semiautomatic oscillometric device. A patient was consi-
dered to have chronic hypertension when during these 30 minutes, her median 
systolic blood pressure was ≥ 140 mmHg and/or her median diastolic blood pres-
sure was ≥ 90 mmHg, or when her physician prescribed antihypertensive medica-
tion.9 Demographic variables considered as potential predictors were age, body 
mass index (BMI), overweight, and obesity, which were assessed during the post 
partum evaluation as well. Obstetric history information included the number of 
spontaneous abortions, sex and birth weight of the first child, the first child being 
small-for-gestational-age (<p10), intra-uterine demise, amenorrhea at the time of 
diagnosis of preeclampsia or HELLP syndrome, and the occurrence of eclamptic 
seizures. After the post partum evaluation the women were informed about de-
tected abnormalities and the possible consequences of abnormal findings for 
course and management of a next pregnancy. In none of the women enrolled in this 
study, a future pregnancy was discouraged. 
We excluded variables with more than 25% missing values from the pool of candi-
date predictors. The number of candidate predictors was further reduced by exclud-
ing those variables with a p-value above 0.10 in univariate logistic regression analy-
sis on complete cases. Missing values of the remaining variables were imputed. 
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Imputation was based on a multivariable single imputation regression procedure.10 
Collinearity was indicated by a tolerance value below 0.10 (or clearly different from 
the others). In case of collinearity the variable that was most commonly used in 
medical practice was preferred. By means of backward logistic regression analysis 
(based on likelihood ratio tests) we developed a model to predict recurrent early-
onset preeclampsia and/or HELLP syndrome. This analysis begins with a full model 
and variables are eliminated from the model in an iterative process. For model fit-
ting we used chi-square tests, Hosmer and Lemeshow Goodness-of-Fit tests, and we 
reported Nagelkerke’s R-squares. The prognostic ability of the models to discrimi-
nate between women with and those without recurrent early-onset disease was 
estimated by means of Receiver Operating Characteristics (ROC) analysis. As quan-
titative indicators of test performance the area under the ROC curve (AUC), predic-
tive sensitivity (Se) and specificity (Sp), predictive values (PV), likelihood ratios (LR), 
and diagnostic odds ratios at different cut-off points were reported with corres-
ponding 95% confidence intervals.11  To adjust for the often too optimistic estimate 
of the predicted performance (AUC) in the derivation study, a standard bootstrap-
ping procedure was used.12 The regression model was estimated in 200 bootstrap 
samples. The 200 models derived from the bootstrap procedure were each eva-
luated in the bootstrap sample and in the original sample. The average difference in 
AUC between the bootstrap sample and the original sample was determined in 
order to indicate the optimism in the initially estimated discriminative ability. All 
analyses were performed using Stata/IC 10.0 for Windows.  
Results 
Of the 701 women with a hypertensive complication during their previous pregnan-
cy, 376 women were primiparous and had had early-onset preeclampsia and/or 
HELLP syndrome. The response rate to the questionnaires concerning the target 
pregnancy was 96% after having contacted the non-responders by telephone. Of 
these women, 186 established a second pregnancy leading to birth before Decem-
ber 2007 (figure 1).  
All women were Caucasian. Mean (± SD) maternal age was 28.6 (± 4.4) years at first 
delivery (table 1). Duration of first pregnancy was 31 (± 3) weeks on average and 
152 (82%) pregnancies resulted in delivery before 34 weeks of gestational age. Of 
the infants 118 (25%) were born small for gestational age (<p10) and the mean (± 
SD) birth weight was 1318 (± 599) g.  Mean maternal BMI was 25 (± 4) kg/m2, with 
13% of the women being obese (BMI > 30 kg/m2). In the study population we also 
encountered the following conditions: chronic hypertension (23%), HHC (19%), 
detectable antiphospholipid antibodies (18%) and thrombophilia (16%). The mean 
interval between the first and second delivery was 3.1 (± 1.7) years. 
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Subsequent ongoing 
singleton pregnancy 
(n=186) 
Women with hypertensive 
disease in their previous 
pregnancy 
(n=701)  
Primiparous women with 
a history of early-onset 
PE/HELLP 
(n=376) 
Multiparae  
(n=133) 
no previous early-onset 
PE/HELLP  
(n=191)  
Missing data  
(n=1) 
 
Lost to follow-up  
(n=15) 
No subsequent pregnancy 
(n=170) 
Missing data on outcomes 
(n=4) 
Herpes infection  
(n=1) 
Recurrent early-onset 
PE/HELLP 
(n=16) 
Late-onset PE/HELLP 
(n=29) 
No PE/HELLP 
(n=141) 
Figure 1: Details on patients selected for the study and their outcome. 
 
In their next pregnancy 16 (9%) women had recurrent early-onset preeclampsia 
and/or HELLP syndrome, and 29 (16%) had late-onset disease (table 2). Recurrence 
was accompanied by the delivery of an SGA infant in 3 (19%) cases with early-onset 
disease and in 5 (17%) cases with late-onset disease. Of the women without recur-
rent disease 19 (10% of total N) gave birth to an SGA infant and 50 (27%) had iso-
lated gestational hypertension. Pregnancy was uneventful in 72 women (39%) (table 
2).  
The variables that we excluded from statistical analysis because insufficient (< 75%) 
data were available were: circulating levels of free thyroxine 4, thyroid stimulating 
hormone, activated protein C resistance, high-sensitivity C-reactive protein (hs-CRP) 
and prothrombin 20210A mutation. After univariate analysis of the remaining va-
riables the following were selected as candidate predictors for recurrent early-onset 
preeclampsia and/or HELLP syndrome and were thus included in further analysis: 
maternal age, circulating level of high-density lipoproteins (HDL), the ratio of HDL to 
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low-density lipoproteins (LDL) and 24-h urinary protein excretion (ratio of total 
protein to creatinine).  
 
Table 1: Clinical characteristics of 186 women and their first pregnancies, which were complicated by 
early-onset PE/HELLP.  
Age at delivery (years) ± sd 28.6 ± 4.4 
Preeclampsia complicated by HELLP syndrome 120 (65%) 
Preeclampsia without HELLP syndrome 47 (25%) 
Isolated HELLP syndrome  22 (12%) 
Gestational age at delivery (weeks) ± sd 31 ± 3 
Delivery ≤ 34 weeks of gestational age 152 (82%) 
SGA infant (<p10) 118 (25%) 
Birth weight (g) ± sd 1318 ± 599 
Maternal BMI (kg/m2) 25 ± 4 
Obesity (BMI > 30 kg/m2) 25 (13%) 
Chronic hypertension 43 (23%) 
Hyperhomocysteïnaemia 35 (19%) 
Anti-phospholipid antibodies  18 (10%) 
Thrombophilia§ 30 (16%) 
Maternal BMI, obesity, chronic hypertension, hyperhomocysteinemia, anti-phospholipid antibodies and 
thrombophilia were assessed during the post partum evaluation. § At least 1 test positive. SGA: small for 
gestational age (birth weight < 10th percentile), BMI: body mass index 
 
 
Less than 1% of the required data were imputed because of missing values. Colli-
nearity was indicated between HDL cholesterol and the ratio of HDL to LDL choles-
terol. We preferred the level of HDL as a predictor because of simplicity (only one 
variable had to be assessed) and better predictive performance. 
By backward analysis the following model was developed (see also table 3): 
Table 2: Hypertensive complications in 186 second pregnancies after previous early-onset PE/HELLP.  
Early-onset PE/HELLP, of which 
- PE and HELLP 
- PE without HELLP 
- HELLP without PE 
 
- SGA infant (<p10) 
- Normal birth weight (≥p10) 
16 (9%) 
11 (79%) 
4 (25%) 
1 (6%) 
 
3 (19%) 
13 (81%) 
Late-onset PE/HELLP, of which 
- PE and HELLP 
- PE without HELLP 
- HELLP without PE 
 
- SGA infant (<p10) 
- Normal birth weight (≥p10) 
29 (16%) 
6 (21%) 
20 (69%) 
3 (10%) 
 
5 (17%) 
24 (83%) 
SGA infant (<p10), no PE/HELLP 19 (13%) 
Isolated gestational hypertension 50 (27%) 
Uneventful pregnancy 72 (39%) 
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Predicted probability = 1 / [1 + e – (1.37 – 3.23 * HDL + 0.09 * P/C)] 
 
In this equation, HDL represents circulating level of high-density lipoproteins (mmol 
L-1) and P/C the protein to creatinine ratio in 24-h urine collection (mg protein / 
mmol creatinine).  
 
Table 3: Logistic regression model with recurrent early-onset PE/HELLP as dependent variable. 
Predictor β SE β Wald’s χ2 df p 
Constant 1.37 1.21 1.13 1 0.26 
HDL (mmol∙L-1) -3.23 1.05 -3.07 1 0.00 
P/C ratio (mg/mmol) 0.09 0.04 2.19 1 0.03 
Test   χ2 df p 
Overall model evaluation: 
Likelihood ratio test 
   
15.22 
 
2 
 
0.00 
Goodness-of-fit test: 
Hosmer & Lemeshow 
   
111.6 
 
8 
 
0.99 
Nagelkerke R2 = 0.14. HDL: circulating level of fasting high density lipoprotein cholesterol, P/C ratio: 24h 
urinary total protein excretion in mg per mmol creatinine 
 
The area under the ROC curve was 0.77 (95% CI: 0.68– 0.87) (fig. 2). The bootstrap-
ping procedure yielded an optimism in the apparent performance of 0.02, resulting 
in an internally validated ROC area of 0.75. Table 4 shows model characteristics with 
different thresholds for the predicted probability. If the threshold was set to 0.05, 
the predictive sensitivity (Se) and specificity (Sp) were 94% (69-99%) and 53% (45-
60%), respectively. Positive and negative likelihood ratios were 1.99 (1.62-2.44) and 
0.12 (0.02-0.79), respectively. The positive predictive value was 16% (9-24%) and 91 
(49%) women would be test negative with a predictive value (PV-) of 99% (94-99%). 
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Figure 2: Receiver Operating Characteristics curve for recurrent early-onset preeclampsia/HELLP. 
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Discussion 
Women who had hypertensive disease in a previous pregnancy are known to be at 
increased risk for recurrent disease. In many Western countries this awareness has 
led to intensified care of pregnant former patients relative to that of their counter-
parts with a history of uneventful pregnancies only. The objective of this intensified 
care is secondary prevention. A considerable proportion of previous patients, how-
ever, will not develop (severe) recurrent hypertensive disease. Therefore, a predic-
tion test would be of great benefit if it would enable the identification of those 
women with a low recurrence risk, e.g. a risk comparable to that of “healthy” nul-
liparae. The care provided to these women may be adjusted to the level of regular 
low-risk care. This could reduce health care expenses substantially without com-
promising on quality of care.   
From that point of view, a clinically relevant screening tool for recurrent hyperten-
sive disease should be highly sensitive (identifying the cases who will actually de-
velop recurrent disease) with a large proportion of negative test results. Preferably, 
risk prediction is established before or in early pregnancy. 
We developed a simple pre-pregnant prediction rule for recurrent early-onset pre-
eclampsia and/or HELLP syndrome that includes the circulating level of starved HDL-
cholesterol and the 24-h urinary protein/creatinine ratio. Cut-off values can be 
varied as for different purposes. With a cut-off value of the predicted probability of 
0.05, almost half (49%) of the population of former patients could be classified as 
being at low risk (<1%) for recurrent early-onset disease. Especially early-onset 
preeclampsia and HELLP syndrome are related to an increased risk of adverse ma-
ternal and perinatal outcome. It predisposes to potentially lethal complications, 
such as eclampsia and placental abruption and is associated with a higher rate of 
small-for-gestational-age infants.13 
 
Table 4: Test characteristics of the prediction rule (95%-CI) at different cut-off points of the predicted 
probability (P). 
P ≥ Se Sp +PV -PV LR+ LR- DOR 
% neg. 
test results 
0.04 
100 
(79-100) 
45 
(37-52) 
15 
(8-22) 
100 
(95-100) 
1.80 
(1.57-2.07) 
0.00 
(0-NaN) 
NaN 41 
0.05 
94 
(69-99) 
53 
(45-60) 
16 
(9-24) 
99 
(94-99) 
1.99 
(1.62-2.44) 
0.12 
(0.02-0.79) 
17 49 
0.06 
88 
(61-98) 
55 
(46-62) 
15 
(8-24) 
98 
(92-99) 
1.93 
(1.50-2.47) 
0.23 
(0.06-0.84) 
10 51 
0.07 
75 
(47-92) 
68 
(60-74) 
18 
(9-29) 
97 
(91-99) 
2.31 
(1.62-3.31) 
0.37 
(0.16-0.86) 
6 64 
Se: sensitivity, Sp: specificity, +PV: positive predictive value, -PV: negative predictive value, +LR: positive 
likelihood ratio, -LR: negative likelihood ratio, DOR: diagnostic odds ratio 
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In accordance with previous reports, our data show that the outcome of a next 
pregnancy in women with previous early-onset preeclampsia/HELLP is more favour-
able than that of the prior complicated pregnancy.14 Relative to the first pregnancy, 
mean duration of the next pregnancy was 7.5 weeks longer and mean birth weight 
1778 g higher. The birth weight criterion for referral to the neonatal intensive care 
unit in the Netherlands is < 1250 g. Of previous pregnancies, 53% resulted in deliv-
ery of an infant with birth weight below this treshold, against only 2% of the subse-
quent pregnancies. Nevertheless, preeclampsia and/or the HELLP syndrome re-
curred in about one-fourth of our study population, in line with previous findings.13  
Although 75% of our study population had the HELLP syndrome during their previ-
ous pregnancy, the recurrence rate of this syndrome was relatively low (11%), an 
observation also reported by others.15  
Previous attempts have been made to predict the risk of recurrent disease in former 
preeclamptic or HELLP syndrome patients, often with disappointing test perform-
ances. Most of these studies focused on single parameters. Among them, parame-
ters related to uterine artery Doppler blood flow velocity profiles might be promis-
ing in the prediction of recurrent preeclampsia. An elevated systolic/diastolic ratio 
(>3.3 or >3.0 combined with a diastolic notch) at 18 weeks of gestational age,16 
increased resistance index (>0.58),17 and the presence of a diastolic notch17 at 24 
weeks of gestational age each predicted recurrent preeclampsia with a sensitivity of 
100%. The specificity was moderate (72%, 60% and 62%, respectively) and 57% of 
the women had negative test results. However, the confidence intervals around the 
estimated sensitivities were quite large and by the time the prediction results had 
been obtained the women were already 4-6 months pregnant. The latter limits the 
possibility of reducing intensity of follow-up during the target pregnancy in test-
negative women.  
Since hypertensive disorders in pregnancy are heterogeneous conditions, probably 
involving several separate pathophysiologic pathways, it is not surprising that pre-
dicting the recurrence of these disorders based on a single variable has been disap-
pointing. Mello and others18 combined the longitudinal patterns of several variables 
during early pregnancy (until 20 weeks) in a logistic regression model to predict 
recurrent preeclampsia. The characteristics of this prediction model showed poten-
tial (Se and Sp were 79% and 89%, respectively), but again the usability of the 
model to reduce intensity of care is limited because of its late application (>20 
weeks) and repeated measurements are needed in the target pregnancy. 
Obviously, the management of next pregnancies in this study may have ameliorated 
the outcome, an effect that could limit the applicability of the model to other popu-
lations, in which management is different. This effect probably only concerns non-
uniformly supported treatments such as low molecular weight heparins (LMWH), 
which we prescribed to about half of the women with thrombophilia (7% of the 
population). These women were equally distributed among the two outcome 
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groups (p=0.721).  Moreover, most women in this study started to use multivitamin 
supplements as per advice before or during the target pregnancy, including the 
women with hyperhomocysteinemia. Another aspect that could hamper the validity 
of the model in future applications is the selection of the study population based on 
the presence of a subsequent pregnancy. If the composition of the study population 
in terms of clinical characteristics is to change, whether or not caused by tests re-
sults of the current prediction rule, this could influence the predictive capacity of 
the model. Therefore, it is important to update the prediction rule regularly.  
Prediction models generally tend to perform better in the patients that provided 
the input for the model (derivation cohort) than on new patients. However, internal 
validation by means of bootstrapping techniques showed that over-optimism is 
limited in the present prediction model. Before introducing the prediction rule in 
daily practice, it should be evaluated and, if necessary, updated in a new compara-
ble population (external validation).19 
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Abstract 
Objective: In this study we tested the hypothesis that not obesity, but the asso-
ciated metabolic abnormalities predispose to recurrent preeclampsia.  
 
Methods: In this observational study, we used hospital data collected between 
1996 and 2008 of 196 women with two consecutive pregnancies, the first pregnan-
cy being complicated by early-onset (diagnosis ≤ 34 weeks, delivery ≤ 37 weeks) 
preeclampsia. After this index pregnancy, all women were screened for underlying 
abnormalities. Using these screening data, we estimated the association between 
obesity (body mass index ≥ 30 kg/m2) and recurrent preeclampsia by logistic re-
gression analysis, controlling for potential confounders (maternal age, inter-
pregnancy interval, thrombophilia, plasma volume, creatinine clearance rate) and 
metabolic syndrome (MetS) related abnormalities defined according to the Interna-
tional Diabetes Federation (triglycerides, HDL-cholesterol, blood pressure, fasting 
plasma glucose).  
 
Results: Overall, 49 (25%) women developed recurrent preeclampsia. The odds 
ratio for recurrent disease in obese (n = 28) versus non-obese (n = 168) women was 
2.5 (95%-CI: 0.9-6.4) after adjustment for confounders. However, after additional 
correction for the presence of the four MetS-constituting parameters, the odds 
ratio was 1.1 (0.4-3.2). By contrast, the odds ratio in women with two or more crite-
ria of the metabolic syndrome versus none was, independent of obesity, 3.8 (1.4-
10.2). 
 
Conclusion: Our results indicate that metabolic abnormalities rather than obesity 
predispose to recurrent preeclampsia. Meeting at least two MetS criteria, irrespec-
tive the presence of obesity, is associated with an increased risk for recurrent dis-
ease. Therefore, in preconceptional counseling of obese women, besides weight 
reduction the components of the metabolic syndrome deserve at least as much 
attention. 
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Introduction 
Obesity is a widely established risk factor for preeclampsia,1 although the mechan-
isms involved are only partially understood. Obesity is associated with hyperten-
sion, chronic inflammation and metabolic abnormalities such as insulin resistance 
and dyslipidemia.2,3 In pregnancy, all these abnormalities may affect placental 
growth and development.4 It is conceivable that these metabolic abnormalities, 
rather than obesity itself, predispose to preeclampsia. 
In clinical practice, obesity is considered an independent risk factor for preeclamp-
sia. Women with a history of preeclampsia are often counseled for recurrent dis-
ease prior to their next pregnancy.3 One objective in preconceptional counseling is 
to reduce modifiable risk factors.5 In obese former preeclamptics, the latter usually 
consists of strategies to promote weight loss. However, if the association between 
obesity and preeclampsia is weaker than the one between underlying metabolic 
abnormalities and preeclampsia, counseling should focus on improvement of these 
abnormalities rather than on advocating weight loss solely. 
Cardiovascular sequels of preeclampsia have prompted a search for a common 
mechanism or predisposing factors. A spectrum of metabolic disorders, known as 
metabolic syndrome (MetS), has been posited as an important connection between 
preeclampsia and cardiovascular disease in later life.6-11 Women with a history of 
preeclampsia frequently exhibit features of MetS.12,13  
The aim of this study was to test the hypothesis that metabolic abnormalities rather 
than obesity itself predispose to recurrent preeclampsia. To this end, we deter-
mined the independent contribution of both obesity and MetS components to the 
recurrence risk of preeclampsia.  
Methods 
This is an observational study performed at Maastricht University Medical Centre in 
the Netherlands. Women with a recent history of preeclampsia are referred to our 
tertiary referral center for the detection of underlying disorders or abnormalities, 
and for counseling prior to their next pregnancy. All measurements reported in this 
study had been obtained as part of the usual care provided to high-risk obstetrical 
patients. It follows that, although observations had been collected prospectively, 
the collection of the data was done retrospectively. All hospital data, including 
those on pregnancy outcome, were collected and entered in a database by a clinical 
research assistant who was not involved in the statistical analysis. Prior to analysis, 
data were anonymized. In the Netherlands, ethical approval of a study based on 
anonymized data originating from clinical care, is not required.  
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For the purpose of this study, we screened women who had had early-onset preec-
lampsia (diagnosed ≤ 34 weeks pregnancy and resulting in delivery ≤ 37 weeks), 
referred from June 1996 onwards, for eligibility (N = 444). We excluded women who 
were multiparous at the time of referral, had no subsequent ongoing (> 20 weeks of 
pregnancy) singleton pregnancy resulting in delivery before December 2008, were 
lost-to-follow up, or had missing data on metabolic variables leading to failure in 
defining MetS.   
 
 
Women who had early-onset 
preeclampsia in previous 
singleton pregnancy 
(N = 444) 
Multiparous (n = 59) 
No subsequent singleton pregnancy (n = 167) 
Lost-to-follow up (n = 15) 
Missing metabolic data (n = 7) 
Women with two consecutive 
singleton pregnancies, of which at 
least the first one was 
preeclamptic 
(N = 196) 
 
Recurrent 
preeclampsia in 
second pregnancy 
(n = 49) 
 
No preeclampsia 
in second 
pregnancy 
(n = 147) 
  
Figure 1: The selection of the study population. 
 
We defined preeclampsia according to the guidelines of the National working group 
on High Blood Pressure in Pregnancy, as new-onset hypertension (blood pressure > 
140/90 mmHg, occurring after the 20th week of pregnancy) accompanied by prote-
inuria (> 300 mg/24h or > 30 mg/mmol creatinine).12 Preeclampsia superimposed 
on chronic hypertension was defined as new-onset proteinuria after 20 weeks’ 
gestation. Late-onset preeclampsia was defined as preeclampsia diagnosed after 34 
weeks pregnancy and/or resulting in delivery after 37 weeks. We used a birthweight 
below the 10th percentile, based on the most recent Dutch birthweight reference 
curves, to diagnose fetal growth restriction. Although screening data were collected 
in our medical center, the location of delivery in the next pregnancy could be in 
other Dutch hospitals, giving rise to variation in diagnostic methods for preeclamp-
sia. For example, the diagnosis of proteinuria was based on a 24-hours urine collec-
tion in some hospitals and on the ratio protein to creatinine in others. In the data-
base available for statistical analysis, women were coded as having had or not hav-
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ing had a next pregnancy complicated by preeclampsia, according to the definition 
described above. Individual in-pregnancy laboratory values were not supplied.  
The screening – at least six months postpartum – also included the measurement of 
metabolic variables. Serum concentrations of triglycerides (TG), total cholesterol 
(TC) and HDL-cholesterol (HDL-C) were determined on a Beckman Coulter LX20 PRO 
Clinical Chemistry analyzer (Beckman Coulter, Fullerton, USA). We calculated low-
density lipoprotein cholesterol (LDL-C) by the Friedewald equation.13 Fasting levels 
of glucose and insulin were assessed using standard laboratory techniques. Body 
length and weight were determined in a standardized fashion. We obtained body 
mass index (BMI) by taking the ratio of weight (kg) and height (cm) squared. We 
defined (central) obesity as BMI ≥ 30 kg/m2. 
The MetS was defined in accordance with the ‘new worldwide definition (2006)’ of 
the International Diabetes Federation, as central obesity with at least two of the 
following criteria: raised triglycerides (≥ 1.7 mmol/L; 150 mg/dL) or specific treat-
ment; reduced HDL-cholesterol (<1.29 mmol/L; 50 mg/dL) or specific treatment; 
raised blood pressure (≥ 130/85 mmHg) or specific treatment; and raised fasting 
plasma glucose (> 5.6 mmol/L; 100 mg/dL) or type II diabetes mellitus.14 
We adjusted the association estimated for a range of maternal conditions and cha-
racteristics, including thrombophilia, plasma volume, creatinin clearance rate, ma-
ternal age, and inter-pregnancy interval. Within the scope of the thrombophilic 
screening, all women had been tested for anticardiolipin antibodies (IgG/IgM > 10 
GPL/MPL) and lupus anticoagulant in peripheral blood, as detailed previously.15 The 
fasting circulating level of homocysteine had been assessed and was considered 
elevated when levels exceeded 15 µmol/L. The factor V Leiden and prothrombin 
20210A mutations had been analyzed by routine PCR techniques after extraction of 
genomic DNA from peripheral leukocytes. Activity of antithrombin (Chromogenix, 
Molndal, Sweden) and protein C (Behring, Marburg, Germany) had been measured 
by chromogenic substrate assays, and protein S antigen levels by enzyme-linked 
immunosorbent assay (ELISA; DAKO, Glostrup, Denmark). We defined deficiency of 
each of these parameters as an activity level below 65% of normal. For the statistic-
al analysis, we created a dichotomous thrombophilic variable that was positive 
when at least one of the following conditions were present: Factor V Leiden muta-
tion, prothrombin 20210A mutation, deficiency of antithrombin AT III, protein C or 
protein S, increased level of fasting homocystein, or positive tests for anticardiolipin 
antibodies or lupus anticoagulant. We quantified plasma volume by the indicator 
dilution technique using 125I - labeled albumin (125I-HSA) as indicator, as detailed 
previously.15 We measured creatinine both in a 24-hour urine sample and in the 
peripheral blood. As an estimate for the glomerular filtration rate, we calculated the 
volume of blood plasma that is cleared of creatinine per unit time (creatinine clear-
ance rate).  
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We used SPSS version 15.0.0 for statistical analysis. In a multiple logistic regression 
model, we estimated the odds ratio (OR) for recurrent preeclampsia in obese wom-
en adjusted for the potential confounders described above. In a second regression 
model, we further adjusted the OR for the metabolic components of the MetS: HDL-
cholesterol, triglycerides, mean arterial pressure (calculated as [(2 x diastol-
ic)+systolic] / 3) and fasting glucose. A third regression model included the presence 
or absence of the MetS instead of obesity as an independent variable, to estimate 
its association. Based on the cut-off values defined for the MetS components, we 
created a variable with three categories: 1) no metabolic criteria fulfilled, 2) one 
metabolic criterion fulfilled and 3) two or more metabolic criteria fulfilled, irrespec-
tive the presence or absence of obesity. We added this variable to a fourth regres-
sion model, which additionally included obesity and the confounders described to 
estimate the association between the presence of these metabolic abnormalities 
and recurrent preeclampsia, independent of obesity. In this fourth model, we also 
tested for interaction between BMI and the number of MetS components. We re-
ported ORs with 95%-confidence intervals (95%-CI).  
 
Table 1: Demographic and clinical characteristics of the study population.  
 Overall 
(N = 196) 
Obese women 
(n = 28) 
Non-obese women 
(n = 168) 
Maternal age (y) 30.0 ± 3.6 29.6 ± 3.6 30.1 ± 3.6 
Body weight (kg) 71.8 ± 13.8 94.5 ± 12.6 68.0 ± 9.8 
Body length (cm) 168 ± 6 167 ± 7 169 ± 6 
Weight class: 
Underweight (BMI < 20) 
Normal weight (BMI 20-25) 
Overweight (BMI 25-30) 
Obesity (BMI 30-35) 
Morbid obesity (BMI > 35) 
 
16 (8%) 
90 (46%) 
62 (32%) 
18 (9%) 
10 (5%) 
 
- 
- 
- 
18 (64%) 
10 (36%) 
 
16 (10%) 
90 (54%) 
62 (37%) 
- 
- 
Fasting glucose (mmol/L) 5.1 ± 0.5 5.4 ± 0.4 5.1 ± 0.5 
Fasting insulin (mmol/L) 11.9 ± 6.2 18.9 ± 7.5 10.8 ± 5.2 
Total cholesterol (mmol/L) 4.9 ± 0.9 5.1 ± 0.9 4.9 ± 0.9 
HDL-cholesterol (mmol/L) 1.37 ± 0.35 1.13 ± 0.30 1.41 ± 0.34 
LDL-cholesterol (mmol/L) 3.1 ± 0.8 3.3 ± 0.7 3.1 ± 0.8 
Triglyceride (mmol/L) 1.1 ± 0.8 1.64 ± 0.81 0.99 ± 0.74 
Systolic blood pressure 
(mmHg) 
122 ± 13 126 ± 15 122 ± 13 
Diastolic blood pressure 
(mmHg) 
76 ± 11 77 ± 9 75 ± 12 
Mean arterial pressure (mmHg) 93 ± 11 96 ± 12 93 ± 11 
Chronic hypertension  71 (36%) 12 (43%) 59 (35%) 
Plasma volume (mL) 2376 ± 376 2680 ± 385 2311 ± 346 
≥ 1 thrombophilic test positive  50 (26%) 7 (25%) 43 (26%) 
Creatinine clearance 
(mL/min/1.73m2) 
112 ± 29 108 ± 31 113 ± 29 
Inter-pregnancy interval (y) 2.3 (2.1) 2.6 (2.4) 2.3 (2.0) 
Inter-pregnancy interval reported as median (IQR).  
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Results 
From the 444 screened women with a history of early-onset preeclampsia, 196 
women were eligible for inclusion, as illustrated in figure 1. Twenty-eight women 
(14%) were obese. Table 1 lists demographic and clinical characteristics of the study 
population. Obese formerly preeclamptic women differed from their non-obese 
counterparts by higher mean circulating levels of fasting total cholesterol, LDL-
cholesterol, triglycerides, glucose and insulin along with lower levels of HDL choles-
terol. Moreover, their plasma volume was larger and their median inter-pregnancy 
interval about 3.5 months longer. 
Table 2 lists the frequencies of metabolic abnormalities. The MetS was diagnosed in 
17 (9%) obese women at least six months postpartum. Four of these women ful-
filled all MetS criteria. The presence of ≥ 2 components of the MetS was positively 
associated with weight class, as shown in figure 2. Nevertheless, 34 (20%) non-
obese women fulfilled ≥ 2 metabolic criteria (table 2).  
 
Table 2: Metabolic syndrome components in obese and non-obese formerly preeclamptic women.  
 Obese women 
(n = 28) 
Non-obese women 
(n = 168) 
Raised triglycerides or specific treatment 12 (43%) 15 (9%) 
Reduced HDL-cholesterol or specific treatment 20 (71%) 56 (33%) 
Raised blood pressure or specific treatment 12 (43%) 59 (35%) 
Raised fasting glucose or type II diabetes mellitus 11 (39%) 23 (14%) 
   
None of these 2 (7%) 57 (34%) 
1 component 9 (32%) 77 (46%) 
2 components 9 (32%) 30 (18%) 
3 components 4 (14%) 4 (2%) 
4 components 4 (14%) - 
raised triglycerides (≥ 1.7 mmol/L; 150 mg/dL); reduced HDL-cholesterol (<1.29 mmol/L; 50 mg/dL; raised 
blood pressure (≥ 130/85 mmHg); raised fasting plasma glucose (> 5.6 mmol/L; 100 mg/dL) 
 
Table 3 summarizes the outcome of the first and the second pregnancy. Overall, 49 
(25%, 95%-CI: 19-32%) women developed preeclampsia in their next pregnancy. The 
second pregnancy lasted on average 7.5 weeks longer and the infant’s birth weight 
was on average 1.8 kg higher as compared to the first pregnancy.   
Table 4 presents the association estimates of obesity and the MetS with recurrent 
preeclampsia. The OR of obesity was 2.5 (95%-CI: 0.9-6.4), after adjustment for 
confounding, which was almost similar to the association between the MetS and 
recurrent preeclampsia (2.4 (95%-CI: 0.7-7.7)). Due to listwise deletion, two women, 
who had not developed recurrent preeclampsia, were excluded from the multivari-
able analysis. After additional adjustment for the fasting circulating levels of trigly-
cerides, HDL-cholesterol, glucose and the mean arterial pressure, the OR of obesity 
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reduced to 1.0 (95%-CI: 0.3-3.0). By contrast, the presence of two or more metabol-
ic syndrome criteria proved, independent of obesity, to be associated with recur-
rent preeclampsia (OR = 3.8, 95%-CI: 1.4-10.2).  
 
Table 3: Outcome of the first and second pregnancies.  
 First pregnancy Second pregnancy 
Early-onset preeclampsia 100% 19 (10%) 
Late-onset preeclampsia - 30 (15%) 
Gestational hypertension - 35 (18%) 
Pregnancy duration (wks) 30.9 ± 3.1 38.4 ± 2.6 
Infant’s birth weight (g) 1307 ± 567 3085 ± 712 
SGA infant (< p10) 41 (21%) 42 (21%) 
IUD 17 (9%) 6 (3%) 
IUD: Intra-uterine demise   
 
 
Table 4: Odds ratios (OR) with corresponding 95%-confidence intervals for recurrent preeclampsia of 
obesity, the MetS and the presence of two or more metabolic components of the MetS (irrespective the 
presence or absence of obesity). 
 N Recurrent 
preeclampsia 
OR 
unadjusted 
OR 
adjusted I 
OR 
adjusted II 
Obesity 
No 
Yes 
 
 
 
 
39 (23%) 
10 (36%) 
 
1 
1.8 (0.8-4.3) 
 
1 
2.5 (0.9-6.4) 
 
1 
1.1 (0.4-3.2)† 
 
MetS 
No 
Yes 
  
 
43 (24%) 
6 (35%) 
 
 
1 
1.7 (0.6-4.8) 
 
 
1 
2.4 (0.7-7.7) 
 
 
- 
- 
 
MetS components 
0 
1 
≥ 2 
  
 
8 (14%) 
20 (24%) 
21 (41%) 
 
 
1 
2.0 (0.8-4.8) 
4.5 (1.8-11.3) 
 
 
1 
2.0 (0.8-5.0) 
4.3 (1.6-11.2) 
 
 
1 
1.9 (0.8-4.8)‡ 
3.8 (1.4-10.2)‡ 
 
Joint effect 
Obesity0 MetS0 
Obesity0 MetS≥2 
Obesity1 MetS≥2 
  
 
7 (12%) 
15 (44%) 
6 (35%) 
 
 
1 
5.6 (2.0-16.0) 
3.9 (1.1-13.9) 
 
 
1 
4.8 (1.6-14.2) 
5.7 (1.3-24.2) 
 
 
- 
- 
- 
OR adjusted I: adjusted for maternal age, inter-pregnancy interval, thrombophilia, creatinine clearance 
and plasma volume. OR adjusted II: † additionally adjusted for triglycerides, HDL-cholesterol, mean 
arterial pressure and fasting circulating levels of glucose; ‡ additionally adjusted for the presence or 
absence of obesity.  
 
No statistically significant interaction was detected between obesity and the pres-
ence of at least two MetS components on a multiplicative scale (p = 0.14). However, 
relative to non-obese women without metabolic abnormalities, the joint effect of 
obesity and the presence of two or more MetS components, after adjustment for 
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confounders, tended to be stronger (OR = 5.7, 95%-CI: 1.3-24.2) than the effect of 
the presence of two or more components in the absence of obesity (OR = 4.8, 95%-
CI: 1.6-14.2).  
 
morbid 
obesity
obesityoverweightnormal
weight
underweight
100%
80%
60%
40%
20%
0%
 
Figure 2: Frequency of the presence of ≥ 2 metabolic components of the MetS in different weight catego-
ries. 
Discussion 
Our results provide evidence that obesity related metabolic abnormalities rather 
than obesity by itself predispose to recurrent preeclampsia. The presence of at least 
two metabolic components of the MetS correlates strongly with the recurrence of 
preeclampsia, independent of the presence of obesity. 
Because of the absence of data on waist circumference, we defined (central) obesi-
ty as BMI ≥ 30 kg/m2. The International Diabetes Federation defines obesity as a 
waist circumference ≥ 80 cm,14 with the remark that central obesity can be assumed 
if the BMI exceeds 30 kg/m2. Consequently, false positive diagnoses of central obes-
ity are unlikely. Nevertheless, in our population the prevalence of central obesity, 
and thus its association with recurrent preeclampsia, mmay be slightly underesti-
mated. Furthermore, we calculated the BMI at the time of screening, which was at 
least six months after the preeclamptic pregnancy. It is possible that obese women 
tried to lose weight between the post-screening counseling visit and the next preg-
nancy. Although we did not have data on maternal body weight shortly before the 
second pregnancy, based upon our experience significant weight loss in the short 
period between screening and the next pregnancy (median: 10 months, IQR: 7-21 
months in obese women) is unlikely. Effective interventions for overweight and 
obesity are currently unavailable.16  
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The pregnancy rate in obese (BMI ≥ 30 kg/m2) primiparous women tended to be 
lower (44%) than in non-obese primiparae (55%), which may be due to menstrual 
dysfunction and anovulation.17 However, the frequency of obesity and morbid obes-
ity in the selected population of women with a second pregnancy (table 1) was 
similar as in the total population of screened former primiparous patients (N = 368; 
11% and 5%, respectively).  
Contrary to expectation, the prevalence of obesity (BMI ≥ 30) in our study popula-
tion was similar to that in the overall population of Dutch women of reproductive 
age, being 10% and 13% among women aged 20-29 and 30-39 years, respectively, in 
2001 and having increased slightly since.18, 19 This might be due to the inclusion of 
women with a history of early-onset preeclampsia only, with possible different 
pathophysiological pathways than late-onset preeclampsia.20 However, since the 
risk of recurrence is highest in women with previous early-onset preeclampsia, 
these women in particular are closely monitored.21 When we analyzed early- (as 
previously defined) and late (diagnosis ≥ 34 weeks and/or delivery ≥ 37 weeks) 
recurrence of preeclampsia separately, the association with obesity was compara-
ble (OR = 2.3, 95%-CI: 0.6-9.3, and OR = 2.7, 95%-CI: 0.8-8.7, respectively), but the 
confounding effect of MetS related variables tended to be stronger in the former 
(OR for obesity = 0.7, 95%-CI: 0.1-3.8, and 1.4, 95%-CI: 0.4-5.1, respectively, after 
adjustment for triglycerides, HDL-C, glucose and MAP). Along these lines, the asso-
ciation of the presence of at least two metabolic components of the MetS with 
early-onset recurrent preeclampsia was stronger (OR = 7.4, 95%-CI: 1.4-38.5) than 
that with late-onset recurrent preeclampsia (OR = 2.1, 95%-CI: 0.6-6.8), indepen-
dent of obesity. In the perspective of the modest statistical power of these sub-
analyses, which included 10 and 7 independent variables, respectively, overall re-
current preeclampsia as primary outcome was preferred.  
To the best of our knowledge, there is no evidence against obesity being an inde-
pendent risk factor for preeclampsia, although others have suggested the hypothe-
sis before.22 The link between the metabolic syndrome and preeclampsia risk has 
gained growing attention.23-27 A metabolic score rather than the traditional defini-
tion of metabolic syndrome or individual risk factors alone has been suggested to 
provide a screening, predictive and eventually a target for intervention.23, 26 These 
studies consider increased BMI as an important component and thus risk contribu-
tor. Although the presence of metabolic abnormalities is associated with BMI, only 
33% of the women in our study population with two or more metabolic abnormali-
ties were also obese. The contribution of obesity to the preeclampsia risk may be 
well overrated. Therefore, we would recommend taking note of metabolic abnor-
malities when counseling for recurrent preeclampsia, regardless the woman’s BMI. 
Other interventions than primary weight loss to manage metabolic disorders and to 
reduce the risk of recurrent preeclampsia might be both more effective and achiev-
able in the relatively short period of time between two pregnancies.  
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In conclusion, our findings indicate that the association between obesity and recur-
rent preeclampsia is a consequence of its relationship with metabolic abnormalities. 
In line with the findings of others, the metabolic components clustered in the MetS 
proved useful to indicate increased recurrence risk. Newsworthy is the observation 
that the role of obesity in this concept is modest. The presence of al least two me-
tabolic syndrome criteria proved to be associated with recurrent preeclampsia, 
independent of the presence of obesity.  
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ABSTRACT  
Objective: To evaluate whether clinical and laboratory variables differ between 
former patients who had HELLP syndrome and former patients who had preeclamp-
sia (PE) without HELLP.  
 
Methods: We compared early-onset HELLP (n = 75) with early-onset PE (n=40) with 
respect to clinical features during the hypertensive complication and to metabolic, 
hemodynamic, and hemostatic variables determined at least six months postpar-
tum.  
 
Results: HELLP differed from PE by a borderline higher frequency of eclampsia (13% 
vs. 3%) during the complication, and by a lower prevalence of hypertension (19% vs. 
33%), proteinuria (2% vs. 23%), thrombophilia (6% vs. 27%), obesity (9% vs. 33%), 
hypertriglyceridemia (1% vs. 15%), hyperglycemia (0% vs. 11%), and elevated levels 
of fasting homocysteine (6% vs. 21%) at least six months postpartum.  
 
Conclusion: Women with HELLP had less signs of abnormalities consistent with the 
metabolic syndrome and a fourfold lower prevalence of thrombophilia as compared 
with preeclamptic women without HELLP.  
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Introduction 
Although preeclampsia and the syndrome of hemolysis, elevated liver enzymes and 
low platelets (HELLP) are considered different clinical entities, the two syndromes 
are strongly related. In both (early-onset) syndromes, abnormal placental growth 
and development are thought to contribute to the initiation of a cascade of events 
that eventually leads to the well-known clinical symptoms of either.1, 2 Together 
with the overlapping symptoms this has led to a comparable clinical management of 
both syndromes, consisting of symptomatic treatment followed by timely termina-
tion of pregnancy.  
However, dissimilarities between preeclampsia and HELLP have also emerged. A 
recent study showed that the molecular signature of the placenta in early-onset 
HELLP differs from that in early-onset preeclampsia.3 Moreover, certain maternal 
features known as risk factors for preeclampsia, such as obesity, have not been 
associated with the HELLP syndrome.4 These observations provide support for the 
view that disentanglement of both syndromes may contribute to improvements in 
the current clinical management. Particularly in the perspective of the increased risk 
of recurrent disease in a next pregnancy, in which the main objective is to reduce 
risk factors before conception,5 the identification of possible differences in risk 
profile between preeclampsia and HELLP seems meaningful. Therefore, our objec-
tive was to evaluate clinical dissimilarities between the HELLP syndrome and preec-
lampsia without HELLP. To this end, we compared pregnancy outcome and the 
frequency of underlying disorders that had been assessed at least six months post-
partum, between women who had their pregnancy complicated by HELLP with 
those whose pregnancy had been complicated by preeclampsia without HELLP.   
Material and Methods 
We reviewed the medical records of women with early-onset HELLP syndrome and 
those of women with early-onset preeclampsia without any signs of the HELLP syn-
drome, who were admitted to Maastricht University Medical Center, the Nether-
lands (between March 1 1996 and December 31 2007), and who had been offered a 
set of tests to identify underlying disorders or abnormalities at least six months 
postpartum. All measurements reported in this prospective observational study 
were obtained as part of the usual care provided to high-risk obstetrical patients in 
our tertiary referral center. We anonymised all data prior to statistical analysis. 
Women with twin pregnancies were excluded from the analysis. We only included 
women with early-onset disease, defined as diagnosis ≤ 34 weeks and delivery ≤ 37 
weeks. 
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We applied the following diagnostic criteria for the HELLP syndrome: platelet count 
≤ 100 x109/L, elevated liver enzymes (serum alanine aminotransferase (ALAT) > 70 
U/L and/or serum aspartate aminotransferase (ASAT) > 70 U/L) and hemolysis cha-
racterized by serum lactic dehydrogenase (LDH) level over 600 U/L. Preeclampsia 
was defined as de novo proteinuria (> 300 mg/24h or > 30 mg/mmol creatinine) in a 
pregnant patient with de novo hypertension (> 140/90 mmHg).6 Chronic hyperten-
sion was defined as hypertension already present before pregnancy, diagnosed 
before the 20th week of gestation or not resolving within six months postpartum.6 
We used new-onset proteinuria as a diagnostic criterion for preeclampsia in these 
women.6 Epileptic seizures in women without history of epilepsy were considered 
to be eclamptic fits. All women who developed eclampsia, received magnesium 
sulfate after their seizure to prevent recurrence. An infant was considered small for 
gestational age (SGA), when his/her birth weight was below the 10th percentile 
according to the most recent Dutch birth weight reference curves.7 Perinatal mor-
tality was defined as infant mortality within 28 days after birth.  
We determined the following metabolic variables between 6 and 10 months post-
partum: circulating levels of fasting glucose, HbA1C, insulin, total cholesterol, low 
density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), 
and triglycerides. We used the criteria stated by the National Cholesterol Education 
Program (NCEP) to define abnormalities related to the metabolic syndrome: fasting 
plasma glucose ≥ 5.6 mmol/L (101 mg/dL), HDL cholesterol ≤ 1.29 mmol/L (49.88 
mg/dL) and triglycerides ≥ 1.7 mmol/L (150.6 mg/dL).8 Hypercholesterolemia was 
defined as total cholesterol > 6.4 mmol/L (247.5 mg/dL) and increased LDL-C was 
defined as a level ≥ 4.5 mmol/L (174.0 mg/dL) according to the laboratory reference 
values. We considered women hyperinsulinemic when fasting insulin exceeded 10 
mmol/L. We defined obesity as a body mass index (BMI) ≥ 30 kg/m2. Furthermore, 
we determined total protein excretion in a 24-hour urine collection and creatinine 
clearance (corrected for body surface area) was estimated by the ratio of urinary 
creatinine concentration to that in peripheral blood.  
Echocardiography was performed in the semi-left lateral position by using a cross 
sectional phased-array Doppler system (Agilent Sonos 5500; Philips Medical System, 
Eindhoven, the Netherlands).9 Aortic flow was measured across the aortic valves 
from an apical approach. The average area under the aortic velocity curve (aortic 
velocity integral) of five consecutive ejections was used to calculate stroke volume 
(SV) and cardiac output (CO). Aortic valve diameter, necessary for the calculation of 
the aortic area, was measured off-line at the orifice during systole using M-mode. 
Total peripheral vascular resistance (TPVR) was calculated by dividing mean arterial 
pressure (MAP) by CO. We obtained blood pressure and heart rate as the median of 
11 measurements recorded at 3 minutes intervals under standardized conditions 
using a semiautomatic oscillometric device (Dinamap Vital Signs Monitor 1846; 
Critikon, Tampa, Florida, USA). An estimate for global arterial compliance 
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(ml/mmHg) was obtained by dividing SV by pulse pressure (systolic minus diastolic 
blood pressure).10  
Within the scope of the thrombophilic screening, all women were tested for cardi-
olipin antibodies (IgG/IgM > 10 GPL/MPL) and lupus anticoagulant in peripheral 
blood, as detailed previously.9 We assessed the circulating level of fasting homo-
cysteine and considered it elevated when the level exceeded 15 mmol/L. The factor 
V Leiden and prothrombin 20210A mutations were analyzed by routine PCR tech-
niques after extraction of genomic DNA from peripheral leukocytes. Activity of an-
tithrombin (Chromogenix, Mo¨lndal, Sweden) and protein C (Behring, Marburg, 
Germany) was measured by chromogenic substrate assays, and protein S antigen 
levels by enzyme-linked immunosorbent assay (ELISA; DAKO, Glostrup, Denmark).  
We defined deficiency of each of these parameters as an activity level below 65% of 
normal.  
In both subgroups, the type of management during pregnancy consisted of symp-
tomatic treatment, stabilization of the maternal condition and eventually pregnancy 
termination when the risks of pregnancy continuation outweighed the benefits for 
either mother or fetus. As part of the screening protocol, the participants discon-
tinued breastfeeding and the use of oral contraceptives and antihypertensive medi-
cation at least 2 weeks prior to the measurements.We used SPSS version 15.0 for 
statistical analysis. Data distribution was evaluated visually using histograms. Conti-
nuous variables were analyzed using independent-samples T-test and Mann-
Whitney-U test, and dichotomous variables using Chi-square and Fisher`s exact 
tests. A p-value < 0.05 was considered statistically significant.  
Results 
In the postpartum screening database we identified 40 formerly preeclamptic and 
75 former HELLP patients with complete hospital records. The majority of HELLP 
patients also had hypertension and proteinuria (n = 70). Thirty-seven HELLP patients 
had class 1 and 38 class 2 HELLP syndrome. All women were Caucasian. Table 1 lists 
clinical and obstetric characteristics of the women and their infants in the two pa-
tient groups. The groups were comparable with respect to maternal age, parity, 
family history of chronic hypertension, the proportion of women with delivery with-
in 48 hours after diagnosis, gestational age at birth, infants’ birth weight, and intra-
uterine mortality. The prevalence of eclampsia, however, tended to be higher in 
women with the HELLP syndrome (13% vs. 3%, p = 0.06).  
Table 2 lists the postpartum observations with respect to the prevalence of abnor-
malities associated with the metabolic syndrome. Obesity, hyperglycemia, and ele-
vated circulating levels of both total cholesterol and triglycerides were more com-
mon in women with a history of preeclampsia without HELLP as compared to wom-
C h a p t e r  5  
 
 
 
72 
en who had had the HELLP syndrome (p < 0.05). Moreover, the prevalence of chron-
ic hypertension tended to be higher in formerly preeclamptic women (table 2).  
 
Table 1: Clinical and obstetric characteristics of women with a recent history of the HELLP syndrome or 
preeclampsia (PE) without HELLP. Data are presented as mean ± SD or n (%).  
 HELLP 
(n = 75) 
PE without HELLP 
(n = 40) 
p 
Maternal age (y) 29.8 ± 4.7 29.8 ± 4.7 0.97 
Family history (1st degree) positive for: 
Preeclampsia/HELLP  
Chronic hypertension 
 
15 (20%) 
44 (59%) 
 
14 (35%) 
23 (58%) 
 
0.09 
0.71 
Multiparous (%) 8 (11%) 8 (20%) 0.17 
Interval between diagnosis and delivery ≤ 48h 6 (10%)  4 (12%)  0.73 
Eclampsia 10 (13%)  1 (3%)  0.06 
Infant birth weight (g) 1150 
(880-1545) 
1280  
(810-2100) 
0.33 
Gestational age at birth (weeks) 30.1 ± 2.6  30.2 ± 2.7  0.83 
IUFD 7 (9%) 5 (13%) 0.59 
SGA infant (<p10) 15 (22%) 13 (33%) 0.19 
Extremely preterm birth (< 32 wks)  60 (81%) 29 (74%) 0.41 
Perinatal mortality 7 (10%) 1 (3%) 0.17 
Interval between delivery and measurements 
(months) 
7.4  
(6.0-9.6)  
7.0  
(6.2-10.4)  
0.85 
Maternal age at infants’ birth day. IUFD: Intra-uterine fetal demise. Birth weight and time interval be-
tween delivery and measurements are expressed as median (IQR). All cases of perinatal mortality were 
born < 32 weeks of gestational age.   
 
Persistent proteinuria (> 300 mg/24h) was detected in only 2% of women who had 
the HELLP syndrome, as opposed to 23% in formerly preeclamptic women (p < 
0.01),  the odds ratio being 18 (95%-CI: 2-152) and persisting after adjustment for 
the in-pregnancy peak values of urinary protein excretion in a logistic regression 
analysis. The median creatinine clearance tended to be higher in formerly preec-
lamptic women (111, IQR: 87-137 mL/min/1.73 m2) as compared to former HELLP 
patients (106, IQR: 90-122 mL/min/1.73 m2) as well.  
Table 3 lists postpartum data on cardiovascular function. Except for a lower mean 
heart rate in former HELLP patients as compared to formerly preeclamptics (73 ± 10 
vs. 79 ± 12 bpm, p = 0.01), both groups were comparable. Finally, thrombophilic 
abnormalities are presented in table 4. Heterozygosity for the factor V Leiden and 
prothrombin 20210GA mutations were less prevalent in former HELLP patients than 
in former preeclamptics (2% vs. 13%, p = 0.04, and 17% vs. 3% p = 0.03). None of 
the women were homozygous for either mutation. Elevated fasting levels of homo-
cysteine were less common in women who had had HELLP (6% vs. 21%, p = 0.02). 
The two groups were comparable with respect to the rates of protein C, S, and an-
tithrombin deficiency and of positive tests for antiphospholipid antibodies and lu-
pus anticoagulant.  
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Table 2: Metabolic syndrome related abnormalities in women with a recent history of the HELLP syn-
drome or preeclampsia (PE) without HELLP. Data are expressed as proportion (95%-confidence interval).  
 
HELLP 
(n =  75) 
PE without HELLP 
(n =  40) 
p 
Obesity 9% (4-19)  33% (19-49) < 0.01 
Hypertension 19% (11-30) 33% (19-49) 0.10 
Hyperinsulinemia 52% (40-64) 50% (33-67) 0.83 
Hyperglycemia 0% (0-7) 11% (4-26)  < 0.01 
High total cholesterol 10% (4-20) 23% (12-40) 0.06 
High LDL-cholesterol 13% (6-24) 21% (10-37)  0.29 
Low HDL-cholesterol 7% (3-17) 10% (3-25) 0.57 
High triglycerides 1% (0-9) 15% (6-31) <0.01 
Comments 
Women with preeclampsia and no HELLP proved to have more often a profile con-
sistent with the metabolic syndrome. Moreover, we observed a fourfold higher 
prevalence of thrombophilia amongst formerly preeclamptics as compared to those 
who had had HELLP. Even though neonatal outcome did not differ appreciably be-
tween both subgroups, eclampsia tended to be more prevalent in women with the 
HELLP syndrome. 
 
Table 3: Cardiovascular variables in women with a recent history of the HELLP syndrome or preeclampsia 
(PE) without HELLP. Data are presented as mean ± SE.  
 HELLP 
(n = 75) 
PE without HELLP 
(n = 40) 
p 
Stroke volume (mL) 75 ± 2 73 ± 1 0.34 
Heart rate (bpm) 73 ± 1 79 ± 2 0.01 
Cardiac output (L/min) 5.4 ±  0.1 5.5 ± 0.1 0.45 
TPVR (dynes.s/cm5) 1410 ± 29 1380 ± 41 0.53 
Arterial compliance (ml/mmHg) 1.61 ± 0.06 1.46 ± 0.07 0.17 
Systolic blood pressure (mmHg) 121 ± 1 123 ± 2 0.41 
Diastolic blood pressure (mmHg) 76 ± 1 75 ± 2 0.68 
Mean arterial pressure (mmHg) 93 ± 1 93 ± 2 0.82 
TPVR: total peripheral vascular resistance 
 
We only included women who had been diagnosed before 34 weeks and gave birth 
before 37 weeks. We expected this selection to contribute to a more homogeneous 
study population as early- and late-onset preeclampsia/HELLP are probably differ-
ent disease entities with different risk profile.11 However, despite the inclusion of 
early cases only, differential participation based on disease severity may have led to 
overrepresentation of HELLP patients in our hospital population. To our opinion, its 
impact on the study results regarding the comparison of HELLP and preeclampsia is 
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negligible, as this did not affect the allocation to either subgroup. Although we per-
formed our diagnostic work-up for maternal abnormalities after the complicated 
pregnancy, abnormalities such as obesity with the associated metabolic syndrome 
are likely to be preexistent. Nevertheless, it is understood that preconceptional 
analysis would have been preferable. 
We did not observe significant differences in perinatal outcomes between pregnan-
cies complicated by HELLP and those complicated by preeclampsia without HELLP, 
an observation in line with others.12-14 Nonetheless, we observed a trend to a higher 
incidence of eclampsia in HELLP relative to preeclampsia, a finding not in line with 
previous reports.12 Although differences between findings may be partly attributa-
ble to differences in demography and overall disease severity, the more expectant 
management in our study to thrive for maximum efficacy of corticosteroids in acce-
lerating fetal lung maturation is expected to have enlarged the window for the de-
velopment of eclampsia. In HELLP circulating levels of reactive oxygen species have 
been found higher than in preeclampsia,15 which suggests activation of the immune 
system, raising endothelial stress. A central role for immune system activation also 
arises from the observation of dose-dependent improvement of laboratory values 
after corticosteroids, even though clinical outcome is not affected.16-18 It follows 
that a more aggressive management, which includes a lower threshold for the ad-
ministration of magnesium sulphate, particularly in early-onset HELLP, may lower 
the risk for eclampsia.  
 
Table 4: Thrombophilic defects in women with a recent history of the HELLP syndrome or preeclampsia 
(PE) without HELLP. Data are expressed as proportion (95%-confidence interval).  
 
HELLP 
(n =  75) 
PE without HELLP 
(n =  40) 
p 
Protein S deficiency 4% (0-14) 3% (0-19) 0.90 
Protein C deficiency 0% (0-6) 3% (0-15) 0.15 
Antithrombin deficiency 0% (0-7) 0% (0-12) - 
Prothrombin 20210GA mutation 3% (0-15) 17% (6-40) 0.03 
Factor V Leiden mutation 2% (0-10) 13% (4-30) 0.04 
Any of the above 6% (2-15) 27% (14-44) <0.01 
Elevated levels of homocysteine 6% (2-15) 21% (10-37) 0.02 
Presence of circulating anticardiolipin 
antibodies IgG and/or IgM 
8% (3-18) 9% (2-25) 0.79 
Lupus anticoagulant 3% (0-6) 0% (0-16) 0.17 
All women detected with factor V Leiden or prothrombin mutation were heterozygous.  
 
Women with preeclampsia differ from those with HELLP by the presence of a small-
er placenta with more infarcts.19 Moreover, contrary to the findings of others,12-14 
Vinnars and coworkers found a higher incidence of fetal growth restriction in preec-
lampsia.19 Although the authors studied the placentas from early - and late-onset 
disease combined, the data support the view of a longer subclinical disease period 
preceding preeclampsia as compared to HELLP. The latter is also in line with our 
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observations and those reported by others,3, 4, 20, 21 suggesting preexistent maternal 
abnormalities capable of jeopardizing microvascular functioning, are more common 
in preeclampsia than in HELLP. 
These inferences led us to postulate that preeclampsia differs from HELLP by a more 
gradual course in early pregnancy due to unfavorable constitutional conditions for 
placental growth and development. Eventually, intervillous hypoxia results in the 
placental release of toxic substances pushing the subclinical condition into the well-
known clinical symptomatology. Conversely, an abnormal immune response to the 
placental allograft with no appreciable negative impact on placental function is 
thought to characterize the subclinical phase of a HELLP pregnancy. The acute 
course and appearance of HELLP with episodic exacerbations, suggests that HELLP 
may resemble a so-called “second hit” or an intermittent Shwartzman-like re-
sponse.22, 23 Obviously, the pathogenetic pathways are interrelated, which explains 
why the clinical presentation of preeclampsia and HELLP are often overlapping. 
In summary, the postpartum lower rate of underlying maternal metabolic and 
thrombophilic abnormalities in HELLP as compared to PE suggests these syndromes 
to have at least in part a different pathophysiology.  
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Abstract 
Objectives: 1. To assess the prevalence of electrocardiographic (ECG) abnormalities 
shortly after a pregnancy complicated by preeclampsia and/or the syndrome of 
Hemolysis, Elevated Liver Enzymes and Low Platelets (PE). 2. To compare the ECG 
dimensions between primiparous formerly early-onset preeclamptics who did, with 
those who did not develop recurrent PE in their next pregnancy.  
 
Methods: Our study population for the first objective consisted of 658 formerly 
preeclamptics, whereas the one for our second objective, consisted of the subgroup 
of primiparae with both a history of early-onset PE (delivery < 34 weeks) and a 
completed second pregnancy, which had either a normal course (n=46) or became 
complicated by recurrent PE (n = 33).  
 
Results: The ECG of 13 (2.0%), 2 (0.3%) and 2 (0.3%) former patients (2.0%) sug-
gested ischemia, left ventricular hypertrophy and left atrial enlargement, respec-
tively.  Primiparae with a history of early-onset PE, who developed recurrent PE in 
their second pregnancy, differed from their counterparts with an uneventful second 
pregnancy by a leftward deviation of both the P and the R-axis, of 11° (p=0.022)and 
12° (p=0.021), respectively with  a prolonged QT-interval.  
 
Conclusions: The prevalence of ECG abnormalities in women with a recent history 
of PE did not differ appreciably from that in a large population of healthy women of 
comparable age. ECG differences between primiparous formerly early-onset preec-
lamptics with and without recurrent PE in their next pregnancy may, at least in part, 
be related to a slightly higher mean blood pressure and/or a higher body mass index 
(BMI) in the recurrence group, the higher BMI being accompanied by more intra-
abdominal pressure, which lifts the diaphragm and with it, exaggerates the normal 
leftward cardiac rotation.  
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Introduction 
Pregnancy induces hemodynamic, metabolic and endocrine changes that impact the 
cardiac function.1 Already in the first trimester, cardiac output begins to increase to 
reach a plateau in the second trimester of 30-40% above prepregnancy levels. This 
adaptive change puts extra strain upon the heart,2 which responds with cardiac 
remodeling resembling the so-called “eccentric” hypertrophy observed in athletes, 
characterized by an increase in the ventricular dimensions and in the left ventricular 
wall thickness.3, 4 The latter changes affects the electrocardiogram (ECG) by prolong-
ing the QT interval corrected for the higher heart rate (QT-c), and by a leftward 
deviation of the QRS and T-axis.5 Although the change in the alignment of the intra-
thoracic organs during pregnancy, which results from lifting of the diaphragm by the 
higher intra-abdominal pressure, explains most of the change of the electrical heart 
field,6 it is likely that the change in cardiac structure and function also contributes to 
the change of the electrical heart field.7   
Women with a history of early-onset preeclampsia, eclampsia or the syndrome of 
Hemolysis, Elevated Liver Enzymes and Low Platelets (HELLP), are at increased risk 
of developing cardiovascular disease later in life.8 These former patients often have 
pre-existing renal, vascular, metabolic, and immune disorders,9-11 which, indepen-
dent of pregnancy, are also associated with premature cardiovascular disease.8, 12 It 
is unknown, whether the higher prevalence of pre-existing disorders in these for-
mer patients is accompanied by a higher prevalence of electrocardiographic (ECG) 
abnormalities. 
In this study, we tested the following two hypotheses: 1) The prevalence of clinically 
relevant ECG abnormalities is higher in formerly preeclamptic women than in age-
matched women in the general population. 2) Formerly early-onset preeclamptics 
with recurrent preeclampsia with or without the HELLP-syndrome (PE) in their next 
pregnancy have different ECG dimensions than their counterparts, who only had PE 
in their first pregnancy. To this end, we recorded an ECG in 658 formerly preec-
lamptics at least 6 months after their complicated pregnancy and compared in a 
subgroup of 79 primiparae with a history of early-onset PE, the ECG dimensions 
between women, who did and did not develop recurrent PE in their second preg-
nancy.  
Materials and methods 
Since 1996, we have screened in our tertiary referral center, all women with a re-
cent history of PE for underlying maternal abnormalities known to be associated 
with hypertensive disorders of pregnancy. The screening program includes the re-
cording of an ECG. To warrant adequate postpartum recovery of all relevant func-
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tions, we perform the screening at least six months postpartum. All measurements 
reported in this observational study are part of the routine care provided to high-
risk obstetrical patients in our center, and derived from a database by a clinical 
research assistant, who was not involved in the statistical analysis. Prior to analysis, 
data were anonymized. In the Netherlands, ethical approval is not required for 
research using anonymized data from a database containing data from routine 
patient care.  
To evaluate the prevalence of ECG abnormalities, we included all women with a 
history of PE (n = 658). To compare ECG dimensions between women with recurrent 
PE and women with an uneventful next pregnancy, we selected a subgroup of for-
mer patients who 1. were screened before February 2008, 2. were primiparous at 
the time of screening, 3. had had early-onset (delivery < 34 weeks) PE in their first 
pregnancy, and 4. had a subsequent ongoing (> 20 weeks) singleton pregnancy (n = 
134), which either had an uneventful course or resulted in recurrent PE. Eventually, 
we were able to compare the computerized ECGs of 33 women who had developed 
recurrent PE in their second pregnancy with 46 former patients with an uneventful 
second pregnancy. The selection procedure is illustrated in figure 1.  
 
Women with PE in previous 
pregnancy
(N = 658)
Primiparous women
(n = 534)
Multiparous women
(n = 124)
History of early-onset PE
(n = 262)
Subsequent singleton 
ongoing pregnancy
(n = 134)
Uneventful pregnancy
(n = 46)
Gestational hypertension
(n = 34)
Isolated SGA infant
(n = 21)
Recurrent PE
(n  = 33)  
Figure 1: Details on patients selected for the study and their outcome. PE: preeclampsia; SGA: small for 
gestational age. 
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We adhered to the definitions for preeclampsia and HELLP-syndrome used by the 
International Society for the Study of Hypertension in Pregnancy (ISSHP).13,14 Fur-
thermore, we defined the birth of an SGA infant as an infant born with a birth 
weight below the 10th percentile according to the most recent Dutch birth weight 
curves.15  
We recorded the ECG with the subject in supine position, using the 12-lead Mar-
quette MacVu and Marquette 12SL analysis program (GE Marquette, Inc., Milwau-
kee, Wisconsin) to enable analysis and calculation of standard ECG interval times 
and the electrical heart axis. Computer-calculated ECG-interval times were ex-
pressed in milliseconds (ms), whereas P, R and T-wave axis were expressed in de-
grees (°). P-wave axis is considered normal between 0° and +75° and reflects atrial 
conduction.16 The R-wave axis gives information about ventricular conduction and 
activation with normal values ranging from -30° to +100°. Finally, the T-axis reflects 
the conduction of ventricular repolarisation.17,18 Figure 2 illustrates the orientation 
of the three cardiac-axis.  The QT-c interval describes cardiac depolarization, and 
excessive prolongation was defined as a QT-c interval over 450 ms, whereas the 
long QT-syndrome was defined as a QT-c complex >500 ms.19  
  
 
Figure 2:  Schematic illustration of the electrocardiographic heart axis. P, R and T-wave axis are derived 
as a vector of all limb leads.  
 
All ECGs were evaluated and classified by cardiologists not involved in this study. 
These ECG findings were defined either as normal or as suspect for clinically rele-
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vant cardiac pathology. Left ventricular hypertrophy (LVH) was defined by the Soko-
low-Lyon criteria.20 We defined left atrial dilatation by a P-wave duration in excess 
of 0.12 s in the frontal plane (usually lead II), accompanied by a notched P-wave in 
the limb leads with an inter-peak duration > 0.04 s, or in case of terminal P negativi-
ty, in lead V1 (i.e., "P-terminal force") with duration > 0.04 s and depth > 1 mm.21 
We used the Minnesota code classification system for ECG findings (code I1-3; code 
V1-3; IV1-3; code VII1) to consider an ECG to be suspect of myocardial ischemia 
(ischemic ECG).22,23 
During the postpartum screening we also recorded blood pressure in standardized 
conditions using a semiautomatic oscillometric device for 30 minutes (Dinamap 
Vital Signs Monitor 1846, Critikon, Tampa, FL). A patient was considered to have 
chronic hypertension, when she was using prescription anti-hypertensive drugs at 
the time of postpartum screening. Important demographic variables such as age, 
body mass index (BMI), and the presence of chronic hypertension were registered 
at the time of postpartum screening. A patient with BMI over 30 kg/m2 was consi-
dered obese. Obstetric history data registered at screening were gender, weight 
and condition at birth of the infant. Variables with a missing value rate of over 25% 
were omitted from further analyses. The results of this postpartum screening 
enables individualized counseling of former patients for possible consequences of 
detected abnormalities, for both future pregnancies and general health later in life.  
We analyzed the data using SPSS version 16.0 for Windows. For data distribution, 
we evaluated histograms visually. Non-normally and normally distributed data were 
analyzed using the Mann-Whitney U test and the independent-samples t-test, re-
spectively. Finally, binomial data were analyzed by Chi-square tests. Data are either 
presented as mean ± standard deviation (SD) or as number of patients with corres-
ponding percentage. Differences between groups were considered significant, when 
the p-value was below 0.05.  
Results 
From January 1996 until February 2008, we enrolled 658 women with a recent his-
tory of PE in our postpartum screenings program. Women were screened at least 6 
months postpartum with a median of 11 months. Table 1 lists the characteristics of 
our study population and ECG dimensions. Mean age at delivery was 29.7 ± 4.4 
years. 320 (49%) women had a history of early-onset preeclampsia with mean ges-
tational age at delivery of 33 ± 4 weeks. Of the total study population, 534 (81%) 
were primiparous and 182 (28%) gave birth to a SGA infant. Mean maternal BMI 
was 25.4 ± 5.2 kg/m2, with 107 (16%) women being obese. A total of 88 (13%) 
women used prescription antihypertensive medication at the time of screening.  
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Table 1: Clinical characteristics of 658 women with a first pregnancy complicated by preeclampsia and/or 
HELLP. 
Index pregnancy (n = 658) 
 Age at delivery (y)  29.7 ± 4.4  
 Age at screening (y)  31.4 ± 4.1 
 Primiparae 534 (81%) 
 Early-onset PE  320 (49%) 
 Gestational age at delivery (wks)  33.0 ± 4.0 
 Birth of an SGA infant 182 (28%) 
 Chronic hypertension  88 (13%) 
 Maternal BMI (kg/m2)  25.4 ± 5.2 
 Obesity (BMI > 30 kg/m2)   107 (16%) 
PE: preeclampsia; SGA: small for gestational age; BMI: body mass index. Pre-existent hypertension, 
maternal BMI, and obesity were obtained at the time of the postpartum screening. Data are listed as 
mean ± SD or n (%), unless otherwise specified. 
 
 
Table 2: Electrocardiographic characteristics of 658 women with a first pregnancy complicated by PE. 
Electrocardiographic findings (n = 658) 
Ventricular rate (bpm)    [60 - 100]30 68 ± 11 
PR interval (ms)              [120 - 200]30 142 ± 20 
QRS-duration (ms)         [<120]30 86 ± 8 
QT-c interval (ms)          [<450]30 404 ± 15 
P-wave axis (degrees)     [0 - +75]16 40 ± 22 
R -wave axis (degrees)     [-30 - +100]17 50 ± 25 
T-wave axis (degrees) [+15 - +75]31 31 ± 22 
Electrocardiographic Rhythm  (n = 658) 
 Sinus Rhythm 651 (98.9) 
 Supra Ventricular Rhythm  7 (1.1%) 
Clinically relevant ECG  findings  (n = 23)  
 Ischemic ECG findings 13 (2.0%) 
 Left Atrial Enlargement  2 (0.3%) 
 LVH  2 (0.3%) 
 Dextrocardia  1 (0.2%) 
 Right heart axis  1 (0.2%) 
 QT-c interval >450ms  4 (0.6%) 
LVH: left ventricular hypertrophy, determined by Sokolow-Lyon criteria. Bpm: beats per minute; QT-c: 
QT-interval corrected for heart rate. [Normal range defined in ms or degrees]. Data are listed as mean ± 
SD or n (%), unless specified otherwise. 
 
None of the 658 women of the original population had an ECG abnormality requir-
ing immediate consultation or intervention by a cardiologist. In the total group, the 
ECG was consistent with LVH, left atrial dilatation and myocardial ischemia in 2 
(0.3%), 2 (0.3%) and 13 women (2.0%), respectively. One former patient (0.15%) 
had an ECG indicative for dextrocardia, confirmed by ultrasound. Four (0.6%) wom-
en had excessive prolongation of the QT-c interval exceeding 450 ms, but none 
C h a p t e r  6  
 
 
 
84 
were diagnosed with the long QT-syndrome. Finally, 1 ECG (0.15%) was interpreted 
as being abnormal because of an extreme rightward deviation of the electrical heart 
axis. Table 2 lists all clinically relevant ECG abnormalities.  
 
 
To determine whether primiparous, formerly early-onset preeclamptics, who devel-
oped recurrent disease in their second pregnancy, differed from their counterparts 
with a normal second pregnancy, we performed a subgroup analysis on 79 primi-
parous women with a history of early-onset disease and a subsequent singleton 
pregnancy. In their second pregnancy, 33 (42%) women developed recurrent PE as 
compared to 46 (58%) former patients, who had an uneventful second pregnancy. 
Baseline characteristics of both subgroups summarized in table 3 were comparable, 
except for a higher MAP in the recurrent subgroup (96 ± 10 and 90 ± 10 mmHg, 
resp., p = 0.004). Only 6 women (7.6%) developed recurrent early-onset PE in their 
second pregnancy. The recurrence subgroup differed from the uneventful subgroup 
by a mean leftward deviation of the P-wave axis (32º ± 23 and 43º ± 18, respective-
ly, p=0.022), along with a mean leftward deviation of the R-wave axis (47º ± 24 and 
59º ± 23, respectively, p=0.021), and a longer QT-c interval (411 ± 15 and 404 ± 12 
ms, respectively, p=0.025). Table 4 lists the ECG indices. Other baseline ECG fea-
tures did not differ appreciably between the two subgroups.  
Besides these differences in ECG characteristics, we found the MAP to be higher in 
the recurrence as compared to the uneventful subgroup (96 ± 10 and 90 ± 10 
Table 3: Clinical characteristics of primiparous former patients with recurrent disease and uneventful 
second pregnancies.  
 
 
Recurrent PE 
(n = 33) 
Uneventful 
 (n = 46) 
 
P 
Index pregnancy 
 Age at delivery first pregnancy (years)  28.5 ± 4.0 28.3 ± 3.2 0.774 
 Age at screening (years)  29.8 ± 4.1 29.6 ± 3.2 0.800 
 Gestational age at delivery (weeks)  29.8 ± 2.0 29.3 ± 2.1 0.293 
 SGA infant  4 (5%) 7 (9%) 0.813 
 MAP (mmHg)  96 ± 10 90 ± 10 0.004 
 Maternal BMI (kg/m2)  26.8 ± 4.4 25.2 ± 5.3 0.165 
 Obesity BMI > 30 kg/m2   9 (11%) 7 (9%) 0.186 
 Pre-existing hypertension  5 (6%) 2 (3%) 0.096 
Subsequent pregnancy    
 Age at the time of delivery (years)  31.8 ± 3.9 31.9 ± 3.4 0.886 
 Gestational age at delivery (weeks)  36.3 ± 3.4  39.1 ± 1.9  <0.001 
 Birth weight (g) 2496 ±912 3357 ± 486 <0.001 
 Birth of an SGA infant  8 (10%) - - 
 Preeclampsia  33 (42%) - - 
 Early-onset PE 6 (8%) - - 
SGA: small for gestational age; MAP: mean arterial pressure; BMI: body mass index; PE: preeclampsia. 
Pre-existent hypertension, maternal BMI, and obesity at the time of the postpartum screening. Data are 
listed as mean ± SD or n (%), unless otherwise specified. 
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mmHg, resp., p = 0.004). Although the recurrence group tended to have a higher 
BMI than the uneventful group (26.8 versus 25.2 kg/m2), this difference did not 
reach statistical significance (p=0.17). 
Discussion 
This study is the first to analyze the prevalence of ECG abnormalities in a large 
group of 658 formerly preeclamptic women. Of the total study population, 19 
(2.9%) were identified with clinically relevant ECG abnormalities suggestive for LVH 
(n=2), left atrial dilatation (n=2), dextrocardia (n=1), rightward deviation electrical 
heart axis (n=1), myocardial ischemia (n=13) and excessive prolongation of the QT-c 
interval (n=4). We did not have a reference group of women with an uneventful first 
pregnancy. Nevertheless, the close resemblance between the low prevalence of 
abnormal ECG findings in our study population and that reported for a large cohort 
of healthy women of comparable age provides indirect evidence for lack of cluster-
ing of abnormal ECGs in women with a recent history of PE.23 Apparently, the twice 
as high risk in formerly preeclamptics to develop cardiovascular morbidity at middle 
age 8 s not accompanied by a higher incidence of abnormal ECGs shortly after the 
complicated pregnancy in spite of the higher incidence of metabolic syndrome, 
hypertension, renal disease, and autoimmune disorders in this population.8,24,25 
Apparently, the increased risk of these women to develop premature cardiovascular 
disorders is not reflected in more abnormal ECGs shortly after PE. Therefore, an ECG 
obtained during a postpartum screening program in women with a recent history of 
PE seems superfluous because of its low yield. 
In a sub-analysis, we compared the computer-analyzed ECG indices between 33 and 
46 primiparae with a recent history of early-onset PE, who did or did not develop 
recurrent disease in their second pregnancy, respectively. Primiparae who devel-
oped recurrent disease in their second pregnancy not only differed from their coun-
Table 4: Baseline electrocardiographic data of primiparous early-onset preeclamptics with recurrent 
disease and uneventful second pregnancies.  
 Recurrent PE  
(n = 33) 
Uneventful  
(n = 46) 
 
P  
Heart rate (bpm)  70 ± 12 68 ± 12 0.279 
PR interval (ms)  140 ± 16 137 ± 20 0.516 
QRS-duration (ms)  84 ± 6 85 ± 8 0.524 
QT-c interval (ms)  411 ± 15 404 ± 13 0.025 
P-wave axis (degrees)  32 ± 23 43 ± 18 0.022 
R-wave axis (degrees)  47 ± 24 59 ± 23 0.021 
T-wave axis (degrees)  29 ± 19 33 ± 19 0.315 
Bpm: beats per minute; QT-c: QT-interval corrected for heart rate. All variables were assessed at the time 
of the postpartum screening. Data are listed as mean ± SD, unless otherwise specified. 
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terparts with an uneventful second pregnancy by a significantly leftward deviation 
of the P-wave and R-wave axis along with a prolonged QT-c interval. They also dif-
fered by a higher MAP. Although previous studies indicated reversal of the shifted 
electrical heart axis and of the prolonged QT-c to prepregnant values immediately 
post partum,5 to the best of our knowledge there are no previous studies compar-
ing the ECG between women with recurrent hypertensive disease and women with 
an uncomplicated pregnancy. The leftward shift of the electrical heart axis in the 
subgroup of women with recurrent PE appears to be a confounder of the trend 
towards a higher BMI in this subgroup. Conversely, the relative leftward shift may 
also be related to a higher cardiac afterload secondary to the higher MAP in that 
subgroup as compared to the subgroup with a normal second pregnancy.26 Previous 
reports support the concept that leftward deviation of the electrical and anatomical 
heart axis vary as a function of left ventricular mass. The latter is expected to be 
higher in the recurrence subgroup with the higher MAP.27 After adjustment for 
MAP, BMI and the presence or absence of pre-existent hypertension by multiple 
linear regression analysis, the inter-subgroup differences in electrical P and R-axis 
persisted (p<0.05), indicating that other still unknown factors are involved. 
A prolonged QT-c interval in the recurrence subgroup relative to the uneventful 
subgroup reflects delayed depolarization and provides indirect evidence for a dif-
ferent left ventricular structure.28,29  The difference may also result from a combina-
tion of a higher left ventricular mass, a higher MAP and a higher BMI. However, in 
contrast to the persisting difference in electrical P and R-axis in the recurrence sub-
group, after adjustment for MAP, BMI and pre-existent hypertension, the QT-c in-
terval did not differ anymore between the 2 subgroups (p=0.197). 
In summary, the prevalence of abnormal ECGs in women with a recent history of PE 
is similar to that reported for women of comparable age in the general population. 
Therefore, the value of the ECG to identify formerly preeclamptic women at risk for 
premature cardiovascular disease is negligible. Differences in the electrical heart 
axis and in QT-c between former patients that do and those that do not develop 
recurrent disease in their second pregnancy appear to result predominantly from 
differences in blood pressure, with possibly some contribution of differences in 
cardiac structure.  
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Abstract  
Objective: To evaluate early-pregnancy changes in lipid profile in women who did or 
did not develop recurrent preeclampsia.  
 
Methods: Design: Retrospective, longitudinal, observational study.  Setting: Tertiary 
referral centre. Population: Women with a history of early-onset preeclampsia. 
Fasting blood samples were obtained before pregnancy and at 12 and 16 weeks 
amenorrhea and analyzed for triglycerides (TG), total-cholesterol (TC), high density 
(HDL-C) and low density lipoproteins cholesterol (LDL-C). Using mixed design re-
peated measurements ANCOVA we compared the longitudinal patterns of lipid 
substrates in women who experienced preeclampsia (n=12) with those who did not 
develop recurrent preeclampsia (n=26). Main outcome measure:  Recurrent preec-
lampsia.  
 
Results: Women who did not develop recurrent preeclampsia showed a transient 
decline in LDL-C by 12 weeks, which was absent in women who did develop recur-
rent disease. The increase in HDL-C in the first 16 weeks tended to be limited in 
women with recurrent preeclampsia as compared to their counterparts without 
recurrent disease. Finally, serum TG rose comparably over the first 16 weeks of 
pregnancy in both subgroups.  
 
Conclusion: These new insights indicate that an abnormal early adaptation of the 
lipid metabolism to pregnancy precedes the clinical manifestation of (recurrent) 
preeclampsia, which may be of pathophysiologic importance and could contribute 
to the development of prediction strategies.  
 
E a r l y - p r e g n a n c y  a d a p t at i o n  o f  t h e  l i p i d  p r o f i l e   
 
 
 
93 
Introduction 
Pregnancy-induced changes in lipid metabolism promote the accumulation of ma-
ternal fat stores in the first half of pregnancy and enhance fat mobilization in late 
gestation. In the early stages, increased estrogen, progesterone, and insulin levels 
favor lipid deposition and inhibit lipolysis.1 After an initial decrease during the first 
trimester, cholesterol and lipoproteins increase steadily throughout gestation.2, 3   
In preeclampsia, plasma lipids have been reported to reach levels substantially 
above those seen in normal pregnancy.4-7 However, in most studies, blood samples 
were collected after diagnosis and, to our knowledge, they all were cross-sectional. 
The pathogenesis of preeclampsia originates in early pregnancy, presumably even 
during the first stages of placentation.8 Unlike normal early pregnancy, when apop-
totic syncytiotrophoblast nuclei are packed into syncytial knots and released in the 
maternal circulation,9-11 in preeclampsia, impaired trophoblast differentiation is 
proposed to lead to mechanisms as necrosis and aponecrosis.12 Eventually, the 
latter may cause systemic alterations of the maternal endothelium and inflamma-
tory system.  
The question arises whether abnormal lipid metabolism and its maladaptation in 
preeclampsia can be detected early in pregnancy. If so, differences in longitudinal 
patterns could improve our understanding of the pathophysiology of preeclampsia 
and offer opportunities for prediction and/or counselling strategies. We aimed to 
study the longitudinal patterns of circulating lipid levels in early pregnancy in for-
merly preeclamptic women who did and those who did not develop recurrent dis-
ease. To this end, we compared the adaptional changes of the lipid profile to preg-
nancy in the two groups.   
Methods 
This is a longitudinal observational cohort study performed at Maastricht University 
Medical Centre in the Netherlands. All measurements reported originate from the 
usual care provided to high-risk obstetrical patients in our centre. In view of their 
increased risk of recurrent disease, pregnant women with a history of early-onset 
(diagnosis ≤ 34 weeks and delivery ≤ 37 weeks of gestational age) preeclampsia are 
being offered a longitudinal screening program to detect abnormalities in the adap-
tation to pregnancy, before clinical symptoms become manifest. The screening 
assessments take place in the non-pregnant condition at least six months after the 
first delivery and at 12, 16 and 20 weeks of the next pregnancy. High-risk obstetrical 
care in this format was initiated in 2002. Although observations had been collected 
prospectively, data collection was done retrospectively. All hospital data, including 
those on pregnancy outcome, were collected and entered in a database by a clinical 
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research assistant who was not involved in the statistical analysis. Prior to analysis, 
data were anonymized. In the Netherlands, ethical approval of a study based on 
anonymous data originating from clinical care as usual is not required. 
In this study, we included all women whose pregnancy outcome was known by 
February 2009 and who had completed at least two check-ups before and/or during 
this pregnancy. We excluded six women because their pregnancy was still ongoing 
and three because two of the three check-ups were missing. Furthermore, we ex-
cluded one woman with a twin pregnancy. Eventually, 38 women with a history of 
early-onset preeclampsia, who had participated in our follow-up program, com-
pleted a subsequent pregnancy and were included in the analysis. 
We defined preeclampsia according to the guidelines of the National working group 
on High Blood Pressure in Pregnancy,13 as de novo hypertension (blood pressure > 
140/90 mmHg, occurring after the 20th week of pregnancy) accompanied by pro-
teinuria (≥ 300 mg in a 24-hour urine sample). Preeclampsia superimposed on 
chronic hypertension was defined as new-onset proteinuria after 20 weeks’ gesta-
tion. We defined the HELLP syndrome as the concomitant occurrence of hemolysis 
(evidence on peripheral blood smear, serum LDH level > 600 IU/L), elevated (≥ 70 
IU/L) serum aspartate aminotransferase (ASAT) and/or alanine aminotransferase 
(ALAT) and a low platelet count (< 100*109/L), as proposed by Sibai et al.14 A small-
for-gestational age (SGA) infant was defined as a child with a birth weight below the 
10th percentile, based on the most recent Dutch birth weight reference curves.15 
Although longitudinal gestational screening data had been collected in our medical 
centre, the location of delivery could be in any of Dutch hospitals, giving rise to 
variation in diagnostic methods for preeclampsia. For example, the diagnosis of 
proteinuria was based on a 24-hours urine collection in some hospitals and on the 
ratio protein to creatinine in others. In the database available for statistical analysis, 
women were coded as having had a next pregnancy complicated by preeclampsia or 
not, according to the definition described above. Individual in-pregnancy laboratory 
values were not supplied.   
Before conception, and again at 12 and 16 weeks pregnancy, venous blood was 
sampled after an overnight fast and - after centrifugation - stored at -30 °C.  Serum 
concentrations of triglycerides (TG), total cholesterol (TC) and high-density lipopro-
tein cholesterol (HDL-C) were determined on a Beckman Coulter LX20 PRO Clinical 
Chemistry analyzer (Beckman Coulter, Fullerton, USA). We calculated low-density 
lipoprotein cholesterol (LDL-C) by the Friedewald equation.16 Pre-pregnant body 
length and weight were determined in a standardized fashion to calculate body 
mass index (BMI). Pre-pregnant fasting levels of glucose and insulin were assessed 
using standard laboratory techniques. 
The statistical analysis was performed using SPSS version 15.0 for Windows. Missing 
values (17% of longitudinal data) were imputed using a single imputation regression 
procedure.17 In case of non-normality, we transformed the data logarithmically. To 
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test differences between longitudinal patterns of lipid substrates during pregnancy 
we used mixed design analysis of covariance (ANCOVA) with a multivariate ap-
proach. Potential confounders were BMI, chronic hypertension, and circulating 
levels of fasting glucose and insulin. Bonferroni’s adjustment for multiple compari-
sons was used in testing within-group differences. Data are presented as mean ± 
standard error (SE), unless otherwise noted. The 95%-confidence intervals pre-
sented in the figures were corrected for between-subject variability according to 
the methods of Loftus and Masson.18,19 All effects are reported as significant at p < 
0.05.  
Results  
Table 1 summarizes the characteristics of the preceding complicated pregnancy. 
Mean gestational age at birth was 30.2 weeks and mean newborn weight 1151 g. 
Ten (26%) women gave birth to an SGA infant and 8 (21%) women had an intra-
uterine fetal demise. In 24 (63%) women, the HELLP syndrome complicated their 
previous early-onset preeclampsia. All women were Caucasian and primiparous. 
None of them had (gestational) diabetes. 
 
Table 1: Obstetric history of 38 women with a history of early-onset preeclampsia. Data are presented as 
mean ± SE or n (%), unless otherwise noted. 
HELLP syndrome  24 (63%) 
Gestational age at 1st birth (weeks) 30.2 ± 0.5 
Birth weight 1st child (g) 1151 ± 95 
Intra-uterine demise 1st pregnancy  8 (21%) 
1st child SGA at birth (< p10) 10 (26%) 
Time between 1st birth and pregravid measurements (months) 9 (6-22) 
Time between pregravid measurements and 12 weeks amenorrhea (months) 6 (5-13) 
Time intervals between 1st birth and pregravid measurements and between pregravid measurements 
and 12 weeks amenorrhea are presented as median (interquartile range). 
 
Table 2 lists the outcome of the next pregnancy. Preeclampsia recurred in 12 (32%, 
95%-CI: 17-46%) women, with 3 early-onset cases, 6 cases with an SGA newborn, 
and 1 with an intra-uterine fetal demise. Eighteen (47%) women did not develop 
maternal hypertensive disease in their next pregnancy, although one of them gave 
birth to an SGA infant.  
Table 3 lists some pregravid clinical features of women with and without recurrent 
preeclampsia. The two subgroups did neither differ clinically nor statistically with 
respect to maternal age, prevalence of overweight, and lipid substrate concentra-
tions. Although not statistically significant, the prevalence of obesity and chronic 
hypertension tended to be lower and that of hyperglycemia and -insulinemia higher 
in women with recurrent preeclampsia.  
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Table 2: Maternal and fetal pregnancy outcome of second pregnancy in formerly preeclamptic women (N 
= 38). Data are presented as n (%). 
Maternal outcome  
Early-onset preeclampsia/HELLP  3 (8%) 
Late-onset preeclampsia/HELLP  9 (24%) 
Pregnancy induced hypertension without proteinuria  8 (21%) 
No hypertensive disease  18 (47%) 
Fetal outcome  
Intra-uterine demise  1 (3%)† 
Extremely preterm birth (< 32 wks) 2 (5%) 
Small for gestational age (< p10)  11 (32%) 
† < 32 weeks amenorrhea, fetal weight < 1500 g (< p2.3), mother had preeclampsia. The two extremely 
preterm births were the result of early-onset preeclampsia. Seven of the pregnancies resulting in a small 
for gestational age infant were complicated by preeclampsia/HELLP.  
 
 
Table 3: Prepregnancy clinical characteristics and lipid profile of women with recurrent preeclampsia (PE) 
and women without recurrent PE. Data are presented as mean ± SE or n (%), unless otherwise noted.   
 PE 
(n = 12) 
No PE 
(n = 26) 
P 
Age (y) 31.6 ± 0.7 31.9 ± 0.8 0.86 
Overweight  5 (42%) 13 (50%) 0.63 
Obesity  1 (8%) 4 (15%) 0.55 
Hyperglycemia  2 (17%) 1(4%) 0.51 
Hyperinsulinemia  4 (33%) 6 (23%) 0.71 
Chronic hypertension  1 (8%) 4 (15%) 0.55 
Total cholesterol (mmol/L) 4.4 ± 0.2 4.7 ± 0.2 0.33 
Triglycerides (mmol/L) 0.88 (0.59-1.41) 0.79 (0.60-1.16) 0.84 
HDL-cholesterol (mmol/L) 1.19 ± 0.09 1.19 ± 0.06 0.95 
LDL-cholesterol (mmol) 2.8 ± 0.1 3.0 ± 0.1 0.36 
Hyperglycemia: fasting glucose level > 5.6 mmol/L; Hyperinsulinemia: fasting insulin level > 15.0 mmol/L. 
Maternal age at 12 weeks amenorrhea. Circulating level of triglycerides are presented as median (inter-
quartile range). Statistical tests: independent samples t-test, Mann-Whitney test, and chi2-test.   
 
Figures 1A to 1D display the changes in lipid parameters with pregnancy. No signifi-
cant differences were observed between groups in the altering circulating levels of 
TC (figure 1A). LDL-C decreased by 12% relative to the pregravid level in the first 12 
weeks of pregnancy in women who did not develop preeclampsia (mean decrease 
0.5 ± 0.1 mmol/L, p < 0.01), to increase again in the period until 16 weeks (figure 
1B). This transient dip in LDL-C was absent in women destined to develop recurrent 
disease (p > 0.99), the pattern being significantly different from women without 
recurrent disease (p = 0.01). HDL-C had increased similarly in both subgroups, with 
no statistically significant differences in patterns of change (p for interaction term = 
0.36) (figure 1C). However, the increase tended to be larger and was statistically 
significant only in the subgroup of women without recurrent preeclampsia (mean 
increase by the 16th week 0.32 ± 0.07 mmol/L, p < 0.01). In women destined to de-
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velop recurrent preeclampsia the increase in HDL-C in 16 weeks was small (0.16 ± 
0.05 mmol/L) and not statistically significant (p = 0.22). Finally, starting at the same 
pregravid level, the increase in serum TG over the first 16 weeks of pregnancy was 
similar in both subgroups, with a median rise of approximately 25% (p < 0.05 in both 
subgroups) (Figure 1D).   
Discussion 
Our results indicate that an initial transient decline in LDL-C was absent in women 
who developed recurrent preeclampsia. Moreover, the increase in HDL-C tended to 
be less strong during the first 16 weeks as compared to women who did not de-
velop recurrent disease. On the other hand, the pre-pregnant circulating levels of 
cholesterol and triglycerides were comparable between women with and without 
recurrent preeclampsia and, throughout the first weeks of pregnancy, triglycerides 
increased in both groups.  
Although partly overcome by evaluating repeated measurements within patients, a 
limitation of the present study is its small sample size. The statistical power to 
detect a within group alteration in cholesterol or triglycerides over time of 0.2 
mmol/L with a standard deviation of 0.3 mmol/L was 90% in women without (n = 
26) and 54% in women with recurrent preeclampsia (n = 12). However, we also 
tested between-group differences in longitudinal patterns (e.g. statistical interac-
tion between the presence of recurrent preeclampsia and gestational age) by 
means of a multivariate approach.  
 We believe that our observations are important, since they address the initial adap-
tation of the lipid profile during the sub-clinical stage of preeclampsia. We aimed to 
evaluate whether these adaptive changes differ between formerly preeclamptic 
women destined to develop recurrent preeclampsia and their counterparts who are 
not. For this reason, we did not include ‘normal’ pregnant women or define a con-
trol group of women without any complications, but compared women who devel-
oped preeclampsia in their second pregnancy with those who did not. To the best of 
our knowledge, early-pregnancy alterations of serum lipid levels in preeclampsia - 
with a preconception level as a starting point- have not been reported previously. 
The initial fall in LDL-C observed in women who did not develop recurrent pree-
clampsia is in line with previous observations in normal pregnancy and is believed 
to result from placental uptake of cholesterol for the synthesis of steroid hor-
mones.1-3,20 Although results are contradictory, oestrogen concentrations have 
repeatedly shown to be reduced relative to levels in uncomplicated pregnancies.21,22 
Since oestrogen is produced by syncytiotrophoblast, the latter could be the result of 
increased aponecrosis of syncytiotrophoblasts in preeclampsia. As we did not 
measure the circulating levels of oestrogen in these women, we can only further 
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speculate that the absence of a decline in LDL-C in women with recurrent pree-
clampsia in our cohort is due to a lower placental steroid production. In a subanaly-
sis, in which we defined a third subgroup (n = 5) of women without preeclampsia 
who gave birth to an SGA infant, the initial fall in LDL-C was absent as well, provid-
ing additional support for reduced placental steroid production to be involved. If 
this hypothesis is to be accepted, the absent decline in LDL-C can be considered a 
marker for recurrent preeclampsia rather than a predisposing factor in its patho-
logical pathway.  
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Figure 1: Circulating levels of: A) total cholesterol, B) LDL-cholesterol, C) HDL-cholesterol, and D) triglyce-
rides, before pregnancy and at 12 and 16 weeks amenorrhea in women with and without recurrent 
preeclampsia. Data are presented as mean with 95%-CI (adjusted for between-subject variability).  
 
Previously, we found cholesterol parameters to be predictive for recurrent early-
onset preeclampsia, with the highest predictive values for HDL-C.23 Due to discrep-
ancy in outcome measures (the present study is not restricted to recurrent early-
onset preeclampsia), pre-pregnant HDL-C levels were comparable between groups. 
However, the mean level of pre-pregnant HDL-C was lower in women with recur-
rent early-onset preeclampsia (n = 3) as compared to women without early-onset 
disease (n = 35) (p < 0.01). 
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Because of the small number of women with this outcome, we did not treat them 
as a separate group in our main analysis. HDL-C is characterized by anti-
inflammatory and endothelium-protective properties.24 In the perspective of pre-
existing low levels of HDL-C, it seems plausible that in affecting endothelial cells or 
the inflammatory system, overkill is facilitated of the mechanisms that dispose 
released apoptotic trophoblast fragments. In turn, this can induce systemic activa-
tion and damage to endothelial cells, which may eventually result in preeclampsia. 
In later pregnancy, circulating levels of HDL-C have repeatedly been proven to be 
reduced in preeclamptic as compared to normotensive women.25,26 In our study, we 
observed a tendency towards an absent increase in the first 16 weeks of pregnancy 
in women who later on developed recurrent preeclampsia as compared to their 
counterparts without recurrent disease.  
Note that the generalisability of our results to nulliparous pregnant women may be 
limited.  To test the hypothesis generated, future research with a larger sample size, 
assessment of steroid hormones and distinguishing early- and late-onset disease is 
needed. 
Conclusion 
The results let us to postulate that the absence of the, for normal pregnancy typical, 
initial decline in LDL-C, observed in women with recurrent preeclampsia, is due to a 
lower placental steroid production in these women. In addition, our data indicate 
that the increase in HDL-C during the first 16 weeks of pregnancy tended to be 
lower in women who later-on developed preeclampsia, possibly heading the re-
duced levels that have been reported later in preeclamptic pregnancy. These new 
insights suggest that an abnormal early adaptation of the lipid metabolism to preg-
nancy precedes the clinical manifestation of (recurrent) preeclampsia, which can be 
of pathophysiologic importance and could contribute to the development of predic-
tion strategies.  
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Abstract 
Objective: To compare the adaptation of the cardiac diastolic function to pregnancy 
between formerly preeclamptics with (RECUR) and without (NORECUR) recurrent 
preeclampsia.  
 
Methods: Retrospective observational cohort study, in which the peak mitral filling 
velocity in early diastole (E) and that at atrial contraction (A) and the E/A ratio were 
assessed before and at 12, 16 and 20 weeks of the next pregnancy in 34 women 
with a history of early-onset preeclampsia.  
 
Results: In 10 (29%) women preeclampsia recurred. By 12 weeks pregnancy, the E/A 
ratio had increased in RECUR, but not in NORECUR (p < 0.01). Moreover, from 16 
weeks onwards, RECUR had a lower cardiac output and higher systemic vascular 
resistance as compared to NORECUR (p < 0.05).  
 
Conclusion: Our results suggest that formerly preeclamptics destined to develop 
recurrent preeclampsia differ from their counterparts who do not develop recurrent 
preeclampsia by impaired first-trimester adaptation of cardiac diastolic function.  
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Introduction 
In normal pregnancy, systemic vascular adaptation starts in the fifth week with a fall 
in vascular tone, resulting in an approximately 30% decline in systemic vascular 
resistance.1-3 As the latter tends to decrease cardiac pre- and afterload, the sympa-
thetic contribution to the autonomic control of the circulation increases.4 The fall in 
systemic vascular tone also activates the volume regulatory system giving rise to 
accelerated volume retention.4 These compensations, which raise cardiac output 
and plasma volume, are paralleled by renal hyperfiltration, hemodilution and acti-
vation of the renin-angiotensin-aldosterone system, eventually resulting in the 
institution of a high flow and low resistance circulation.1  
Data on the concomitant changes in cardiac function are scarce. Pregnancy-induced 
higher tidal volumes modify cardiac pre - and afterload by the concomitant magni-
fied negative intrathoracic pressures.5 Early-onset preeclampsia has been shown to 
be preceded by impaired early-pregnancy hemodynamic and cardiac adaptation.6 
However, it is currently unknown whether maladaptation of the cardiac diastolic 
function to pregnancy is involved in its pathophysiology. In their next pregnancy, 
these women have an increased risk of recurrence of preeclampsia.7  
Our objective was to evaluate whether the adaptation of the cardiac diastolic func-
tion to pregnancy differs between women who develop recurrent preeclampsia and 
those who do not. If true, this phenomenon may eventually offer opportunities for 
future prediction or counseling purposes. We observed a cohort of 34 women with 
a history of early-onset preeclampsia and compared the adaptation of the cardiac 
diastolic function to the next pregnancy between those who did and those who did 
not develop recurrent preeclampsia. Diastolic function parameters had been as-
sessed before the second pregnancy and at 12, 16 and 20 weeks gestation. 
Methods 
This is a longitudinal observational cohort study performed at Maastricht University 
Medical Centre in the Netherlands. All measurements reported originate from the 
usual care provided to high-risk obstetrical patients. It follows that, although obser-
vations were collected prospectively, data collection was done retrospectively. All 
hospital data, including those on pregnancy outcome, were collected and entered in 
a database by a research assistant who was not involved in the statistical analysis. 
Prior to analysis, data were anonymized, making ethical approval superfluous.   
Because of their increased risk for recurrent disease, pregnant women with a histo-
ry of early-onset (diagnosis ≤ 34 weeks and delivery ≤ 37 weeks of gestational age) 
preeclampsia receive high-risk obstetrical care in our hospital, which consists of a 
thorough medical check-up at 12, 16 and 20 weeks pregnancy. Combined with a 
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preconceptional check-up (at least 6 months after first delivery), these measure-
ments serve to detect abnormalities in the adaptation to pregnancy before clinical 
signs become manifest. High-risk obstetrical care in this format was initiated in 
2002.  
In this study, we included all women whose pregnancy outcome was known by 
December 2008 and who had completed at least three check-ups. We excluded four 
women because their pregnancy was still ongoing and two because two or more 
check-ups were missing. Furthermore, we excluded one woman with a twin preg-
nancy and one because of chronic renal failure. Eventually, 34 women with a history 
of early-onset preeclampsia, who had participated in our in-pregnancy follow-up 
program, completed a subsequent pregnancy, and were included in the analysis.  
Although screening data were collected in our medical centre, the location of deli-
very in the next pregnancy could be in any of Dutch hospitals. Diagnostic methods 
for preeclampsia varied between hospitals. For example, the diagnosis of proteinu-
ria was based on a 24-hours urine collection in some hospitals and on the ratio 
protein to creatinine in others. Preeclampsia was defined according to the guide-
lines of the National working group on High Blood Pressure in Pregnancy, as de 
novo hypertension (blood pressure > 140/90 mmHg, occurring after the 20th week 
of pregnancy) accompanied by proteinuria (> 300 mg/24h or > 30 mg/mmol creati-
nine).8 Preeclampsia superimposed on chronic hypertension was defined as new-
onset proteinuria after 20 weeks’ gestation. In the database available for statistical 
analysis, women were coded as having had a next pregnancy complicated by preec-
lampsia or not. Individual in-pregnancy laboratory values were not supplied.  A birth 
weight below the 10th percentile, based on the most recent Dutch birth weight 
reference curves,9 was used to diagnose fetal growth restriction in the preceding 
pregnancy.  
Echocardiography was performed with the patient in the left-lateral position, after 5 
minutes of rest, with an S5-1 (bandwidth 5-1 MHz) phased array transducer inter-
faced with a Philips IE33 system (Philips Medical Systems, Best, The Netherlands). 
Pulsed wave (PW) Doppler-derived transmitral velocities were obtained at the mi-
tral leaflet tips according to the guidelines of the American Society of Echocardio-
graphy.10 From the parasternal long axis view we performed the following mea-
surements: left ventricular end-diastolic diameter (LVEDD), left ventricular end 
systolic diameter (LVESD), interventricular septal end diastolic wall thickness, post-
erior wall end diastolic wall thickness and left atrial diameter (LAD) according to 
criteria of the American Society of Echocardiography.11 The diameter of the inferior 
caval vein was measured from a substernal M-Mode recording. Left ventricular 
mass was calculated by the Devereux formula.12 Left atrial volume was measured in 
the apical four- and two chamber view at mitral valve closure using the biplane 
method of discs.13 In the apical 4 chamber view, right atrial volume was estimated 
using the area-length formula.11 Cardiac dimensions were indexed to body surface 
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area. All data were stored digitally and calculations were performed offline using 
dedicated software (Excelera, Philips, The Netherlands) by a single observer, who 
was blinded to the clinical data.  
LV function was assessed using Teicholz formula applied to ventricular diameters 
measured parasternally, resulting in LV ejection fraction.14 Cardiac output (CO, 
L/min) was obtained by multiplying stroke volume (SV) with heart rate (HR). The HR 
was obtained by taking the reciprocal of the mean of 3-5 consecutive R-R intervals 
on the electrocardiogram. From an apical approach, aortic flow across the aortic 
valve was measured using continuous wave (CW) Doppler. SV was calculated by 
multiplying aortic velocity time integral (VTI) with the cross-sectional area measured 
at the level of the aortic annulus in the parasternal long axis view. The mean VTI, 
used to calculate SV, was measured by averaging the outer edge tracings of 3-5 
consecutive CW Doppler registrations.  
Diastolic function was measured using PW Doppler echocardiography to obtain 
transmitral flow determined from the apical 4-chamber view. The PW Doppler sam-
ple volume (5mm) was carefully positioned at the tip of the mitral valve leaflets. 
The sweep rate was set at 50 mm/s. We defined E/A ratio as the ratio of peak mitral 
flow velocity in early diastole (E) and that during atrial contraction (A). In addition, 
the E-wave deceleration time was measured.15 Doppler derived indices were aver-
aged from 3-5 consecutive cardiac cycles.  
We recorded blood pressure in standardized environmental conditions with exter-
nal disturbances kept to a minimum and the subject laying on her back. Participants 
did not eat for at least 10 hours prior to the measurement. We registered blood 
pressure every three minutes, using a semiautomatic oscillometric device (Dinamap 
Vital Signs Monitor 1846; Critikon, Tampa, Florida, USA), during 30 minutes. 
SPSS package version 15.0.0 was used for statistical analysis. We transformed non-
normally distributed data logarithmically. To evaluate the response of the cardiac 
diastolic function to pregnancy and differences in this response between groups we 
used mixed design analysis of covariance (ANCOVA). Missing values were imputed 
using a single imputation regression procedure to avoid listwise deletion.16 In order 
to control for regression to the mean, we adjusted for baseline (prepregnancy) 
values in all between groups comparisons of patterns.17 Pregravid body mass index 
(BMI), mean arterial pressure and gestational age at previous delivery as a measure 
for disease onset were considered potential confounders and therefore were added 
to the model as well.  
The p-values reported for interaction resulted after adjustment for these confound-
ers. In the mixed design ANCOVA analysis, statistically significant interaction indi-
cates different longitudinal patterns in women with recurrent preeclampsia as 
compared to those without recurrence. Bonferroni’s adjustment for multiple com-
parisons was used in testing within-group differences. Data are presented as mean 
± SD, unless otherwise stated. The 95%-confidence intervals presented in the fig-
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ures are corrected for between-subject variability according to the methods of Lof-
tus and Masson.18 All effects are reported as significant at p < 0.05. 
Results 
Ten (29%, 95%CI: 13-42%) of the 34 formerly preeclamptic women developed re-
current preeclampsia (RECUR) in their next pregnancy. The remaining 24 women 
had no recurrent event in their next pregnancy (NORECUR), although five of them 
developed gestational hypertension.  
 
Table 1: Pregravid demographic, clinical and obstetric history characteristics of  formerly pree-
clamptic women with (n = 10) and without recurrent preeclampsia (n = 24) in their next pregnancy. 
Data are presented as mean ± SD or n (%) unless otherwise noted. 
Variable RECUR  
(n = 10) 
NORECUR  
(n = 24) 
Maternal age (y) 30 ± 5 33 ± 5 
BMI (kg/m2) 24.5 ± 3.5 27.0 ± 5.2 
Height (cm) 164 ± 4 169 ± 6 
Mean arterial pressure (mmHg) 96 ± 7 94 ± 15 
Chronic hypertension 3 (30%) 6 (25%) 
Smoking  1 (10%) 1 (4%) 
Multiparity 1 (10%) 1 (4%) 
Gestational age previous birth (wks) 29.6 ± 2.9 30.6 ± 3.8 
Very preterm birth (< 32 wks)  8 (80%) 15 (63%) 
Birth weight of previous child (g) 890 (599-1348) 990 (615-1680) 
Very low birth weight (< 1500 g) 8 (80%) 17 (71%) 
Previous SGA newborn (< p10) 4 (40%) 10 (42%) 
IUFD in previous gestation 3 (30%) 7 (29%) 
Maternal age at 12 weeks pregnancy. Birth weight is presented as median (inter-quartile range).  
BMI: body mass index; IUFD: intra-uterine fetal demise.  
 
Table 1 lists pregravid demographic, clinical and obstetric characteristics of the 
women in both subgroups (leaving statistical significance of the differences aside). 
The groups did not differ from one another with respect to mean arterial pressure, 
chronic hypertension, smoking status and parity. None of the women had diabetes 
mellitus. Mean maternal age, BMI and height were lower in the RECUR group. 
Moreover, duration of previous pregnancy in RECUR was on average one week 
shorter with a higher frequency of very preterm births (< 32 weeks), and with me-
dian birth weight being 100 g lower as compared to NORECUR. Furthermore, fre-
quencies of very low-birth-weight infants (< 1500 g), small-for-gestational-age (SGA) 
infants and intra-uterine fetal demise did not differ between groups. Tables 2 and 3 
list the mean prepregnancy values for cardiac dimensions and cardiac function va-
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riables. None of these variables differed appreciably between RECUR and NORE-
CUR. 
Table 2: Pregravid cardiac dimensions in 10 formerly preeclamptic women, who developed recurrent 
preeclampsia in their subsequent pregnancy (RECUR) and 24 formerly preeclamptics who did not (NORE-
CUR). Data are presented as mean ± SD. 
Variable RECUR  
(n = 10) 
NORECUR  
(n = 24) 
P 
Left atrium diameter (mm) 2.0 ± 0.2 1.8 ± 0.1 0.12 
Left atrium volume (mL) 30.9 ± 7.52 30.4 ± 5.8 0.82 
Left ventricular mass (g) 74.3 ± 12.4 77.2 ± 11.0 0.51 
Left ventricular end-diastolic diameter (mm) 26.1 ± 2.5 25.1 ± 2.2 0.22 
Left ventricular end-systolic diameter (mm) 16.8 ± 1.8 16.7 ± 1.7 0.79 
Vena cava diameter (mm) 7.9 ± 1.8 9.3 ± 2.3 0.10 
The independent t-test was used. All cardiac dimensions were indexed to body surface area (m2).  
 
 
Table 3: Pregravid cardiac function variables in 10 formerly preeclamptic women who developed recur-
rent preeclampsia in their subsequent pregnancy (RECUR) and 24 formerly preeclamptics who did not 
(NORECUR). Data are presented as mean ± SD. 
Variable RECUR  
(n = 10) 
NORECUR  
(n = 24) 
P 
Peak E-wave velocity (cm/s) 80.5 ± 13.6 85.4 ± 12.7 0.32 
Peak A-wave velocity (cm/s) 58.8 ± 10.9 58.4 ± 9.1 0.91 
E/A ratio 1.4 ± 0.3 1.5 ± 0.3 0.60 
E deceleration time (s) 0.15 ± 0.3 0.17 ± 0.04 0.27 
Cardiac output (mL) 5.12 ± 0.78 5.25 ± 0.88 0.68 
Stroke volume (mL) 68.3 ± 11.2 73.7 ± 12.8 0.26 
Heart rate (bpm) 76.2 ± 16.6 72.5 ± 14.0 0.51 
TPVR (dynes∙s∙cm-5) 1532 ± 249 1477 ± 325 0.64 
The independent t-test was used. TPVR: total peripheral vascular resistance.  
 
Overall, 4% of the longitudinal data were imputed because of missing values. The 
pregnancy-induced changes in E/A ratio are displayed in figure 1. As opposed to no 
appreciable first-trimester change in E/A ratio in NORECUR, we observed a consis-
tent rise in this ratio in RECUR (p < 0.01 for interaction). The latter resulted from a 
trend towards a steeper rise in E-wave velocity relative to NORECUR ( p = 0.33 for 
interaction), along with a fall in A-wave velocity (p = 0.02 for interaction). In con-
trast, in NORECUR, pregnancy had induced a consistent rise in the A-wave velocity, 
on average by 4.9 ± 1.8 cm/sec (p = 0.05) (fig. 1). An increase in E/A ratio of more 
than 7% by 12 weeks pregnancy (difference score, cut-off was estimated by receiver 
operating characteristic curve) was associated with an increased risk for recurrent 
preeclampsia, the relative risk being 4.80 (95%-CI: 1.86-12.37). The responses of the 
E deceleration time and left atrial diameters and volumes to pregnancy did not 
differ between both groups. 
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Figures 2 and 3 show the changes in cardiac output and total peripheral vascular 
resistance in the first 20 weeks of gestation. From 16 weeks onwards, cardiac out-
put was lower and systemic vascular resistance higher in RECUR as compared to 
NORECUR (p < 0.05).  
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Figure 1: Mean and 95% confidence intervals (corrected for between-subjects variability) of the E/A ratio 
in the first 20 weeks and the E and A wave velocity in the first 12 weeks of pregnancy in women who 
developed recurrent preeclampsia (black squares) and those who did not (gray squares).    
Comment 
Our results indicate that formerly preeclamptic women destined to develop recur-
rent disease in their next pregnancy differed from their counterparts with no recur-
rent disease by a rise in E/A ratio in the first trimester, together with a lower cardiac 
output and higher peripheral vascular resistance between 16 and 20 weeks. In the 
recurrence group, the first-trimester increase in E/A ratio resulted from an increas-
ing trend in the E-wave velocity along with a decrease in A-wave velocity. In con-
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trast, in women without recurrent disease both E- and A-wave velocity had in-
creased in response to pregnancy, resulting in an absent initial change in E/A ratio.  
This study is limited to a small sample size. Nevertheless, we believe that our obser-
vations are important, as they address the initial changes in cardiac function in the 
period of pregnancy when they are expected to be largest. We wanted to find out 
whether these adaptive changes differ between formerly preeclamptic women who 
do and do not develop recurrent preeclampsia in their next pregnancy. For this 
reason, we did not include ‘normal’ pregnant women or define a control group of 
women without any complications, but compared RECUR with NORECUR. The non-
invasive assessment of cardiac diastolic function by echocardiography is complex. 
Besides the basic parameters reported in this study, more sophisticated methods 
exist to determine left ventricular diastolic function, based on complex analysis of 
transmitral flow, pulmonary vein flow, color M-mode velocity propagation and 
tissue Doppler imaging.  
Nine women in the NORECUR subgroup had gestational hypertension without 
proteinuria and/or gave birth to a growth-restricted infant. To verify that these 
women had not distorted our findings we performed a sub-analysis in which they 
were considered a third subgroup. The response in these women was similar to the 
remainder of the women in NORECUR with respect to the main variables evaluated.  
In a previous study, early cardiac adaptation to pregnancy was found to differ be-
tween formerly preeclamptic women with subnormal (≤ 48 mL/kg lean body mass) 
and normal plasma volume.1 In the present study, the proportions of women with 
subnormal plasma volume were similar in RECUR and NORECUR (60% vs. 55%, re-
spectively), indicating that plasma volume had not influenced the effects observed.  
It is well established that the mitral E-wave velocity primarily reflects the pressure 
gradient between the left atrium (LA) and left ventricle (LV) during early diastole. 
The E-wave velocity is thus affected by both preload and alterations in LV relaxa-
tion. Meanwhile, the mitral A-wave velocity reflects the LA-LV pressure gradient 
during late diastole, affected by LV compliance and LA contractile function. During 
normal pregnancy, there is a reversible shift in transmitral flow velocities from early 
to late filling leading to a decreased E/A ratio in late pregnancy. This is strongly 
related to physiologic changes in HR, preload, LV compliance and contractility, as 
well as to gestational age.19 The increase in A-wave velocity observed in NORECUR is 
in line with previous findings,20 but in contrast with others,21,22 and is consistent 
with enhanced LA contraction in the face of the pregnancy-induced increase in LA 
preload and LV compliance.3  
In diastolic dysfunction, atrial contribution to LV filling is reduced due to impaired 
left ventricular relaxation and increased LV end-diastolic filling pressures. 24, 25  
Although a parallel with preeclampsia should be drawn with caution, we believe the 
steeper increase in E-wave velocity observed in the RECUR group during early preg-
nancy, together with a trend in A-wave velocity to decline, reflects impaired relaxa-
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tion and higher LV end-diastolic filling pressures due to increased LV stiffness in 
these women. Future studies including more detailed assessment of pregnancy-
induced response of the cardiac diastolic function (even in normal pregnancy), are 
needed to prove the importance of this phenomenon. The results of this study may 
provide a starting point to further explore the possibilities of this phenomenon for 
early counseling and predictive purposes.  
 
 
 
 
Figure 2: Mean and 95% confidence intervals (corrected for between-subjects variability) of cardiac 
output (CO) and total peripheral vascular resistance (TPVR) in the first 20 weeks of pregnancy in women 
who developed recurrent preeclampsia (black squares) and those who did not (gray squares).   
 
In summary, we found that formerly preeclamptic women, who developed recur-
rent preeclampsia in their next pregnancy differed from their counterparts who did 
not. Formerly preeclamptic women showed an initial rise in E/A ratio, which is con-
sistent with an initially impaired adaptation of the cardiac diastolic function. In the 
recurrence group this phenomenon was followed by a lack of increase in cardiac 
output in concert with a rise in systemic vascular resistance, providing indirect evi-
E a r l y - c a r d i a c  a d a p t a t i on  t o  p r e g n a n c y   
 
 
 
111 
dence for a higher sympathetic contribution to the autonomic control of the circula-
tion in the second trimester. The latter supports the view that impaired adaptation 
of the cardiac diastolic function might be an important contributor to the subnor-
mal cardiovascular adaptation to pregnancy preceding overt preeclampsia.  
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Abstract 
Studies of recurrent abnormal pregnancy outcome are becoming increasingly im-
portant for the development of evidence-based guidelines in clinical management. 
Therefore, it is important to emphasize that these studies may be subject to a rela-
tively unknown type of bias, the so-called “collider bias”. This type of bias may lead 
to seriously distorted, even inverted association estimates. In this report, we illu-
strate the concept of collider bias using a quantitative example of recurrent adverse 
pregnancy outcome and discuss scientific and clinical implications of this methodo-
logical problem. Collider bias may, however, distort associations in any study on the 
influence of factors on recurrence risk.  
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Introduction 
Women with a certain pregnancy complication or adverse pregnancy outcome 
usually have an increased risk of that outcome in a next pregnancy. Data gathered 
from women with a history of a certain adverse pregnancy outcome may provide 
clues about causation and can be used for the development of prediction models or 
the evaluation of risk factors for recurrent disease.1 This may help care providers in 
their future clinical management of high-risk women.  
In this report, we will focus on a relatively unknown type of bias that may affect 
studies of recurrence risk. The bias, referred to as collider bias,2,3 is introduced 
when a study population is restricted to persons who previously experienced the 
outcome under study, a strategy commonly employed in reproductive recurrence 
studies. Specifically, the bias affects strength and sometimes direction of estimates 
of association between risk factors and recurrence. We will illustrate the phenome-
non of collider bias using a fictitious example of obesity as a risk factor for preec-
lampsia in both the first and second pregnancy. Furthermore, we discuss general 
scientific and clinical impact of the bias and provide some recommendations to deal 
with it. 
 
Prior pregnancy outcome as a collider in studies on reproductive recurrence risk  
A collider is a factor that is affected by two or more other variables in a causal dia-
gram.2, 3 An example is low birth weight, being affected by - among others - smoking 
and genetic factors. Within strata of a collider, associations among its causal factors 
are different than they are without stratification; associations may even arise that 
were non-existent before stratification.2, 3 Smoking women delivering a low birth 
weight child may have a lower probability of carrying certain genetic factors leading 
to low birth weight than non-smokers with small infants, even when the occurrence 
of these genetic factors and smoking are unrelated in the unselected population. In 
studies on recurrence risk of a certain adverse reproductive outcome, restriction to 
women with that outcome in a previous pregnancy is a common procedure. Be-
cause of the resulting association (either introduced or altered) between potential 
risk factors of the outcome, their crude individual effects on recurrence risk will be 
biased.    
 
Figure 1 schematically depicts the introduction of an association between two risk 
factors, A and B, through restriction to previous pregnancy outcome. Consequently, 
the crude association between factor A and recurrence of the pregnancy outcome is 
distorted by factor B (or vice versa). All recurrence-risk studies with prior occur-
rence of the outcome as an inclusion criterion may in theory be affected by collider 
bias, with the involvement of a wide range of causal factors.   
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Figure 1: Possible relations among risk factors A and B, prior pregnancy outcome and recurrent outcome 
in a next pregnancy.   
Obesity and recurrent preeclampsia, a quantitative example 
Preeclampsia is a hypertensive disorder of pregnancy with potentially serious con-
sequences for mother and child. Women with a history of preeclampsia are at in-
creased risk of developing the disease in a next pregnancy.4 The magnitude of this 
risk depends, among others, on maternal preexisting medical disorders or constitu-
tional genetic factors. One of the objectives of counseling former patients is to mi-
nimize the impact of these risk factors before a next conception.4  
Contrary to expectation, but in line with the methodological problem described 
above, some risk factors for preeclampsia in primigravid women remain unidenti-
fied as such in women with a history of preeclampsia. An example is a high maternal 
body mass index (BMI). Being a generally accepted risk factor for preeclampsia in 
unselected women,5 with a BMI of 21 as a reference, the risk of preeclampsia 
doubles at a BMI of 26 (odds ratio 2.1), triples at a BMI of 30 (odds ratio 2.9) and 
increases further with severe obesity (odds ratio 3.5), its association with recurrent 
preeclampsia has been reported to be weaker (relative risk = 1.27 (95%-CI: 1.07-
1.50) for BMI 25.0-29.9 kg/m2 and 1.68 (95%-CI: 1.45-1.95) for BMI ≥ 30 kg/m2),6 
absent (relative risk = 1.07 (95%-CI: 0.46-2.46) for BMI > 25 kg/m2),7 or even inverse 
(hazard ratio = 0.9 (95%-CI: 0.8-1.0) for BMI as a continuous factor).8 Although an 
absent or even protective effect of high BMI on the recurrence risk of preeclampsia 
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does not seem plausible, an explanation for this paradoxical finding has not been 
provided so far. Using a quantitative example, in which obesity is evaluated as a risk 
factor for both preeclampsia in the first pregnancy and recurrent preeclampsia in 
the second pregnancy, we will try to show that collider bias is a possible explanation 
for this finding. 
We assumed a population of 100,000 nulliparous women who eventually completed 
two consecutive pregnancies. These women each had a combination of two charac-
teristics: obesity (OB) or not, and another (non-specified) risk factor of preeclampsia 
(OTHER) or not. We set the prevalence of OB at 20% and that of OTHER at 5%, and 
stipulated marginal independence between the two variables (i.e. the probability of 
having one risk factor is independent of having the other or not). During the wom-
en’s first pregnancy, the risk of preeclampsia was assumed to be 10% in the pres-
ence of OB and 50% in the presence of OTHER. Furthermore, the combined effect of 
the presence of OB and OTHER was assumed to be 60%. We set the risk of preec-
lampsia in the absence of both factors at only 1%, implying that OB and OTHER are 
responsible for the great majority of cases of preeclampsia.  Finally, all women had 
a second pregnancy with the risk of developing preeclampsia being the same as in 
the first pregnancy, given each woman’s individual combination of risk factors. We 
thus assumed that these risk factors did not change across pregnancies.  
Tables 1 and 2 list the results of the quantitative example in this cohort of women. 
As shown, 4660 (5%) women developed preeclampsia in their first pregnancy (table 
2). Obesity was a risk factor for preeclampsia in this first pregnancy, with a crude 
relative risk of 3.0. The absolute risk of preeclampsia was 10% in obese and 3.3% in 
non-obese women. Among women with preeclampsia in their first pregnancy, the 
probability of having OB, given that OTHER was present, was 24%, and given that 
OTHER was absent, 64% (in the total population this figure was 20% for both com-
binations).  
 
Table 1: Quantitative example of the occurrence of preeclampsia in the first pregnancy (N = 100,000) and 
its association with obesity (OB). 
Cross-table: Occurrence of preeclampsia (expressed as proportion of total in each cell) in 100,000 nul-
liparous women. 
 OTHER+ OTHER- Total  
OB+ 600 / 1,000 1,400 / 19,000 2,000 / 20,000  
OB- 1,900 / 4,000 760 / 7,6000 2,660 / 80,000  
Total 2,500 / 5,000 2,160 / 95,000 4,660 / 100,000  
Risk of preeclampsia:    
OB+ 10%    
OB- 3%    
Overall 5%    
Crude relative risk (RR) of preeclampsia (OB+/OB-): 3.0 
Stratum specific RR of preeclampsia (OB+/OB-) if OTHER+:  1.3 
Stratum specific RR of preeclampsia (OB+/OB-) if OTHER-: 7.4 
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In their next pregnancy, preeclampsia recurred in 29% of formerly preeclamptics 
(table 2). The crude relative risk of recurrent preeclampsia in obese versus non-
obese women was 0.7, whereas the relative risk was 3.0 in the first pregnancy. 
However, the relative risks of recurrent preeclampsia in each stratum of OTHER 
were identical to those in the first pregnancy (table 2).  
OTHER distorted the crude association between OB and recurrence of preeclampsia 
in the second pregnancy in such a way that the crude RR points to a protective ef-
fect of OB, while in facts it was as strong a risk factor for recurrent disease as it was 
for preeclampsia in the first pregnancy. Although, in this example, the bias could be 
removed through stratification on OTHER, this maneuver is seldom feasible in prac-
tice because of incomplete knowledge of the relevant other factors.   
Implications for studies on recurrence risk 
Collider bias can occur in any recurrence risk study in which sample selection is 
based on prior occurrence of the disorder studied. The bias has different implica-
tions for etiologic and prediction studies. In etiologic studies, this kind of confound-
ing may distort the crude association between a factor and recurrence, leading to 
false conclusions with respect to disease etiology. In prediction studies, potential 
predictors for recurrence of an event are usually selected on the basis of knowledge 
of prognostic factors for the initial event. As a consequence of collider-stratification 
bias and corresponding confounding, these factors may lose their predictive value in 
the selected population.  
Possibly, collider bias is also a source of heterogeneity across study populations 
selected on the basis of a previous event. In the example of OB and recurrent preec-
lampsia described above, the factor OTHER may in fact refer to a collection of sev-
eral maternal conditions predisposing to preeclampsia. We have seen that sample 
Table 2: Quantitative example of recurrence of preeclampsia in the second pregnancy of formerly 
preeclamptic women (N = 4,660) and its association with obesity (OB). 
Cross-table: Recurrence of preeclampsia (expressed as proportion of total in each cell) in 4,660 
formerly preeclamptics. 
 OTHER+ OTHER- Total  
OB+ 360 / 600 103 / 1400 463 / 2000  
OB- 903 / 1900 8 / 760 910 / 2660  
Total 1263 / 2500 111 / 2160 1373 / 4660  
Risk of preeclampsia:    
OB+ 23%    
OB- 34%    
Overall 29%    
Crude relative risk (RR) of preeclampsia (OB+/OB-): 0.7 
Stratum specific RR of preeclampsia (OB+/OB-) if OTHER+:  1.3 
Stratum specific RR of preeclampsia (OB+/OB-) if OTHER-: 7.4 
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selection based on the collider ‘prior preeclampsia’ can introduce confounding bias; 
meanwhile, also the prevalence of maternal conditions predisposing to preeclamp-
sia may differ between populations and with it the strength of confounding. In eti-
ologic studies, this may result in heterogeneous association estimates with some-
times inconsistent or even contradictory results across studies. In prediction stu-
dies, variations in the magnitude of the bias can affect external validity of prediction 
tools in independent populations. 
In our example, we assumed the risk of preeclampsia in the second pregnancy for 
the different combinations of OB and OTHER to be the same as in the first pregnan-
cy. However, the uterine environment in the next pregnancy may be different, due 
to aging, a different interaction with a new fetal genome, and ongoing exposure to 
only partly known environmental stressors. Obviously, our numerical example 
merely serves to demonstrate the possibility of collider bias when a study popula-
tion is selected based on prior pregnancy outcome. In empirical recurrence risk 
studies, other than methodological explanations for paradoxical associations are 
also possible.   
The finding that prior pregnancy outcome can be a collider in the causal diagram 
leading to recurrence of a pregnancy outcome has been described before in the 
light of adjusting for reproductive history in analytic models.9,10 Controversy exists 
whether it is appropriate to adjust for reproductive history, when the objective is to 
obtain an unbiased estimate of the effect of a certain variable  on recurrent disease 
or outcome.9-11  
Recently, collider-stratification bias was subject of debate in the field of reproduc-
tive medicine in conjunction with paradoxical findings of the effect of partner 
change on preeclampsia risk and that of birth weight on infant-mortality.12,13 Not 
reproductive history, but exposure variables were identified as colliders in these 
studies. The type of collider bias presented in the present paper, has, to our know-
ledge, not been reported before.   
Clinical implications 
Pregnancy is an attractive condition for studying recurrence risk. The effects of 
having had a certain complication in the first pregnancy often carry over into a next 
pregnancy, either through changes in health, changes in clinical management, or 
through stress and anxiety.14 Research on recurrent pregnancy complications is 
essential for the provision of clinicians with information for counseling and im-
provement of management plans for patients with a history of adverse outcomes.14 
Most pregnancy complications tend to recur in a next pregnancy.14 It has become 
clear that these conditions have a complex mix of risk factors and etiologies. This 
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heterogeneity in particular makes it challenging to study and quantify recurrence 
risk.  
Much of the quantitative assessment of recurrence risk of adverse pregnancy out-
comes is based on epidemiological data. Assessing associations between a particu-
lar risk factor and a recurrent outcome may provide important clues to both etiolo-
gy and clinical care. Awareness of the phenomenon of collider bias is crucial, as in 
risk factor studies these estimations can become distorted. This is also true for pre-
diction studies. Coefficients in prediction models should always be interpreted with 
caution as these models are not designed to estimate associations. In addition, 
collider bias may lead to coefficients in the model suggesting a protective effect of a 
(potential risk) factor. Therefore, absent or invert associations of factors known to 
be strong risk factors for the initial occurrence of a certain complication or pregnan-
cy outcome, should be interpreted with caution as they are likely to be biased by 
sample selection. Nevertheless, predicted risks themselves are not expected to be 
subject to collider bias.  
Recommendations 
The possibility of collider bias should be taken into account in the design stage of a 
study on recurrent pregnancy outcome. In recurrence risk studies, an observational 
cohort design is commonly applied. In such a design, women with an index preg-
nancy are followed longitudinally over time and outcomes are observed in the next 
pregnancy. Including all women with an index pregnancy in this cohort, rather than 
limiting the cohort to women with prior adverse outcome only, enables analysis of 
the two strata (with or without prior outcome) both combined and separately.  
In theory, completely removing the bias caused by sample selection is only possible 
by means of adjustment for all causal factors in the pathological pathway of the 
recurrent disease or outcome. Unfortunately, this solution is elusive as many causal 
factors are still unknown. In reproductive medicine, often three sources of causa-
tion (mother, father, and child) are involved, hampering appropriate correction 
even further. However, adjustment for as many maternal, paternal and fetal condi-
tions as possible may reduce the confounding effects, its success rate depending 
largely on the quantity of causes.  
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Abstract 
Risk estimates derived from preconception prediction models can be used to coun-
sel women with regard to any future pregnancies. Women with a high predicted risk 
of an adverse pregnancy outcome may decide more often not to try for another 
pregnancy again than women with a low predicted risk. This prediction guided se-
lective fertility can cause a change in the composition of the pregnant population 
with respect to those parameters that are comprised in the prediction model. The 
question can be raised whether such a change in composition could influence per-
formance parameters of the prediction model, such as sensitivity, specificity, posi-
tive- and negative predictive values and discriminative ability, when evaluating risks 
in the new population and whether it could compromise the longevity of the model. 
Using a hypothetical example, we show that the original sensitivity and specificity 
estimates of a preconception prediction model for an adverse pregnancy outcome 
do not hold anymore when the model is applied in a population affected by model-
based selective fertility: sensitivity decreases, while specificity increases. However, 
individual patient risk estimates remained unbiased, and discriminative ability, ex-
pressed as the area under the receiver operating characteristic (ROC) curve, remain 
unaffected. In diagnostic research, several types of bias with similar mechanisms 
have been described. 
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Introduction 
Multivariable models for the prediction of individual risks of adverse health out-
comes are increasingly being developed and used within a wide range of clinical 
disciplines. In gynecology, models have been developed for the prediction of, 
among others, fertility after in vitro insemination,1 small-for-gestational-age fetus-
es,2 preeclampsia,3 and recurrence of preeclampsia.4 Some models estimate risks of 
adverse reproductive outcome on the basis of preconception factors only, while 
others (additionally) take parameters into account that are measured during the 
target pregnancy. 
Individual risk estimates derived from preconception prediction models may be 
used for counseling purposes and the optimization of preconception and antepar-
tum care. In this way, the result of preconception prediction models may influence 
women’s choices whether or not to try for a subsequent pregnancy. Such influence 
could be regarded as a variant of selective fertility, a phenomenon earlier defined as 
the tendency to adjust reproduction after the outcome of previous pregnancies.5 
Women with a high predicted risk of an adverse pregnancy outcome may decide 
more often not to get pregnant again than women with a low predicted risk, and 
vice versa. This prediction-guided type of selective fertility may thus cause changes 
in the composition of the population of pregnant women with respect to those 
parameters that are comprised in the prediction model. The question can be raised 
whether such a change in composition can have implications for the future predic-
tive ability of the model. 
In this paper, using a hypothetical example with simulated data, we will show that 
predictive sensitivity and specificity at different cutoff points of predicted probabili-
ties can change under the influence of selective fertility, while the discriminative 
ability of the model as well as individual risk predictions remain unaffected. 
Methods 
Measures of model performance 
Predicted probabilities, derived from the prediction model, that exceed a pre-
specified cutoff point are usually defined as a positive test result, while values be-
low the pre-specified cutoff point are considered a negative test result. Frequently 
used measures of prediction model performance are predictive sensitivity and spe-
cificity. Sensitivity is the number of subjects with a positive test result who develop 
the outcome, divided by the total number of subjects who develop the outcome. 
Specificity, on the other hand, is the number of subjects with a negative test who do 
not develop the outcome, divided by the total number of subjects who do not de-
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velop the outcome. Sensitivity and specificity are inversely related, and if both pa-
rameters are computed for several cutoff values, a receiver operating characteristic 
(ROC) curve can be plotted. The area under the ROC curve (AUC), or the concor-
dance statistic (c-statistic), is a measure of the discriminative ability of the model. 
The AUC represents the chance that a randomly selected subject who develops the 
outcome has a higher test score than a randomly selected subject who doesn’t 
develop the outcome.  
Two performance measures that are often more relevant to clinical practice are the 
positive and negative predictive value of a test. The positive predictive value is the 
number of subjects with a positive test result who develop the outcome, divided by 
the total number of subjects with a positive test result. The negative predictive 
value is the proportion of subjects with a negative test who do not develop the 
outcome, divided by the total number of subjects with a negative test result. The 
positive and negative predictive values thus denote the chance of developing the 
disease (or its complement), giving the outcome of the test. 
Illustration  
Consider the hypothetical data of 5000 women who experienced severe preeclamp-
sia in their first pregnancy. We emphasize that all following assumptions are made 
for simulation purposes. We assumed that, although all women in the population 
wished to get pregnant again, 20 percent of them refrained from trying because of 
fear of recurrent disease. Not having been exposed to the future prediction rule, 
these women represented a random selection of the population. 
In order to keep the illustration straightforward, we further assumed that all wom-
en who tried to get pregnant, succeeded in achieving an ongoing pregnancy, so that 
consecutive pregnancy outcomes are known for all of the remaining 4000 women. 
This population will henceforth be referred to as the derivation population (table 1). 
Suppose a simple prediction model was developed using recorded data of the deri-
vation population, in which individual risk estimates of recurrent preeclampsia were 
determined by the presence or absence of one or more of a total of 4 risk factors. 
Extremely simplified, the mean risk of recurrence among women with no risk fac-
tors present was set at 5%, and 10, 15, 20 and 25% among women with 1, 2, 3 and 4 
risk factors present, respectively. In order to achieve a high sensitivity, women with 
a predicted risk >5% were set to test positive. For this specific cut-off point, sensitiv-
ity, specificity, positive predictive value and negative predictive value were com-
puted. Using estimates of sensitivity and specificity for all predefined cut-off points, 
the ROC curve was plotted and the area under curve was estimated. After develop-
ment, this prediction model was proven valid in an independent population, and it 
was decided to apply the model in routine clinical practice. 
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Next, consider the population in which the prediction model is applied (henceforth 
referred to as the application population). In this population of 5000 women, which 
is in essence the same as the true underlying population we obtained the derivation 
population from, the choice to try to get pregnant again is not random, but it is now 
influenced by prediction model outcome (i.e. high risk or low risk). In this scenario, 
we stipulated that 40% of all high risk women decide not to get pregnant again, 
while all low risk women are reassured and try (and succeed in) getting pregnant. 
Thus, only a subset of the application population chooses to get pregnant again, 
conditional on prediction model outcome. Using data of this selection (N=4000) of 
the application population, performance parameters of the prediction model were 
again estimated, and compared to values obtained in the derivation population. 
Results 
Since the aim is to illustrate bias as a result of selective fertility, only point estimates 
are reported, without any confidence intervals. Table 1 shows the data of the 4000 
women used to derive the prediction model from. Lower risks of recurrent preec-
lampsia are more prevalent than higher risks. Of these women, 1200 (30%) had no 
risk factors, corresponding to a low risk of recurrent preeclampsia, and thus a nega-
tive test result; 2800 (70%) women had one or more risk factors, corresponding to a 
high risk of recurrence and a positive test result. In total, 500 women (12.5%) de-
veloped recurrent preeclampsia. 
 
Table 1. The recurrence risk of preeclampsia for each score on the prediction model (number of risk 
factors present) in the next pregnancy of formerly preeclamptic women in the derivation population (N = 
1000). 
No. of risk factors 
present 
True underlying population  
n (%) 
Derivation population 
n (total of true under-
lying pop.) 
Recurrent preeclampsia 
n (% of derivation pop.)  
4 500 (10%) 400 (80%) 25 (25%) 
3 750 (15%) 600 (80%) 30 (20%) 
2 1000 (20%) 800 (80%) 30 (15%) 
1 1250 (25%) 1000 (80%) 25 (10%) 
0 1500 (30%) 1200 (80%) 15 (5%) 
Total 5000 4000 500 
 
Table 2 shows the cross tabulation of predicted outcomes (positive and negative 
test result) and the observed recurrence of preeclampsia, based on the risk cutoff 
point of >5% for a positive test result. Of all women who developed recurrent 
preeclampsia, 440 had a positive test result, corresponding to a sensitivity of 88%. 
Specificity was only 33%, because only 1140 of 3500 women who did not develop 
recurrent preeclampsia, had a negative test result. Of all 2800 women with a posi-
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tive test result, only 440 developed recurrent preeclampsia (positive predictive 
value was 16%), and 1140 of 1200 women with a negative test result did not devel-
op recurrent preeclampsia (negative predictive value was 95%). The discriminative 
ability of the model in the derivation population, quantified by the area under the 
ROC curve, was approximately 0.67 (Figure 1, black graph).  
 
Table 2. Cross tabulation of predicted outcomes (positive or negative test result) and observed recur-
rence of preeclampsia in the derivation population (N = 4000) and corresponding test characteristics. A 
positive test result refers to the presence of at least one risk factor. 
 
Recurrent  
preeclampsia 
No recurrent  
preeclampsia Total 
Positive test 440 2360 2800 
Negative test 60 1140 1200 
Total 500 3500 4000 
sensitivity = (440/500)*100% = 88% 
specificity = (1140/3500)*100% = 33% 
positive predictive value = (440/2800)*100% = 16% 
negative predictive value = (1140/1200)*100% = 95% 
 
Data of the women of the application population who chose to try for a subsequent 
pregnancy (N = 2900) are shown in table 3. The composition of this population, with 
respect to the presence of the risk factors, was considerably different than that of 
the derivation population, because of selective fertility. In this case only 1400 (48%) 
of women had 1 or more risk factors present, 1500 (52%) had no risk factors 
present. Of all women, 295 (10%) developed recurrent preeclampsia. 
 
Table 3. Application population of women with preeclampsia in their first pregnancy (N=5000), the 
subpopulation who were exposed to the prediction model result and try for another pregnancy 
(N=2900), and the numbers of recurrent preeclampsia. 
No. of risk 
factors present 
Application  
population 
N (% of total) 
Subset  
who try for next pregnancy 
N (% of application pop.) 
Recurrent  
preeclampsia 
N (% of subset)  
4 500 (10%) 200 (40%) 50 (25%) 
3 750 (15%) 300 (40%) 60 (20%) 
2 1000 (20%) 400 (40%) 60 (15%) 
1 1250 (25%) 500 (40%) 50 (10%) 
0 1500 (30%) 1500 (100%) 75 (5%) 
Total 5000 2900 295 
 
The cross tabulation of predicted outcomes and observed recurrent preeclampsia 
for women from the application population who tried for a subsequent pregnancy 
shows the number of patients with true positive and true negative test results and 
false positive and false negative test results (Table 4). Sensitivity of the prediction 
model in these data was 75%, only 220 of 295 women who developed a subsequent 
pregnancy had a positive test result. Of 2605 women who did not develop recurrent 
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preeclampsia, 1425 had a negative test result, corresponding to a specificity of 55%. 
Positive and negative predictive values were the same as in the derivation popula-
tion, 16% (220/1180) and 95% (1425/1500) respectively. The ROC curve of the 
model is depicted in figure 1 (grey graph); the area under the curve was approx-
imately 0.67.  
 
Table 4. Cross tabulation of predicted outcomes (positive or negative test result) and observed recur-
rence of preeclampsia in the application population (N = 2900) and corresponding test characteristics. A 
positive test result refers to the presence of at least one risk factor.  
 
Recurrent preeclamp-
sia 
No recurrent preeclamp-
sia Total 
Positive test 220 1180 1400 
Negative test 75 1425 1500 
Total 295 2605 2900 
sensitivity = (220/295)*100% = 75% 
specificity = (1425/2605)*100% = 55% 
positive predictive value = (220/1180)*100% = 16% 
negative predictive value = (1425/1500)*100% = 95% 
 
 
 
Figure 1. ROC curves of the prediction model in the derivation population and in the subset of the appli-
cation population who tried for subsequent pregnancy. Points in the graph correspond to the different 
predefined risk-cutoff points of the prediction model result. 
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Discussion 
We have illustrated how exposure of women to the results of a preconception risk 
prediction model can change performance parameters of the model. In our exam-
ple, women with a high predicted risk of recurrent disease were less likely to try for 
subsequent pregnancy. We saw a decrease in sensitivity from 88% to 75% when the 
model was evaluated in the subset of the application population of whom next 
pregnancy outcomes were available, whereas specificity increased from 33% to 
55%. Individual risk predictions remained unaffected; in the application population 
both positive and negative predictive values remained the same as in the derivation 
population. Furthermore, the discriminative ability of the model, as quantified by 
the area under the ROC curve, was the same in both populations. Even though the 
area remains virtually unchanged, the different cutoff points in the ROC curve mi-
grate to the lower left corner, a phenomenon described earlier in another context 
(6). This is because of the decrease in sensitivity (cutoff point moves down on the y-
axis) combined with an increase in specificity (cutoff point moves left on the x-axis). 
Sensitivity and specificity are of less clinical relevance than predictive values, but 
are still popular measures of performance in prognostic and diagnostic research, 
because of the false belief that they are fixed properties of a test. It is often stated 
that, when introducing a test in a different population, only the positive and nega-
tive predictive values are subject to change. In our simulation we have shown that 
because of selective fertility, and thus a selection conditional on test result, sensitiv-
ity and specificity change while, remarkably, the predictive values seem fixed. This 
might seem a strange phenomenon, even more because the change in our popula-
tion is merely a change in mean risk (12.5% in the derivation population versus 10% 
in the subset of the application population who tried for subsequent pregnancy). 
However, the explanation is quite straightforward. Because of the selection condi-
tional on test result instead of selection conditional on disease status, in our cross 
tabulations (tables 2 and 4), only the ratios between numbers of women with posi-
tive and negative test results (different rows) change rather than those between 
numbers of women with or without recurrent preeclampsia (different columns). 
Although this selective fertility-related form of bias has not been described yet in 
prognostic research, in diagnostic research, however, biases with similar mechan-
isms have been identified. These biases are referred to as work-up bias,7 verification 
bias,8 or referral bias.6 The mechanisms of these biases are in essence similar to one 
another. Patients with a positive test result tend to be referred more often for veri-
fication by the gold standard than patients with a negative test result (selection 
conditional on test result). Thus, the probability of verification of disease is higher in 
subjects with a positive test result. As a result, sensitivity is overestimated and spe-
cificity underestimated. In the present example from prognostic research, it is the 
other way around.  
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Our example is undoubtedly a simplified version of the truth. In the true underlying 
population, we assumed that the choice to try for a subsequent pregnancy was 
random over the risk groups. However, this assumption may not hold. In a more 
realistic scenario, it is likely that the choice to try for a next pregnancy, without 
knowing an individual risk estimate, is amongst other factors guided by the severity 
of the first occurrence of preeclampsia. Severity of the first occurrence of preec-
lampsia is most likely related to the risk of recurrent preeclampsia (despite it was 
not comprised in our prediction model), and therefore selection might not be ran-
dom with respect to the risk groups. This may imply that in our example the 
strength of the bias was overestimated. On the other hand, perinatal loss is asso-
ciated with severity of preeclampsia and thus associated with a risk of recurrence, 
yet reproduction is increased after a perinatal loss.9 
Our scenario of a preconception prediction model estimating the risk of an adverse 
pregnancy outcome is probably the only scenario this phenomenon can occur. Pa-
tients altering their risk profile (e.g. lifestyle changes) after risk estimation or coun-
seling can be observed in many disciplines, yet the choice to be ‘at risk’ or have an 
absolute risk of zero is unique to pregnancy-related outcomes (i.e. women who do 
not get pregnant again will never develop an adverse pregnancy outcome). This 
makes it hard to generalize this bias to other clinical disciplines. 
In summary, using a simulated example, we have shown that the original sensitivity 
and specificity estimates of a preconception prediction model for an adverse preg-
nancy outcome can become biased when the model is applied in practice. However, 
positive and negative predictive values, as well as the discriminative ability of the 
model, remain unbiased. Therefore, the prediction model still yields valid individual 
risk estimates, and can still be used to evaluate risks and counsel these women 
accordingly. 
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CHAPTER 11 
General Discussion 
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General discussion 
Preeclampsia is a relatively common pregnancy disorder with not only short-term 
complications, such as the HELLP syndrome and eclampsia, but also long-term con-
sequences, such as an increased risk of developing hypertension, ischemic heart 
disease, stroke and thromboembolic disease.1 Perinatal risks include impaired 
growth and complications associated with elective preterm birth. Although fortu-
nately preeclampsia has a favorable outcome in many cases, from a public health 
perspective, it is an important cause of maternal and perinatal morbidity and mor-
tality worldwide. In the Netherlands, it even is the number one cause of maternal 
death.2 Moreover, from a health economic perspective, preeclampsia accounts for 
an estimated 20% of antenatal admissions, 33% of referrals to day-care assessment 
units and 25% of obstetric admissions to intensive care units.3-5 
Although prevention of preeclampsia seems illusive, there is indirect evidence for 
the concept that the onset of preeclampsia can be postponed and the severity of its 
clinical presentation alleviated by the timely institution of tailored preventive 
measures. As repeatedly stated in this thesis, formerly preeclamptic women are at 
increased risk of developing recurrent preeclampsia in their next pregnancy. There-
fore, the management of these women will benefit from the prepregnancy identifi-
cation of underlying disorders and their adequate treatment. Consequently, tailored 
preventive measures can be instituted prior to and in the first trimester of the next 
pregnancy. An important part of antenatal care in this next pregnancy consists of 
the earliest possible detection of imminent recurrent disease. However, in the 
Netherlands, guidelines for screening, early detection and management of preec-
lampsia, and a generally accepted threshold for disease severity for referral are 
lacking.  
Approximately 5 to 8% of all pregnant women develop preeclampsia. Risk factors 
for preeclampsia include medical conditions such as chronic hypertension, diabetes, 
multiple pregnancies, and previous preeclampsia.6 About one out of four women 
with a history of early-onset preeclampsia develops recurrent preeclampsia in the 
next pregnancy.7 Therefore, prediction of and counseling for preeclampsia is partic-
ularly relevant for these women.  
Prediction of recurrent preeclampsia, implications for future studies   
As outlined in chapters 2 and 3 of this thesis, the ability to predict the risk of recur-
rent preeclampsia has several advantages. Clinicians would have the possibility to 
better identify women who require closer surveillance and would benefit from 
timely referral to specialized treatment. Conversely, it would also enable the identi-
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fication of low-risk women who then could be reassured and offered the appropri-
ate regular low-risk care.  
Important in prediction issues in general is the level of accuracy required to allow 
the systematic application of a test.
8
 Ideally, one would aim for a test with perfect 
accuracy; that is to say, 100% sensitivity and 100% specificity. Such a test would 
have a zero false-negative and false-positive rate. Unfortunately, this is unreal in 
clinical practice. Usually, we are dealing with a test characterized by a certain error 
rate of false positives and false negatives. There is a trade-off between these two; 
reducing false positives may lead to an increase in false negatives and vice versa, 
which corresponds with the reciprocal relation between sensitivity and specificity.  
Understanding the balance of benefit and harm between false positives and false 
negatives is critical to define the level of accuracy a predictive test for preeclampsia 
should achieve. False positive test results refer to women falsely identified as des-
tined to develop preeclampsia. Consequently, their management may include su-
perfluous close surveillance along with unnecessary prophylactic measures. This is 
inconvenient for the mother, but is unlikely to lead to relevant adverse health se-
quels, as the surveillance is generally non-invasive and preventive measures such as 
low-dose aspirin are not associated with serious side effects. In contrast, counseling 
of women with a false negative test result implies that they receive unjustified reas-
surance about having a low risk of recurrent preeclampsia in their next or current 
pregnancy. Close surveillance and preventive measures will be erroneously withheld 
from these women. Therefore, in preeclampsia, the negative impact of a false nega-
tive test result is larger than that of a false positive test result.9 High sensitivity is 
thus preferred over high specificity in the prediction of preeclampsia. When the 
negative predictive value of a test reaches values that correspond with the risk in 
nulliparae, the care provided to these women could be adjusted to the level of 
regular low-risk care. 
Preeclampsia is known to be preceded by a wide range of causes and pathophysio-
logical pathways, which eventually culminate into a clinical presentation of the 
disorder that may vary widely in time of onset, severity of hypertension and prote-
inuria, and the concomitant presence or absence of the HELLP syndrome (chapter 
5). Therefore, more emphasis should be put on the development of different pre-
diction tests for homogeneous subpopulations. Moreover, it may be more appro-
priate to explore combinations of tests of different categories instead of a single 
predictor (chapter 3). Surprisingly, only one study evaluated the predictive perfor-
mance of a multivariable prediction model for recurrent preeclampsia previously 
(chapter 2).  
An interesting challenge for future research is to evaluate whether the combination 
of pre- and in-pregnancy tests can improve predictive capacity. A highly sensitive 
prediction test for recurrent preeclampsia, applied prior to or early in the next 
pregnancy, with adequate predictive specificity, has not proven achievable so far. At 
C h a p t e r  1 1  
 
 
 
138 
preferred high levels of sensitivity, corresponding specificity levels of the prediction 
rule presented in chapter 3 of this thesis were relatively poor. This implies that a 
rather large proportion of tested women would receive unnecessarily intensive 
surveillance. Hypothetically, a model like this may benefit from the concept of hie-
rarchical testing. That is to say, the application of more than one consecutive pre-
diction tests for recurrent preeclampsia between 6 months post-preeclampsia and 
the 20th week of the next pregnancy. This approach is likely to reduce the false-
positive rate without raising the false-negative rate. According to this concept, a 
pre-pregnancy prediction rule could reassure women with a (very) low risk of de-
veloping recurrent preeclampsia, while the women with a positive test outcome are 
retested in the first half of the next pregnancy. This second stage of testing may, for 
example, involve longitudinal patterns to identify abnormal hemodynamic and me-
tabolic adaptations to the next pregnancy, as proposed in chapters 7 and 8 of this 
thesis, respectively. The rationale is that women with constitutional risk factors who 
adapt normally to the next pregnancy are more likely to have normal initial placen-
tal development and therefore, are less likely to develop the prodromes of dysfunc-
tional endothelium in preeclampsia, which include an increased inflammatory re-
sponse, excessive circulation of anti-angiogenetic factors and accelerated platelet 
turnover. 
Common methodological problems inherent to developing a clinically useful predic-
tion model concern, among others, the management of missing values, selection of 
potential predictors, the model-building approach itself and occasionally, setting 
justified cut-off values of the predicted probability. Before being applied in clinical 
practice, validation analyses are required for which a wide range of methodological 
options are available. Relatively unknown is the phenomenon of collider-bias, as 
described and illustrated in chapter 9 of this thesis. It can affect various stages of 
the development of a prediction model for recurrent adverse pregnancy outcome. 
Due to this type of bias, clues on potentially relevant variables derived from pre-
vious reports can be misleading, resulting in incorrect selection of candidate predic-
tors. Furthermore, inter-population variation in the prevalence of risk factors may 
potentially lead to different effects of confounding. Although this is not likely to 
influence the individual risk prediction, it could affect model performance on a 
population level with implications for external validation and updating. Also impor-
tant in this stage is the phenomenon of selective fertility that may occur after appli-
cation of a prepregnancy prediction model for a certain reproductive outcome 
(chapter 10). Prediction test results may influence women and their partners in 
their decision whether or not to choose for a next pregnancy. In formerly preec-
lamptic patients, this may imply that women refrain from a new pregnancy after 
being informed about their high risk of recurrence in a next pregnancy. In theory, 
this would change the composition of the pregnant population with respect to the 
predictors in the model. Although this concept proved to have a modest effect on 
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the sensitivity and specificity of the prediction model (chapter 10), individual risk 
estimates, positive and negative predictive values and the c-statistic are not af-
fected.     
Counseling for recurrent preeclampsia, clinical implications 
The potential recurrence of preeclampsia is a matter of serious concern for pa-
tients, their families, and healthcare providers, especially after having experienced 
early-onset preeclampsia. The latter is related to an increased risk of adverse ma-
ternal and perinatal outcome and predisposes to severe co-morbidity. Fortunately, 
the outcome of a next pregnancy is generally favorable.7,9 Although the recurrence 
risk of preeclampsia in women with a history of early-onset disease is high, the risk 
of developing recurrent early-onset preeclampsia is only 5-9%, as described in sev-
eral chapters of this thesis and reported by others.7  
The ability to predict the individual risk of recurrent (early-onset) preeclampsia 
would be a valuable tool in preconception counseling of formerly preeclamptic 
women. As outlined in chapter 2 of this thesis, accurate clinically useful prediction 
tests for recurrent preeclampsia are lacking. Chapter 3 of this thesis delineates that 
preconception prediction can be achieved by a combination of relatively simple 
maternal parameters. For clinical prediction rules to be widely used in practice, it is 
essential that clinicians know how to take advantage of the incremental predictive 
value provided.10 Underlying the development of prediction rules is the unproven 
assumption that better predictions will have a positive effect on subsequent man-
agement. However, at present, coupling of the predicted risk of recurrent preec-
lampsia and clinical management decisions remains vague. It is not realistic to ex-
pect even the most accurate predictions to contribute to the post-testing clinical 
management of a patient. Nevertheless, impact analyses are important to deter-
mine whether the application of a prediction test and adjustment of clinical man-
agement to the outcome of the test is beneficial for pregnancy (and health) out-
come. This is one of the aims of the PreCare study, a follow-up study that evaluates 
the cost-effectiveness of recurrence-risk guided care (i.e. based on the outcome of a 
prediction tool) of pregnant former preeclamptic or HELLP patients.11 For practical 
reasons, the prediction tool applied in this multicenter study differs from that pre-
sented in chapter 3. At any rate, in order to strive for optimal clinical strategies, the 
final test result of a prediction model for recurrent preeclampsia should be available 
at the latest by the end of the first half of pregnancy. Only the latter warrants ad-
justment of the intensity of care to the test result.  
Influenceable risk factors, such as lifestyle-related factors, are of particular impor-
tance in counseling for recurrent preeclampsia, since they are modifiable with po-
tential beneficial effects on the recurrence risk of preeclampsia. An explicit example 
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is the metabolic syndrome.12 The presence of metabolic abnormalities contributing 
to this syndrome proved associated with recurrent preeclampsia, even in the ab-
sence of obesity (chapter 4). Besides, the recognition of these abnormalities identi-
fies women with potentially increased risk of cardiovascular disease later in life.13,14 
This will allow for early intervention, either primarily by modifying risk factors or 
secondarily by instituting specific prophylaxis.15 However, follow-up of women with 
a recent history of preeclampsia is currently insufficient and undeveloped in prima-
ry care in the Netherlands.16  
Concluding remarks  
Part I  - Preconception prediction of and counseling for recurrent preeclampsia  
Until recently, no multivariable preconception prediction model had been available 
for recurrent preeclampsia (chapter 2). 
We developed a prediction model based on easily obtainable preconception mater-
nal parameters with moderate to good predictive accuracy (chapter 3). Potentially, 
combining this model with early-pregnancy prediction tests will improve its predic-
tive potential. 
Metabolic abnormalities are important indicators for increased risk of recurrent 
preeclampsia, regardless the woman’s body mass index (chapter 4). Therefore, the 
efficacy of lifestyle changes in the reduction of preeclampsia recurrence risk is an 
interesting topic for future study.  
In HELLP syndrome, these metabolic abnormalities proved to be less important and 
so did thrombophilic abnormalities (chapter 5). 
The relatively high prevalence of metabolic abnormalities and the presumably re-
lated increased risk of cardiovascular disease later in life were not reflected in more 
frequent abnormal electrocardiograms (ECGs) shortly after preeclampsia (chapter 
6). Therefore, the postpartum ECG assessment in women with a recent history of 
preeclampsia seems superfluous. 
Part II – Early-pregnancy adaptation 
Early-pregnancy adaptation of the lipid profile and diastolic function tended to 
differ between formerly preeclamptic women destined to develop recurrent disease 
later in pregnancy as compared to their counterparts who are not (chapters 7 and 
8). 
These findings may be of pathophysiologic importance and could contribute to the 
development of prediction strategies. Future studies are needed to test the hypo-
theses generated about the observed dissimilarities in early-pregnancy adaptation. 
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Part III – Methodological challenges in predicting reproductive outcomes 
Studies on recurrence risk may be affected by collider bias, which can seriously 
distort and even invert association estimates (chapter 9). 
Collider bias may occur in any recurrence risk study in which sample selection is 
based on prior occurrence of the disorder studied. 
Collider bias may affect correlation coefficients in a prediction model to such an 
extent that they suggest a protective effect of a potential risk factor. Therefore, 
unexpected absent or invert associations of factors with recurrent outcome should 
be interpreted with extra caution as they are likely to be biased by sample selection. 
Prediction-based selective fertility may arise when prediction test results influence 
the women and their partners in their decision to choose for a next pregnancy, 
which in turn affects the composition of the pregnant population with respect to 
the predictors in the model (chapter 10). 
After application, predictive sensitivity and specificity of preconception prediction 
models for adverse pregnancy outcome may be different when evaluated in the 
new pregnant population, as a result of prediction-based selective fertility.  
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In hoofdstuk 1 van dit proefschrift worden de zwangerschapsaandoening 
preëclampsie, het ontstaansmechanisme, het herhalingsrisico in een volgende 
zwangerschap en de mogelijkheden tot counseling (adviesgeving) kort 
geïntroduceerd. Preëclampsie omvat de ontwikkeling van hypertensie (verhoogde 
bloeddruk) en proteïnurie (verhoogde eiwituitscheiding in de urine) na 20 weken 
zwangerschap. Het syndroom compliceert 5-8 procent van alle zwangerschappen en 
is een belangrijke oorzaak van morbiditeit en mortaliteit bij zowel moeder als kind. 
Hoewel nog steeds geen open boek, is de laatste 20 tot 30 jaar meer bekend 
geworden over de oorzaken van preëclampsie. Tegenwoordig beschrijft men het 
ontstaan van preëclampsie als een tweefasen model, waarbij afwijkende 
ontwikkeling van de bloedvaten in de baarmoederwand in de eerste fase resulteert 
in een verslechterde doorbloeding van de placenta (de moederkoek). Hierdoor 
komen factoren vrij in de moederlijke bloedsomloop die een stress reactie 
veroorzaken, welke uiteindelijk kan leiden tot de klinische symptomen. Vrouwen die 
eenmaal preëclampsie hebben doorgemaakt, hebben een verhoogde kans op 
herhaling in de volgende zwangerschap. Het is dan ook belangrijk hen counseling te 
bieden voorafgaand aan een volgende zwangerschap. Daarbij kan ondermeer 
worden ingegaan op aanwezige risicofactoren en mogelijke strategieën om het 
herhalingsrisico te verlagen. 
 
Het eerste deel van dit proefschrift beslaat mogelijkheden tot predictie 
(voorspelling) van het herhalingsrisico op preëclampsie en daaraan gekoppeld 
mogelijkheden tot counseling van voormalige patiënten, voorafgaand aan de 
volgende zwangerschap. Hoofdstuk 2 biedt een literatuuroverzicht van 
beschikbare predictoren (voorspellers) voor het herhalingsrisico op preëclampsie. 
Hierbij wordt ingegaan op de mate waarin de testen hiertoe in staat zijn en hun 
toepasbaarheid in de klinische praktijk. In 33 artikelen werden 24 verschillende 
predictoren geïdentificeerd. Daarvan waren het plasma volume, de stroomsnelheid 
van het bloed in de baarmoederslagaders en een combinatie van herhaaldelijk in de 
zwangerschap gemeten variabelen het meest veelbelovend. Deze voorspellers 
kennen echter ook praktische bezwaren, zoals een laat moment van toepassing. 
Tevens was de vastgestelde voorspellende capaciteit in veel gevallen 
onbetrouwbaar. Preëclampsie is een heterogene aandoening. Daarom wordt 
verondersteld dat een combinatie van verschillende typen voorspellers tot een 
betere voorspelling van de kans op herhaling kan leiden.  
Hoofdstuk 3 presenteert een predictiemodel voor het herhalingsrisico op 
preëclampsie vroeg in de zwangerschap, waarin meerdere predictoren 
gecombineerd worden. Deze predictoren zijn ten minste zes maanden na de eerste 
en nog voor de volgende zwangerschap bepaald. De combinatie van HDL-
cholesterol (het “goede” cholesterol) en  de hoeveelheid eiwit dat in de urine wordt 
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uitgescheiden binnen 24 uur in één model bleek de beste voorspelling van het risico 
op te leveren. Dit model bleek in staat om 94% van de vrouwen die in de volgende 
zwangerschap opnieuw een vroege preëclampsie ontwikkelen te identificeren. Bijna 
50% van de vrouwen kunnen zo gerustgesteld worden dat het risico op herhaling 
zeer laag is (<1%).  
In hoofdstuk 4 wordt obesitas (zwaarlijvigheid) als risicofactor voor preëclampsie 
tegen het licht gehouden. Obesitas is geassocieerd met andere aan preëclampsie 
gelinkte factoren, zoals hypertensie, chronische ontsteking en afwijkingen in de 
stofwisseling. Het is dan ook denkbaar dat obesitas niet zozeer direct, maar eerder 
indirect effect heeft op het ontstaan van preëclampsie. De bevindingen in 
hoofdstuk 4 bevestigen deze stelling. Het risico op preëclampsie na de aandoening 
te hebben doorgemaakt in een vorige zwangerschap was weliswaar verhoogd bij 
obese vrouwen in vergelijking tot vrouwen zonder obesitas, maar indien metabole 
afwijkingen in ogenschouw werden genomen was de associatie verdwenen. 
Bovendien bleek de aanwezigheid van metabole afwijkingen, onafhankelijk van de 
aan- of afwezigheid van obesitas, een risicofactor voor preëclampsie. Het advies 
luidt dan ook de aandacht bij het counselen van voormalige preëclampten minder 
specifiek op obesitas te richten en meer op metabole factoren in het algemeen, 
ongeacht de lichaamsomvang. 
In hoofdstuk 5 worden de verschillen tussen preëclampsie en het HELLP 
syndroom (gekenmerkt door hemolyse, verhoogde leverenzymen en verlaagde 
bloedplaatjes)  geëvalueerd. De ontstaanswijze en symptomen van het HELLP 
syndroom overlappen deels met die van preëclampsie. Dit heeft geleid tot 
vergelijkbare behandelmethoden van beide syndromen. Omdat de syndromen wel 
degelijk twee afzonderlijke ziektebeelden zijn valt te betwijfelen of dit wel terecht 
is. In hoofdstuk 5 wordt duidelijk dat het HELLP syndroom verschilt van 
preëclampsie op enkele belangrijke punten, waaronder het frequenter voorkomen 
van eclampsie (stuipen) tijdens de zwangerschap en het minder vaak voorkomen 
van hypertensie, proteinurie, verhoogde stollingsneiging, obesitas, verhoogde 
bloedsuikerspiegel, verhoogde triglyceriden, en verhoogd homocysteine in de niet-
zwangere conditie. 
In hoofdstuk 6 wordt het voorkomen van electrocardiografische afwijkingen 
(afwijkingen op het ECG, ook wel hartfilmpje) beschreven bij voormalige 
preëclampsie patiënten. Bovendien worden de ECG dimensies vergeleken tussen 
vrouwen die in de volgende zwangerschap preëclampsie ontwikkelen en vrouwen 
waarbij dat niet gebeurd. Voormalige preëclampsie patiënten hebben een verhoogd 
risico op hart- en vaatziekten op latere leeftijd. Of zich dit recent na het doormaken 
van preëclampsie uit in het vaker voorkomen van ECG afwijkingen is onduidelijk, 
evenals de vraag of vrouwen met herhaaldelijke preëclampsie vaker afwijkingen 
hebben dan vrouwen met eenmalige preëclampsie. De prevalentie (frequentie) van 
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ECG afwijkingen bleek bij expreëclampten niet hoger te zijn dan in de algemene 
populatie vrouwen van vruchtbare leeftijd. Vrouwen met herhaaldelijke 
preëclampsie vertoonden verschillen in elektrische hartas (een middeling van alle 
ontladingen in het hart) en QT-interval (geleidingstijd), maar dit bleek met name 
veroorzaakt te worden door verschillen in bloeddruk. 
 
Het tweede deel van dit proefschrift gaat in op de vroege aanpassingen aan de 
zwangerschap bij voormalige preëclampten. Hoofdstuk 7 behandelt de 
veranderingen in het lipidenprofiel. Hoewel bekend is dat bij preëclampsie de 
hoeveelheid lipiden (vetten) in het bloed hogere waarden bereikt dan bij gezonde 
zwangerschap, is het onduidelijk of deze verschillen al vroeg in de zwangerschap 
detecteerbaar zijn. De bevindingen in hoofdstuk 7 zijn afgeleid van metingen voor 
de zwangerschap en 8 en 16 weken tijdens de zwangerschap. Wat bleek is dat bij 
vrouwen die opnieuw preëclampsie ontwikkelen de gebruikelijke tijdelijke daling in 
LDL-cholesterol na het eerste trimester niet waarneembaar is. Mogelijk wordt dit 
veroorzaakt door een lagere productie van steroïde hormonen door de placenta. 
Bovendien was de stijging in HDL-cholesterol bij deze groep minder sterk, 
vermoedelijk voorafgaand aan de verlaagde waarden die eerder zijn waargenomen 
bij reeds gediagnosticeerde preëclampsie. Geen verschillen in aanpassing van de 
concentratie triglyceriden werden waargenomen.  
In hoofdstuk 8 ligt de focus op de aanpassingen van de diastolische hartfunctie 
aan de zwangerschap. Preëclampsie vroeg in de zwangerschap blijkt te worden 
voorafgegaan door verminderde adaptatie van het hart- en bloedvaten systeem. 
Hoeverre maladaptatie van de diastolische hartfunctie hierbij betrokken is, is 
onbekend. In hoofdstuk 8 worden verschillende diastolische functie parameters 
geëvalueerd voor de zwangerschap en bij 12, 16 en 20 weken tijdens de 
zwangerschap bij voormalige preëclampsie patiënten. Bij 12 weken bleek de E/A 
ratio (een parameter voor diastolische functie) sterker te zijn toegenomen bij 
vrouwen die later in de zwangerschap preëclampsie ontwikkelen ten opzichte van 
vrouwen die dit niet doen. Bovendien was het hart-minuut volume lager en de 
systemische vaatweerstand hoger. Indirect zou dit kunnen betekenen dat het 
sympatische aandeel van de autonome controle van de bloedsomloop in het 
tweede trimester groter is onder vrouwen die opnieuw preëclampsie ontwikkelen. 
Dit laatste ondersteunt dan weer de gedachte dat verminderde adaptatie van de 
diastolische hartfunctie bijdraagt aan de abnormale adaptatie van hart en 
bloedvaten aan de zwangerschap bij preëclampsie.  
 
Het derde en laatste deel van dit proefschrift heeft betrekking op twee 
methodologische uitdagingen waar men in onderzoek naar recidiverende 
(herhalende) zwangerschapsgerelateerde uitkomsten tegenaan kan lopen. In 
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hoofdstuk 9 betreft dit het fenomeen collider bias. Met de term collider wordt in 
dit verband een factor bedoeld die in een causale (oorzakelijke) keten beïnvloed 
wordt door twee andere factoren. Wanneer op basis van de collider wordt 
gestratificeerd (gecorrigeerd) ontstaat een associatie tussen die twee factoren, 
waardoor confounding wordt geintroduceerd. Schattingen van de associatie tussen 
dergelijke factoren en herhaling van een bepaalde uitkomst kunnen daardoor 
ernstig vertekend raken en in extreme gevallen zelfs een andere richting aannemen. 
Dit kan verstrekkende klinische gevolgen hebben. Het is dus belangrijk deze vorm 
van bias op zijn minst te herkennen. Collider bias is reeds eerder beschreven, maar 
vrij nieuw in deze context is de bevinding dat, in studies naar recidiverende 
uitkomsten, selectie van de onderzoekspopulatie op basis van het voorkomen van 
die uitkomst in het verleden ook collider bias kan veroorzaken. Het al dan niet 
eerder hebben gehad van de uitkomst is in dit geval de collider. We illustreren dit 
principe aan de hand van een denkbeeldig getallenvoorbeeld waarin obesitas als 
risicofactor voor recidiverende preëclampsie wordt geëvalueerd. In hoofdstuk 10 
wordt ingegaan op de invloed van risicopredictie-gerelateerde keuze voor een 
nieuwe zwangerschap op de prestatie van predictiemodellen. In feite betreft het 
een variant op een fenomeen wat we kennen als selectieve fertiliteit; de neiging om 
reproductie (voortplanting) aan te passen op basis van de uitkomsten van eerdere 
zwangerschap(pen). Dit kan bij de toepassing van predictiemodellen in de praktijk 
een rol gaan spelen. Individuele risicoschattingen aan de hand van 
predictiemodellen kunnen gebruikt worden voor counseling doeleinden. 
Dientengevolge is het denkbaar dat vrouwen met een hoog voorspeld risico van een 
ongewenste uitkomst besluiten niet zwanger te worden. Deze risicopredictie-
gerelateerde selectieve fertiliteit kan veranderingen teweegbrengen in de 
samenstelling van de populatie zwangeren met betrekking tot de predictoren in het 
predictiemodel. Aan de hand van een hypothetisch voorbeeld met gesimuleerde 
data illustreren we dat dit invloed kan hebben op de sensitiviteit en specificiteit van 
een predictiemodel, maar dat de c-statistic (een maat voor het onderscheidend 
vermogen) en de individuele risicoschattingen onaangedaan blijven.  
 
Hoofdstuk 11 levert ten slotte een algemene discussie over de onderwerpen 
aangesneden in dit proefschrift. Benadrukt wordt de ernst van de aandoening en 
het ontbreken van goede richtlijnen voor screening op verhoogd risico, vroege 
detectie en behandeling van vrouwen met een verhoogd risico op preëclampsie. 
Een belangrijk aandachtsgebied voor toekomstig onderzoek is het verder 
exploreren van combinaties van testen, met toepassingen zowel voor als tijdens de 
volgende zwangerschap. Voor de clinicus is het belangrijk in te zien op welke manier 
voordeel te halen valt uit de predictieve waarde van een predictie test voor het 
risico op herhaling van preëclampsie. Op dit moment is de koppeling tussen 
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risicovoorspellingen, klinisch handelen en te behalen successen met betrekking tot 
gezondheidsuitkomsten nog vaag. Impact analyses moeten hierover meer 
duidelijkheid verschaffen.   
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Dankwoord 
Beste Louis, al vanaf het eerste kennismakingsgesprek voor aanvang van mijn 
afstudeerstage binnen de opleiding Gezondheidswetenschappen werkte uw 
enthousiasme, impulsiviteit, veelzijdigheid aan ideeën en geweldige kennis van 
hypertensieve aandoeningen in de zwangerschap aanstekelijk. Dit eerste gesprek 
was tegelijk mijn eerste kennismaking met preëclampsie. Na een half jaar was ik 
volledig overtuigd van de noodzaak van onderzoek naar dit onderwerp, hetgeen 
met recht uw passionele levenswerk genoemd mag worden. Ik ben dan ook 
dankbaar dat we uiteindelijk, samen met Martin Prins, een promotie project 
hebben kunnen starten. De wekelijkse bijeenkomsten samen met Luc heb ik als 
stimulerend, verhelderend, indien nodig verlichtend en uiterst leerzaam ervaren. 
Achteraf stel ik vast dat niet in de laatste plaats de interessante combinatie van 
klinisch inzicht en epidemiologische kunde hieraan ten grondslag ligt. Juist de 
botsingen en dilemma’s die de welbekende ‘fishing expeditions’ en ‘het leegknijpen 
van de spons’ soms met zich meebrachten, heeft mij als onderzoeker gesterkt in 
mijn inzichten. Onuitputtelijk is de vraag naar nieuwe onderzoekstalenten 
uwerzijds. Iedere arts in spé die zijn onderzoekershart voelt kloppen, zou ik een 
gesprek met dr. Peeters willen aanraden. Want hoewel we dat van de longitudinale 
data uit de follow-up niet kunnen zeggen, zijn er onderzoeksvragen in overvloed.  
 
Beste Luc, al vrij snel na de start van mijn promotieproject kwam jij het 
begeleiderteam versterken. Jouw bijdrage aan dit proefschrift was onmisbaar. Ik 
heb veel gehad aan jouw verhelderende inzichten. Je hebt een talent om complexer 
wordende problemen terug te brengen naar het eenvoudige noodzakelijke en de 
focus te bewaren. Deze laatste vaardigheid heb je (misschien wel) tot vermoeiends 
toe mogen toepassen gaande het project, maar hopelijk heb je gemerkt dat ik er 
ook wat sterker in ben geworden. Fijn hoe na een week wikken en wegen gevolgd 
door een 5-minuten gesprek met jou resulteert in de conclusie: “Nee inderdaad, dat 
is ook zo. Bedankt.”. Jouw deur stond, net als die van Louis, altijd voor me open. 
Alleen al het idee is een grote steun geweest. Excuses voor het feit dat ik ook na 
vier jaar nog de afstand tussen UNS 50 en Deb 1 weet te onderschatten heb ik al zo 
vaak gemaakt. Het is een geaccepteerd feit geworden. Dank voor de input, 
kennisoverdracht en zeer betrokken support!  
 
Martin, promotor van het eerste uur. U was reeds mijn begeleider tijdens de 
afstudeerstage en ik ben blij dat het mogelijk is gebleken hier vervolg aan te geven 
middels een promotieproject. Vanaf het begin uitte u een rotsvast vertrouwen in 
mijn kunnen. Dat heeft mij enorm gesterkt. Ook toen de publicaties nog op zich 
lieten wachten, bleef u immer positief over de te behalen doelen. Net wat ik nodig 
had, zo bleek, want binnen vier jaar lag het manuscript van dit proefschrift bij de 
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beoordelingscommissie. De dagelijkse begeleiding werd overgedragen en terecht 
toevertrouwd aan Luc, maar, voor zover de agenda dat toeliet, weet ik dat ik altijd 
bij u terecht kon met vragen of andere kwesties. Bewonderenswaardig vond ik het 
dan hoe snel de draad weer opgepakt kon worden om over (voor mij) complexe 
problemen te discussiëren.  
 
Via deze weg wil ik ook Prof. Nijhuis bedanken. Hoewel we minder direct hebben 
samen gewerkt ben ik vereerd dat hij mijn promotor wil zijn.  
 
De onderzoeksgroep bij Obstetrie en Gynaecologie, het warme nest dat PeRIM 
heet. De collegialiteit die ik bij jullie heb mogen ervaren was een heerlijkheid, 
evenals de zeer frequente uitstapjes en de niet te missen jaarlijkse BBQ. 
Teambuilding staat bij PeRIM hoog in het vaandel, liefst onder extreme 
weersomstandigheden. Inez en Timo, jullie vormen de spil van de afdeling. Zonder 
jullie verbluffende inzet waren de promovendi en WESPers nergens. De combinatie 
organisatietalent (Inez) en creativiteit (Timo) komt perfect uit de verf. Henny, met 
de Mestreechter geis waait sinds jouw komst ‘e fris windsje’ (al dan niet afkomstig 
van de wapperende witte jas, die je, toegegeven, goed staat). Mooi hoe het jou 
binnen korte tijd gelukt is een stevige brug te slaan tussen onderzoek en kliniek. 
Rob de computerbouwer, bedankt voor de ondersteuning. De inzet, het 
doorzettingsvermogen en de gezelligheid van alle (WESP) stagiaires die in de 
afgelopen jaren werkzaam zijn geweest bij PeRIM waren van toegevoegde waarde. 
In het bijzonder wil ik Jef, Philippe, Robijn en Malou bedanken voor hun directe en 
onmisbare bijdrage aan de totstandkoming van dit proefschrift. Malou, ik denk met 
plezier terug aan ‘onze nachten samen’ in Glasgow en Edinburgh. Hoewel reeds 
uitgevlogen voor mijn komst wil ik de oudPeRIM-leden Olivier, Robert, Dorette (nu 
lange afstandslid) en Hugo, danken voor hun inspirerende werk. Eline, mijn eerste 
roommate op de uni. Ik heb genoten van de tijd dat wij collega’s waren en denk nog 
vaak terug aan onze dinertjes c.q. roddelsessies. Het Amerika-avontuur was er een 
om nooit te vergeten. De tip dat Market Street in San Francisco niet de meest 
veilige plek is om ’s nachts de Mc te bezoeken heb ik wijd verspreid (dat Twin Peaks 
net na zonsopgang met een jetlag juist wel is aan te raden trouwens ook). Bedankt 
voor de warme vriendschap die ook na jouw vertrek naar Brussel standhield. 
Carmen R. en Julia, mijn onvergetelijke paranimfen. Blij was ik toen ik niet langer de 
enige promovendus was en jullie als fijne collega’s (en meer dan dat) het team 
kwamen versterken. Naast het feit dat ik vereerd ben dat jullie mijn paranimfen 
willen zijn, hebben jullie ook direct een onmisbare bijdrage geleverd aan de 
totstandkoming van dit proefschrift. Mijn dank is groot! 
 
Een woord van dank gaat ook uit naar het ondersteunend personeel van de afdeling 
obstetrie en gynaecologie. Manon en Trudy, jullie zagen me alweer aankomen met 
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de lege cartridge in de hand. Manon wil ik in het bijzonder bedanken voor de 
verzorging van de correspondentie rondom dit proefschrift. Annemie, de heerlijke 
Franse wijn is goed gevallen (of bevallen om in de termen van dit proefschrift te 
spreken) na de bbq in Scharn in september. Gelukkig hebben we de foto’s nog. 
Artsen en assistenten, ik heb veel opgestoken van jullie  interessante discussies over 
voor mij vaak onbekende onderwerpen tijdens de journal clubs en high-risk 
besprekingen.  
 
Verder wil ik de meiden van Sapienza University of Rome bedanken, the Italian girls: 
Silvia, Sara, Angela and Claudia. Thanks a lot for the good company, support, Italian 
lessons and delicious food! Silvia, we met three years ago and despite the long dis-
tance we have been friends ever since. Your hospitality is amazing. I enjoyed our 
stay in Rome and felt honored to be part of your wedding in Abruzzo. I would have 
liked to say that I will always remember the ‘11de van de 11de’ we celebrated to-
gether, but I would lie. You know why. In 2009, you were back in Maastricht for 
another research project, which now is part of this thesis. Thank you for your 
contribution! 
 
De ontwikkeling van een predictiemodel voor de herhalingskans op preëclampsie 
was een voedingsbodem voor nieuwe onderzoeksideeën. In 2009 ging de PreCare 
studie van start. Projectleiders Luc en Carmen D. wil ik bedanken voor de 
mogelijkheid om mee te denken en van de brainstormsessies te leren. De 
samenwerking met Utrecht ontsprong op de WEON van 2008 in Groningen. Marie-
Elise, de match van onze onderwerpen bood inspiratie. We hadden grootse plannen 
voor een validatie studie met enorme patiënten aantallen. De praktijk bleek anders 
uit te pakken, maar de krachten zijn gebundeld! De promovendi van PreCare, 
Sander en Denise wil ik bedanken voor hun collegialiteit. Leuk dat we het 
onderwerp van studie gemeenschappelijk hebben. Sander, jouw eerlijke, kritische 
blik is er een om trots op te zijn. Jouw betrokkenheid bij de totstandkoming van dit 
proefschrift was van grote waarde. Ik weet zeker dat heel wat epidemiologen jouw 
dankbaar gaan zijn voor het veelbelovende gestoei met getallen. 
 
Dit laatste brengt mij op de op prognostiek gerichte methodologische sessies bij de 
afdeling Epidemiologie, in het leven geroepen door Luc. De sessies zijn een 
waardevolle aanvulling op de niet altijd even gemakkelijk te interpreteren 
methodologische literatuur en vormen een bron van inspiratie. Dat er vele 
publicaties mogen volgen!! Luc, Martin, Pieter, Patty, Adri, Isabella, Arina, Sander, 
Audrey en Paul, dank voor de leerzame discussies. 
Alle collega´s bij Epidemiologie, bedankt voor jullie kunde, medeleven en interesse. 
Mijn werkplek was elders, maar ik heb mogen genieten van de collegialiteit die op 
de afdeling heerst. Verbazingwekkend hoe het ieder jaar weer lukt om de 
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bestemming en invulling van het altijd geslaagde dagje-uit tot het moment suprème 
geheim te houden. Nathalie en Yvonne, bedankt voor de ondersteuning in de brede 
zin van het woord. John, bedankt voor het geduld wanneer ik weer eens in de 
laatste minuut mijn verlofregistratie in orde zat te maken. Jos en Harry, niet dat de 
server nu optimaal functioneert op mijn pc, maar hij is wel geïnstalleerd, dankzij 
jullie. Docenten van het CAT-onderwijs, over de perikelen hoef ik niemand bij de 
praten - de ‘sensitiviteit’ van 40 soloCAT’s is feitelijk hoger dan die van 20 - maar 
laten we vooral de mooie methodiek niet vergeten. De interactie (ook wel 
effectmodificatie) met studenten was leerzaam en vormde (eerlijk is eerlijk) een 
welkome afwisseling op de SPSS analyses (waar dan weer geen uren voor stonden). 
 
De groep uit Nijmegen: Marc, Prof. Lotgering, Ineke, Joris en Ralph, bedankt voor de 
prettige samenwerking en ontmoetingen op de SGI. Marc, zonder jou was het 
zogenaamde na-onderzoek in de huidige vorm er niet geweest en dit proefschrift 
dus ook niet. Dat realiseer ik me terdege. Jouw interesse in en kennis van de 
pathophysiologie van preëclampsie is ongekend. Ineke, onze hotelkamer in Reno 
was een oase van rust tussen de piepende en flitsende gokkasten. Jouw promotie 
vorig jaar, regelmatig als voorbeeld gesteld door Louis, was met recht een 
bekroning op je inspanningen.     
 
Uiteraard wil ik alle nog niet genoemde co-auteurs van de in dit proefschrift 
opgenomen manuscripten hartelijk bedanken voor hun samenwerking, interesse, 
kunde, geduldige uitleg, input en inspiratie: Dr. Koek, Dr. Dassen, Dr. Gorgels, Dr. 
Bekkers, Dr. Kruse (Arnold), Dr. van Bilsen en Dr. Bekers.  
 
(Schoon)familie en vrienden, ook jullie hebben bijgedragen aan de totstandkoming 
van dit proefschrift. De onuitputtelijke interesse en het medeleven waren 
hartverwarmend. Eindelijk kan ik de vraag: “Zeg, wanneer is nu dat feest?” 
beantwoorden. Ik zal bij dezen nog één keer uitleggen dat de titel “doctor” niet 
verward moet worden met “dokter”. Hoewel ik nu heel wat afweet van de 
zwangerschap en alles wat daarbij komt kijken, heb ik nog steeds geen pasklare 
oplossing voor allerhande gezondheidsproblemen. Annemieke en Hilde, goede 
vriendinnen en oud-studiegenootjes, fijn dat ik altijd bij jullie terecht kon om in GW-
ers taal over werkgerelateerde onderwerpen te praten. Uiteraard bespreken we 
andere aspecten ook, maar dat leek me hier minder relevant. Miek, Ik ben vereerd 
dat ik jouw paranimf mag zijn. Een week voor jouw eigen promotie heb ik je die rol 
bespaard, al beleef ik het hetzelfde. Bedankt voor alle steun. Esther, we leerden 
elkaar kennen toen ook jij met de preeclampsie groep aan de slag ging. Wat hebben 
we veel lief en (promotie)leed gedeeld. Na een dinertje samen, uit of thuis, zag ik de 
toekomst veel zonniger in (dan ie al was). Wees bovenalles trots op jouw prestaties. 
De hoeveelheid klussen die jij de afgelopen jaren geklaard hebt zijn niet te 
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evenaren. Ik vind het ontzettend jammer dat je niet bij mijn promotie aanwezig 
kunt zijn, maar de stage in Amerika is een absolute topkans. We drinken op jouw 
feest een extra pilsje (of twee).  
 
Pap en mam, bedankt voor het onvoorwaardelijke vertrouwen en de 
onovertreffelijke steun bij alles wat ik doe (en laat). Het was niet altijd eenvoudig 
uit te leggen waar ik me zoal mee bezig hield, maar de krantenknipsels over 
zwangerschapsvergiftiging getuigen van het juiste begrip. Pap, de rit naar Wijk aan 
Zee (en terug) was dubbel en dik de moeite waard. Ik ben erg blij met de foto’s die 
zowel op de voor-, achter- als binnenkant van dit proefschrift prijken. Woorden 
schieten te kort om te beschrijven wat jullie voor me betekenen, maar met een stuk 
of vier kom ik toch een heel eind. Iech haw vaan uuch! Gilbert, je moet me al heel 
wat jaren ‘missen’ in Neerbeek, maar met msn blijkt dat goed te verkroppen. Heel 
erg bedankt voor de layout van omslag en uitnodigingen. Je denkt je roeping nog 
niet te hebben gevonden, maar ik zou niet heel veel verder zoeken als ik jou was, 
toch Lindsay? 
 
Bas, lieve Bas, je hebt wat gezellige avonden en weekenden aan je neus voorbij zien 
gaan door de perikelen rond dit proefschrift. Uit het feit dat je zelf op een blauwe 
maandag het promoveren overwoog, hoop ik echter af te leiden dat ik het binnen 
de perken heb weten te houden. Jouw simpele kijk op voor mij complexe 
dilemma’s, vertrouwen in mijn kunnen en trots (over mij) waren en zijn een grote 
steun. Sinds vorige zomer wonen we in ons eerste echte eigen huis (ook dat was me 
het projectje wel) en ik vind het heerlijk, met jou. Ik hoop dat we de vele 
herinneringen die we de afgelopen tien jaar samen hebben opgedaan nog lang 
kunnen aanvullen (dus laat die mooie reizen maar komen). De gelukkigste mens is 
degene die het denkt te zijn. Heb ik geluk!  
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Curriculum vitae 
Simone Sep werd op 2 januari 1983, net een uur na nieuwjaarsdag, geboren in het 
Sint Barbaraziekenhuis in Geleen. Ze groeide op in het kerkdorp Neerbeek. In 2001 
slaagde ze voor het VWO aan het Graaf Huyn College (eerder: scholengemeenschap 
Sint Michiel) te Geleen. In datzelfde jaar startte ze met de opleiding 
Gezondheidswetenschappen aan de Universiteit Maastricht en al vrij snel verhuisde 
ze naar de Limburgse hoofdstad. 
Binnen de doctoraalfase koos ze voor de studierichting Biologische 
Gezondheidkunde, om zich tijdens het keuzeonderwijs verder toe te spitsen op de 
Epidemiologie. Tijdens haar wetenschapsstage (onder begeleiding van Dr. Peeters 
en Prof.dr. Prins) bij de afdelingen Obstetrie & Gynaecologie en Epidemiologie 
(MUMC+) nam de affiniteit met preëclampsie, toen ook al het onderwerp van 
studie, toe. In 2006 zette zij dan ook haar werk voort als promovenda bij deze 
afdelingen. Het onderzoek naar het herhalingsrisico op preëclampsie heeft 
geresulteerd in dit proefschrift.  
 
Simone deelt het leven met haar jeugdliefde Bas Krekels. 
 
 
